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ABSTRACT

IMPACT OF MEDICARE PART D COVERAGE GAP ON BENEFICIARIES‟
ADHERENCE TO PRESCRIPTION MEDICATIONS
By: URVI S DESAI, Ph.D.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University
Virginia Commonwealth University, August 2011
Advisor: Norman V Carroll, Professor, Department of Pharmacotherapy and Outcomes Sciences

INTRODUCTION: Medicare Part D provides prescription drug coverage to seniors through a
benefit plan with a major deductible inserted in the middle. It is important to study the extent to
which this structure affects seniors‟ adherence to prescription medications. Therefore, this study
had the following objectives: (1) To identify characteristics of beneficiaries reaching and not
reaching the coverage gap, (2) To study the entry and exit times from the coverage gap, (3) To
study the impact of a complete gap in coverage on beneficiaries‟ adherence to prescription
medications, (4) To study the impact of a partial gap in coverage on beneficiaries‟ adherence to
prescription medications
METHODS: This was a retrospective quasi-experimental analysis with matched control groups
using a nationally representative sample of Part D enrollees from 2008 Centers for Medicare and
Medicaid (CMS) datasets. Adherence to each oral medication taken for one or more of the seven
pre-defined therapeutic classes before and after reaching the coverage gap was measured using
the Medication Possession Ratio (MPR). Appropriate statistical tests for significance were
performed for each analysis

xi

RESULTS: A quarter of our sample (24.42%) reached the coverage gap in 2008. Most of the
beneficiaries reaching the coverage gap did so by end of September. Those reaching the
coverage gap and losing all coverage experienced significantly greater reductions in adherence
(3% more for beta-blockers to 9% more for oral anti-diabetic agents), compared to those not
reaching the coverage gap. A considerable proportion of beneficiaries stopped taking
medications in both the groups and the proportion of beneficiaries considered adherent also
dropped in both the groups during the coverage gap period.
CONCLUSIONS: Medicare Part D beneficiaries face significant barriers to adherence and this is
especially highlighted among those reaching the coverage gap. Interventions to improve
adherence in this group should target all beneficiaries, especially those with several chronic
conditions.

CHAPTER 1:
INTRODUCTION

This chapter presents background information about the concept of health insurance and
demand, which is the underlying conceptual framework guiding this study, followed by historical
issues surrounding prescription drug coverage for the seniors in the United States and the newly
introduced Medicare Part D benefit. The first section of conceptual framework also contains
information about the empirical evidence to support the theory that presence (or absence) of
insurance affects utilization of healthcare services; especially prescription drugs. The second
section details the historical issues surrounding prescription drug coverage for seniors. This
section provides an overview of Medicare and its efforts to provide coverage for prescription
drugs to beneficiaries prior to implementation of Medicare Part D. It also contains results from
pre-Part D studies that explored the need for prescription drug coverage for the Medicare
beneficiaries. Next, it contains information about the Medicare Prescription Drug and
Modernization Act of 2003 and its provisions for prescription drug coverage, including the
structure of Medicare Part D. It also explores the projected impact of this policy change on
access to and use of medications using the pre-Part D literature. Finally, the chapter provides a
brief overview of the remainder of the document.
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Section 1: Conceptual Framework
The Concept of Health Insurance
Healthcare is an area of great uncertainty because illnesses are often difficult to predict
and the associated treatments are often very costly. This leaves individuals in constant fear of
losing a significant amount of their income in a relatively short period of time. Insurance is an
arrangement that allows risk-averse people to reduce the uncertainty associated with these events
by making regular contributions (premiums) to an agency that provides them assurance of
financial assistance at the time of need. While it is not possible to predict the probability of
illness per individual, the average probability of illnesses can be predicted fairly well for a large
group of people. This is done based on the law of large numbers, which shows that for a given
probability of illness, the distribution of the average rate of illness in a group will collapse
around the probability of illness as the group size increases1. Thus, insurance reduces the
variability of the insureds' income by pooling their risks into a large group.
Most insurance agencies in the healthcare industry require that insured individuals share a
percentage of the cost of treatment of an illness. This percentage to be paid by the insured at the
time of the event is typically referred to as co-insurance1. For example, if the total cost of
treatment is $100, then with a 20% co-insurance rate, the insured will pay $20 (out-of-pocket
(OOP)) at the time of treatment and the insurer will pay the remaining $80. The purpose of
requiring some form of cost sharing at the time of treatment (in addition to the premiums) is to
make consumers more aware of the true costs of the treatment and to prevent unnecessary use of
healthcare services1. This concept can be better explained using the economic theory of price
elasticity of demand for goods and services.
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The Economic theory of Price Elasticity of Demand
The demand curve for most goods and services is downward sloping, indicating an
inverse relationship between price charged and the quantity demanded. Thus, for a given service,
as the price of the service increases, the quantity demanded decreases and vice versa. This
relationship between price change and quantity demanded is explained economically using the
concept of “price elasticity”. The price elasticity of demand can be defined as the ratio of percent
change in quantity demanded to percent change in price of the service2. Thus, if the initial price
for a given product is P0, the quantity demanded at this price is Q0 and if the price changes to P1
and the quantity demanded changes to Q1, then
𝒑𝒓𝒊𝒄𝒆 𝒆𝒍𝒂𝒔𝒕𝒊𝒄𝒊𝒕𝒚 𝒐𝒇 𝒅𝒆𝒎𝒂𝒏𝒅 =

𝑸𝟏 − 𝑸𝟎 ÷ 𝑸𝟎 / 𝑷𝟏 − 𝑷𝟎 ÷ 𝑷𝟎

The sign of the ratio indicates the direction of change in quantity demanded with respect
to change in price. It is typically negative because quantity demanded decreases with increase in
price or vice versa. The greater the absolute value of the price elasticity of demand, the greater is
the effect of change in price on quantity demanded. In absolute terms (ignoring the sign), the
farther the ratio is from 1,the greater the elasticity of demand for a product or service and the
closer the ratio is to 1, the less the elasticity of demand for a product or service.2
As mentioned earlier, the relationship between insurance cost sharing and utilization of
healthcare products and services can be explained using this fundamental principle of price
elasticity of demand. Economic theory suggests that presence of insurance (versus patients
having to pay the full cost themselves) makes the demand for healthcare services less elastic,
thereby, increasing the quantity demanded at any given market price.3 In other words, in the
presence of insurance, changes in the market price for a service will not affect the consumer as
much as they did when the price was paid out of pocket. This is illustrated in Figure 1 below. In
3

this figure, the graph presents a hypothetical example of the relationship between market price
and quantity of a health service demanded for various price levels. It further provides
information on the changes that would occur in the presence of different co-insurance rates.
According to this figure, for a person with a 100% co-insurance rate (complete self-pay or no
insurance), for a market price of $40, quantity demanded is X1; for $20, quantity demanded is
X2 and for $10, the quantity demanded is X3. However, if the co-insurance rate drops to 50%,
the quantity demanded will correspond to the quantity demanded at 50% of the actual market
price. Thus, now, for market price of $40, the quantity demanded will be X2, because now the
patient is paying only $20 and so he/she will demand the service as if the price was $20. If the
co-insurance rate further decreases to 25%, the quantity demanded for a market price of $40 will
be X3.
Demand curve for 100% OOP

Market Price

Demand curve for 50% Co-insurance
Demand curve for 25% Co-insurance

$40

$20
$10
X1

X2 X3

Quantity

Figure 1: Relationship between co-insurance and demand for healthcare services Adapted
from Figure 9-7: The effect of coinsurance rate on healthcare demand on Pg: 1843
This change in demand for services at any given market price is represented graphically
by the outward rotation of the demand curve with decreasing co-insurance rates. Thus,
4

decreasing co-insurance rates increases the utilization of healthcare services beyond what a
patient would normally consume at any given market price. In other words, a decrease in patient
cost sharing leads to an increase in utilization of healthcare services. The opposite of this is also
true; i.e. an increase in co-insurance rates decreases the utilization of healthcare services. The
following section provides the empirical evidence to support this theory, focusing on its
relevance to prescription drug utilization.
Empirical Evidence
Empirical evidence suggests that the economic theory of cost sharing and demand for
services is true for most healthcare products and services including prescription drugs. The
breakthrough study by RAND Corporation in 1985 was among the first to provide evidence in
support of the above theory. The study found that the quantity of prescription drugs demanded
increased with a decrease in cost sharing.4 For example, the group with free care filled about 5
prescriptions per month compared to 4 prescriptions used by enrollees of plans with 25% and
50% cost sharing.
Coulson et al. concluded that within a Pennsylvania Health Plan Medicare population,
enrollees with some form of coverage for prescription drugs filled and refilled more prescriptions
compared to those who did not have any form of coverage for prescription drugs. 5 Upon
analyzing the completed surveys, it was observed that enrollees with insurance for both
physician visits and prescription drugs filled and refilled approximately 1.87 prescriptions
whereas those without supplemental insurance filled and refilled only 0.80 prescriptions in the
given two week reference period.
Using data from the RAND Elderly Health Supplement to the 1990 panel study of
income dynamics, Lillard et al. concluded that presence of insurance coverage for prescription
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drugs significantly increased the probability of use of these drugs.6 Using simulations to estimate
the effects of providing insurance to Medicare enrollees without prior drug coverage, the
researchers observed that under such a provision, the probability of medication use would
increase by 8.8% (p < 0.01) in this population. The study further estimated a 12.2% increase
among beneficiaries with no private insurance (Medicare only) and 7.5% among beneficiaries
with private insurance but with no drug coverage.
A study of the existing data of 7,285 community dwelling Medicare beneficiaries from
the Cost and Use files for the 2000 Medicare Current Beneficiary Survey (MCBS) found that
enrollees with drug coverage had 4.5 times higher probability of any drug use compared to those
with no coverage.7 A more recent study of Medicare beneficiaries from the MCBS of 1992-2000
estimated that presence of prescription drug coverage increased utilization by 4%-10%
depending on the type (i.e. public coverage vs. HMO or employer sponsored coverage) and
generosity of coverage compared to lack of coverage altogether.8
There is ample literature indicating that the opposite of these findings is also true; i.e. the
demand for prescription medications decreases with increased cost sharing. In a 2007 systematic
review, Goldman et al.9 reviewed 132 articles to study the effect of cost sharing on utilization of
prescription drugs from 1985 to 2006. The studies reviewed looked at several types of cost
sharing strategies employed by insurers including incentive based formulary design, capped
benefits and not providing coverage for certain classes of drugs. From this comprehensive
review, the authors concluded that irrespective of the strategy used, increases in cost sharing led
to decreases in utilization of prescription medications. The authors summarize their findings
using the principle of price elasticity of demand by stating that for every 10% increase in costsharing prescription drug use decreased by 2%-6% depending on the drug and therapeutic class;
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i.e. the price elasticity of demand for prescription drugs according to this study ranges from -0.2
to -0.6.
In other words, the result is consistent among the articles reviewed: presence (or absence)
of insurance and the generosity of cost-sharing structures affects the demand for prescription
drugs. The next section outlines the historical issues surrounding prescription drug coverage for
seniors and presents an overview of the basic structure of the recently implemented Medicare
Part D prescription drug benefit
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Section 2: Prescription Drug Coverage and the seniors
History of Medicare
The need for financial assistance for the seniors was first recognized in the United States
with the passage of the Social Security Act (SSA) of 1935. While it was originally intended to
include government sponsored health insurance for the seniors eligible for receiving Social
Security, health insurance coverage was omitted from the final Act of 1935 due to political
concerns10. Proponents of compulsory health plans were no more successful for the next two
decades. However, immediately after his election in 1964, President Johnson, who was a strong
proponent of health insurance for the aged even before his election, signed Medicare and
Medicaid into law on June 30, 196510, 11. Through this law, Medicare was established under Title
XVIII of the SSA to provide federally administered health insurance to individuals age 65 and
older regardless of income or medical history12. Under Title XIX of the SSA, Medicaid was
established as a federal-state administered program to provide health insurance coverage to
certain low-income groups of people who could not otherwise afford health insurance10. In 1972,
Medicare expanded coverage to citizens under the age of 65 years who were either permanently
disabled or suffered from End-Stage Renal Disease (ESRD)11, 12.
Historically, Medicare provided compulsory hospital insurance (called Part A) to the
seniors and disabled that helped pay for inpatient care, skilled nursing facility, and hospice care,
with an optional medical insurance program (called Part B) that helped pay for physician
services, home health and preventive services including physician administered drugs for
beneficiaries who wish to subscribe. However, Medicare did not provide any coverage for
outpatient drugs.
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With the passage of the Medicare Catastrophic Coverage Act of 1988, Medicare
proposed provision of outpatient prescription drug coverage to beneficiaries with a cap on outof-pocket (OOP) expenses11. Through this act, Medicare planned to cover a set percent of
catastrophic expenses for outpatient drugs including insulin and immuno-suppressants used after
organ transplant surgeries after meeting a certain deductible each year. The proposed timeline of
implementation was that Medicare would cover 50% of the costs of such medications after a
deductible of $500 in 1990 and $600 in 1991 and 60% of the costs after a deductible of $652 in
199213. In the long term, the deductible value was proposed to be set so that 16.8% of all
Medicare beneficiaries would exceed the amount and Medicare paid 80% of the costs in excess
of that amount. The program was proposed to be financed through an increase in premium based
on a beneficiary‟s income13. The act was repealed in 1989 following increasing political pressure
and protests by higher income seniors who were likely to be faced with increased premiums 11, 14.
Since then, Medicare did not provide coverage for outpatient prescription drugs until the passage
of the Medicare Prescription Drug Improvement and Modernization Act (MMA) of 200311.
The Need for a Medicare Drug Benefit
Studies done before 2003 concluded that most seniors suffered from several chronic
conditions, took a number of medications, and paid a significant proportion of their income
towards prescription medications. For instance, results from the 1980 National Medical Care
Utilization and Expenditure Survey indicated that four out of five seniors used prescription drugs
in a given year15. It also found that although seniors constituted 10.1% of the national population,
they accounted for about 33% of the total spending on prescription drugs. Approximately 68% of
this cost was paid out-of-pocket. Mueller et al.16 used data from the 1987 National Medical
Expenditure Survey and found similar results: 12% of the population comprised seniors, who in
9

turn accounted for 34% of total spending on prescription drugs. They also found that 36% of the
seniors in their sample had more than three chronic conditions.
Davis et al.17 used data from 1995 MCBS and found that Medicare beneficiaries paid half
of their prescription costs OOP compared to the much lower national average OOP spending by
the entire U.S population (34%) and an even lower percent paid by Medicaid enrollees (21%).
Crystal et al.18 also used 1995 MCBS data. They found that beneficiaries spent 19% of their
income on healthcare, 50% of which was spent on prescription drugs and dental services. The
burden was higher in sicker (28.5% of income) and low income beneficiaries (31.5% of income).
Several studies reported that a lack of insurance for prescription drugs adversely affected
medication adherence among seniors. The International Society for Pharmacoeconomics and
Outcomes Research (ISPOR) defines medication adherence as “the extent to which a patient acts
in accordance with the prescribed interval and dose of a dosing regimen”.19 Thus, to be adherent
to a prescribed regimen, a patient must first purchase the medication and then utilize it as
prescribed. A lack of insurance has been found to result in decreased procurement of drugs
which in turn resulted in non-adherence among seniors. For example, Davis et al.17 reported that
nearly 35% of Medicare beneficiaries living in the community did not have coverage for
prescription drugs. It was further found that beneficiaries without prescription drug coverage
used 31% less prescription drugs compared to the national average usage (12.7 vs. 18.5).
Steinman et al. concluded that 8% of seniors without insurance reported medication restriction
due to cost compared to 3% with partial coverage and 2% with full coverage20.
A national survey of Medicare beneficiaries aged 65 and older revealed that almost a
quarter of seniors did not have prescription drug coverage in 2003 and almost half of lowincome seniors lacked coverage in some states21. The study also found that cost was cited as the
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most common reason for non-adherence (26.3%) as compared to non-adherence due to
unfavorable experiences like side effects (24.5%) or perceived need for taking the medications
(14.5%). The effect was even more pronounced among beneficiaries with low income and/or
multiple chronic conditions and/or no coverage. For example, among beneficiaries with low
income and complex chronic conditions, almost 50% of those without coverage for prescription
drugs reported some form of cost-related non-adherence compared to 25% of those beneficiaries
who had some form of coverage for prescription drugs21.
A number of studies have concluded that medication non-adherence leads to severe
clinical and economic implications. A study by Mojtabai and Olfson used the Health and
Retirement Study (HRS) data which is an ongoing longitudinal survey of community dwelling
older Americans and concluded that participants with cost related poor adherence were more
likely to have been hospitalized compared to their peers (43% vs. 33% respectively)22.
In a study of hypertensive patients, Psaty et al. observed that patients with less than 80%
adherence to their medication (as measured from a computerized pharmacy database) have a 4
fold increase in risk of developing acute cardiac events compared to those with adherence ratio
of 80% or higher23. Horwitz et al. reported that among patients on beta-blocker therapy, poor
adherers (i.e. those who took less than or equal to 75% of the prescribed medication) were 2.6
times more likely to die compared to good adherers (i.e. those who took more than 75% of the
prescribed medication) (95% CI (1.2, 5.6)) and that such non-adherence to medications (i.e.
taking less than or equal to 75% of the prescribed medication) was independently associated with
a higher mortality risk24.
A study involving epileptic patients25 found that non-adherence to medications (defined
as Medication Possession Ratio, (MPR) less than or equal to 0.80) was associated with
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significantly higher incidence of hospitalizations [incident rate ratio (IRR) = 1.39, 95% CI =
1.37-1.41], inpatient days (IRR = 1.76, 95% CI = 1.75-1.78), and ED visits (IRR = 1.19, 95% CI
= 1.18-1.21). Non-adherence was also associated with cost increases related to serious outcomes,
including inpatient ($4,320 additional cost per quarter, 95% CI = $4,077-$4,564) and ED
services ($303 additional cost per quarter, 95% CI = $273-$334).
Balkrishnan et al. found that adherence to anti-diabetic medications (defined as MPR >
0.70) was a greater driver of cost reduction than use of other medications in this population. The
results indicated that a 10% increase in adherence to anti-diabetic medications resulted in 8.6%
reduction in total annual health care costs (including ER visits and hospitalization)26.
Svarstad et al. studied Medicaid patients suffering from mental illnesses and observed
that within the total sample, patients with an irregular use of medications (defined as patients
taking oral medications who had one or more quarters without a claim) had significantly higher
rates of hospitalization than regular users (42 percent versus 20 percent), more hospital days (16
days versus four days), and higher hospital costs ($3,992 versus $1,048). Irregular medication
use was one of the strongest predictors of hospital use and costs even after the analyses
controlled for other confounders27.
From the

pre-MMA literature, it is reasonable to conclude that lack of sufficient

financial assistance (in other words, “insurance”) posed a significant burden to seniors which
compelled them to forego medications; this in turn increased their chances of developing adverse
clinical outcomes that led to unnecessary increases in the treatment costs . A systematic review
of the literature has indicated that non-adherence leads to anywhere from 5-40% of all hospital
admissions in the seniors28. As noted by Haynes et al., “Increasing the effectiveness of adherence
interventions may have a far greater impact on the health of the population than any
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improvement in specific medical treatments”
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. Partly in response to studies like these, the

MMA was signed into law on December 8, 200314.
Structure of Medicare Part D
Administration
Beginning January 1, 2006, Medicare Part D, a voluntary outpatient prescription drug
benefit program, was implemented for all Medicare beneficiaries except for those who are dually
eligible for Medicare and Medicaid and certain low-income beneficiaries. These patients are
automatically enrolled into a plan if they did not choose one during the open enrollment period
beginning in November of every year. Medicare Part D is delivered through private plans, either
stand-alone prescription drug plans (PDPs) or Medicare Advantage prescription drug (MA-PD)
plans, that contract with Medicare to provide either the “standard benefit” required by the MMA
(explained in section: Benefit Structure), or a benefit structure that is “actuarially equivalent” or
enhanced.
As of April 2010, approximately 27.6 million beneficiaries were enrolled in Part D, of
which two-thirds were enrolled in PDPs30. It is important to distinguish between beneficiaries
enrolled in PDPs and MA-PDs because of the difference in the benefit structure offered. Most
PDPs offer coverage using some modification of this basic structure

31

. In 2010, about 60% of

the PDPs required the standard deductible (compared to 11% of MA-PDs), 80% of PDP plans
had the “coverage gap” and offered no coverage for drugs during that time (compared to 51% of
MA-PDs). The 20% of the plans that did offer gap coverage limited it to generic drugs only. By
comparison, 49% of MA-PD plans offered generic with some brand name drug coverage during
the gap

30, 32

. Thus, 80% of beneficiaries enrolled in PDPs were solely responsible for the full
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cost of their medications during the coverage gap while about half of those enrolled in MA-PDs
received some assistance. Now in its fifth year of implementation, Medicare Part D is funded by
general revenues, beneficiary premiums, and state payments and accounted for 10% of the total
Medicare spending in 2009 12.
Benefit Structure
The prescription drug coverage offered though Medicare Part D includes a small
deductible at the front end and a major coverage gap inserted in the middle. The coverage gap,
where the beneficiary is responsible for full cost, is also called the “doughnut-hole”; and the limit
above which the coverage resumes is called the “catastrophic coverage limit”. In 2010, there was
an initial deductible of $310, followed by 25% coinsurance until total drug spending reached
$2,830. At this point the coverage gap began and continued until total drug spending reached
$6,440 30. Thus, in addition to monthly premiums, in 2010, an average beneficiary paid $310 +
25% ($2,830 - $310) = $940 in OOP costs before reaching the coverage gap. After this, the
beneficiary was responsible for paying 100% of the cost until the total drug spending reached
$6,440. In other words, the beneficiary was responsible for the next $3,610 in prescription
spending before reaching the catastrophic coverage limit after which Medicare would cover 95%
of drug costs. This structure is pictorially represented in Figure 2 below.
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Catastrophic Coverage: 5%
coinsurance after total
spending exceeds $6,440
(Very few beneficiaries reach
this phase)
Coverage Gap: No coverage till
total spending reaches $6,440
Deductible ($310) + 25% coinsurance up to total spending of
$2,830 (Most beneficiaries stay in
this phase)

Figure 2: Standard Benefit Structure of Medicare Part D for 2010
Medicare Part D beneficiaries have the choice to enroll in plans that offer coverage
through either the Medicare defined standard benefit structure (shown above) or some alteration
of the same. There are three different alternatives to the standard benefit design. The “actuarially
equivalent” designs are those that have a deductible at the front end followed by Medicare
defined limits for beginning of coverage gap and catastrophic coverage limits. They differ from
the Medicare defined “standard benefit” only in the fact that these plans are allowed to charge
beneficiaries various cost-sharing structures in lieu of the standard 25% co-insurance in the
standard benefit. A “basic alternative” is a design where the deductible can be eliminated or
reduced and the cost-sharing structures can be altered compared to the Medicare Standard but the
limits for the coverage gap and catastrophic coverage are not altered. In contrast, plans offering
coverage through an “enhanced alternative” have the freedom of whether or not to charge a
deductible as well as whether or not to include a coverage gap. They can change the cost-sharing
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structure as well as spending limits to determine the beginning of the coverage gap. The
catastrophic limit and cost-sharing, however, stay in place similar to the other designs. In
addition, these plans are allowed to offer coverage for some or all drugs for beneficiaries in the
coverage gap.
The novel cost-sharing structure employed by Medicare Part D generated interest in
trying to estimate the proportion and characteristics of beneficiaries who would reach the
coverage gap under the standard Part D benefit structure using historical (pre-MMA) data.
Further the research community was interested in estimating the effects of reaching the coverage
gap on beneficiaries‟ medication taking behavior and costs. The following section summarizes
the findings of the pre-MMA studies.
Projections pertaining to the coverage gap
Stuart et al. used data from the MCBS for years 1998-2000 and estimated that about 40%
of all Part D enrollees will spend some time in the coverage gap each year from 2006-2008 and
only 15% of these would have spending high enough to reach the catastrophic coverage level33.
Tjia and Schwartz studied medication utilization behavior of seniors with diabetes
mellitus from the 2001 Medical Expenditure Panel Survey (MEPS) and estimated that the
percentage of beneficiaries having expenditures in excess of the initial gap limit of 2006 ranged
from 60% for those using traditional hypoglycemic agents to 75% for those on novel agents34.
Tjia and Schwartz also concluded that having three or more co-morbid conditions as well as
clinical indicators of greater illness burden and poorer health status significantly increased the
likelihood of falling in the coverage gap34. However, they concluded that sociodemographic
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factors were not significantly associated with the risk of falling in the coverage gap in their
sample of diabetic beneficiaries.
Using historical data of patients diagnosed with atrial fibrillation between January 2001
and June 2003, Evans-Molina et al. projected that the percentage of beneficiaries in their sample
expected to enter the coverage gap in 2006 ranged from 27% to 46%, of which 3% to 11% would
have spending high enough to exit into catastrophic coverage before the end of the year35.
Patel and Davis analyzed the MCBS data for 1997 through 2001 and estimated that
approximately 43% of beneficiaries without ESRD would fall in the coverage gap in 2006 of
which about 14% would be able to exit before the end of the year36. These numbers were even
higher for those with ESRD. The researchers predicted that70% of those with ESRD would reach
the coverage gap in 2006 and almost 40% of those would reach the catastrophic phase before the
end of the year.
There was much ado about beneficiaries reaching the coverage gap, because there is
ample evidence to conclude that experiencing a gap in coverage or having an annual spending
limit (cap) for prescription drugs leads to decrease in medication use and increase in OOP
spending. The next section highlights the effects of such gaps and/or caps imposed on drug
spending among non-Medicare Part D beneficiaries.
Impact of caps and gaps
Research aimed at examining the impact of gaps in coverage or caps on total spending for
prescription drugs on non-Medicare Part D (pre or post implementation) seniors‟ utilization of
medications has concluded that beneficiaries with caps or gaps in coverage were more likely to
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forego medications due to cost. Studies outlined in the next few paragraphs also identified cost
lowering strategies used by seniors having some form of insurance coverage with capped
benefits.

These strategies include reducing drug use, reducing use of other necessities,

borrowing money to pay for prescriptions, and finding less expensive prescriptions including
free samples from their physicians.
Stuart et al. studied a representative sample of Medicare beneficiaries with gaps in their
coverage using information from MCBS files for 1998 and 2000 and concluded that such
interruptions in drug coverage led to significant reductions in medication use and spending,
especially among beneficiaries with many chronic illnesses37.
A survey of beneficiaries with coverage for prescription drugs capped at $500 or $1,000
annually found that almost 70% of the respondents engaged in one or more of the
aforementioned cost-lowering strategies despite having some coverage for their drugs38. Another
survey of Medicare beneficiaries with capped benefits found that taking less than prescribed
amounts and discontinuing prescribed medications were among the top mentioned strategies to
cope with prescription costs (23.6% and 16.3% respectively)39. Tseng et al.40 reported that a
greater proportion of beneficiaries exceeding the cap imposed on their prescription spending or
those who experienced a gap in their coverage used less medication compared to those who had a
higher annual cap that they did not exceed (18% vs. 10%, p-value < 0.001). The researchers also
found that a greater proportion of these beneficiaries reported shopping around for drugs and
having difficulty with paying for prescriptions compared to their peers.
Soumerai et al. analyzed responses to questions about cost-related non-adherence
(measured as self-reported skipping or taking smaller doses to make the medicine last) as well as
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cost-cutting strategies (e.g. obtaining free samples, using generic drugs, shopping for best price)
added to the MCBS41. The researchers found that although only 13% of the elderly and 29% of
the non-elderly disabled beneficiaries reported cost-related non-adherence; almost 70% of all
Medicare beneficiaries (both elderly and non-elderly disabled) surveyed engaged in some form
of cost-cutting strategy to cover prescription drug costs. The most frequently cited strategy was
either using generic drugs or requesting samples from physicians (~50% for each), followed by
shopping around for best pricing and spending less on other needs.
In a cross-sectional study of 222 homebound older adults aged 60 and older, Sharkey et
al. found that 20.3% of the sample population reported using one or more strategies to restrict
medication use because of cost (skipping doses or taking less than prescribed) while another
21.2% of the sample reported using strategies to cut OOP expenses (e.g. choose between food
and medicine). While shopping around and reducing expenses on other household expenditures
is prudent, to stop taking medications or to take less than prescribed or to reduce expenditures on
daily necessities including food could adversely affect the health outcomes of these
beneficiaries38.
Conclusion
Medicare Part D is a major expansion to the Medicare program. In addition, the costsharing structure used by this prescription benefit is highly unusual. Therefore, there has been a
tremendous interest in studying the impact of the program as well as its design before and after
its implementation.
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Overview of the Remaining Document
The remaining chapters of this document present a detailed review of the literature
focused on studying the effects of Medicare Part D, the rationale for doing the study, followed by
the research objectives and specific aims, methods used to achieve these aims, results and a
discussion of the findings. Finally, we present the main conclusions drawn from the study
findings and a bibliography of cited literature.

20

CHAPTER 2:
LITERATURE REVIEW

This chapter is divided into two sections. The first section presents results of the literature
that studied the overall impact of Medicare Part D program on Medicare beneficiaries. This
includes a review of the impact on medication utilization and spending as well as medication
adherence. This is followed by a section that presents a review of studies focused on examining
the impact of the coverage gap on Medicare Part D enrollees. This includes studying the
proportion of beneficiaries reaching the coverage gap and the characteristics of these
beneficiaries, the impact on utilization of prescription medications and cost-cutting strategies
used by beneficiaries affected by the coverage gap. Finally, the chapter discusses gaps in the
existing literature that merit attention in future research.
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Section 1: Impact of Medicare Part D
On Overall Medication Use and Spending
Despite its novel structure for cost-sharing, the intention of Medicare Part D was to
improve utilization of necessary prescription medications by making them more affordable. Prior
to its implementation, Pauly used the economic principles of price elasticity of demand for
prescription drugs and healthcare utilization in the presence of insurance presented earlier and
estimated that following implementation of Medicare Part D, there would be a 20% increase in
utilization of prescription drugs for those who previously lacked coverage and a 6% increase for
those who had some form of prior coverage42.
Several studies done since the implementation of Part D uphold Pauly‟s estimates.
Lichtenberg and Sun used prescription claims data from one of the nation‟s largest retail
pharmacy chains for the period of September 2004-December 2006 to estimate the impact of
Medicare Part D on user cost (defined as cost of a day of therapy to the beneficiary) and
medication use (defined as days of therapy). They used a difference-in-difference research
design to evaluate the impact of Medicare Part D on the elderly compared to the non-elderly. The
researchers found that the average user cost for both the groups increased between September
2004 and December 2005. However, the average cost of therapy decreased gradually for the
seniors group from January 2006 through June 2006 while the cost for the non-seniors remained
unchanged. They attribute this finding to the gradual enrollment in Part D from January 2006June 2006. Overall, the study estimated that Medicare Part D reduced user cost by 18.4% and
increased their use of prescription drugs by 12.8%43. These results, however, need to be
interpreted with caution because of the lack of information on the characteristics of groups
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compared. Additionally, the study used data from a single pharmacy chain and did not account
for baseline characteristics like demographics and chronic conditions.
Yin et al.44 used data from a 5% random sample of drug users from a single pharmacy
chain aged 60 – 79 years from September 2004 to April 2007. The researchers compared the
utilization pattern of the Part D eligible group (age 66-79 years as of January 1, 2006) to that of
the Part D ineligible group (age 60-63 as of January 1, 2006). Using a generalized estimating
equation modeling technique and accounting for baseline characteristics by including the similar
(except for age) Part D ineligible comparison group, they estimated that the implementation of
Medicare Part D reduced beneficiaries‟ OOP spending by 13% in 2006 compared to that in 2005.
The researchers further estimated that implementation of Medicare Part D increased the number
of prescriptions used by the eligible seniors by 7%.
Ketcham and Simon used data from the Wolters Kluwer Health‟s Source Lx database for
December 2004 through December 2007 to estimate the change in utilization and OOP costs for
beneficiaries enrolled in Part D in 2006. To achieve their goals, the researchers compared the
data for beneficiaries aged 66 and older to that of near-elderly (those aged 58-64 years)45. Their
analysis indicated that the elderly had 8.1% greater increase in utilization in 2006 over their level
of use in 2005 compared to the change in utilization for the near-elderly patients. However, the
change from 2006 to 2007 was much smaller; with only about 1% increase in utilization in 2007
over 2006. The researchers also found that the number of beneficiaries filling prescriptions in
2006 increased by 4.8% when compared to the number in 2005. Additionally, their results
indicate that Part D enrollees‟ OOP costs declined by 15.9% and 8.3% in 2006 and 2007
respectively, as compared to a 1.39% increase and 2.42% decrease in the OOP of near-elderly
patients in 2006 and 2007 respectively. The relative decrease in cost for the elderly compared to
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the near-elderly was found to be 17.2% in 2006 and 5.8% in 2007.The price elasticity of demand
based on utilization from 2005-2007 in this study was -0.44, which is in accordance with the
previous literature.
A common limitation of all three studies mentioned above is that they used a near-elderly
or non-elderly comparison group. It is well known that elderly have different drug utilization
patterns and requirements compared to the non-elderly. In addition, there is a difference in
financial characteristics of the two groups and, therefore, comparing the cost and utilization
among these two groups may generate spurious results.
A study of nationally representative claims data for beneficiaries with Type 2 Diabetes
Mellitus aged 65 years or older from July 1, 2004 through September 30, 2007 concluded that
enrollees in PDPs experienced an 11.2% increase in utilization whereas those enrolled in MAPDs increased their use by 6.2%. The study also concluded that OOP costs per prescription were
35% lower among PDP enrollees and 25% lower in MA-PD enrollees compared to beneficiaries
not enrolled in Part D plans, some of who had coverage from other sources while others
completely lacked drug coverage46
Schneeweiss et al. performed a time-trend analysis of patient level dispensing data of
seniors aged 65 years or older as obtained from three large pharmacy chains from January 1,
2005 through December 31, 2006. The researchers reported that among seniors without prior
coverage, the use of statins, clopidogrel and proton-pump inhibitors was 11%-37% higher than
their expected utilization without implementation of Medicare Part D47.
A recent study by Joyce et al. used administrative claims data to compare pharmaceutical
use and OOP spending of beneficiaries enrolled in the 10 largest Part D plans in 2006 to that of
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utilization information from 2004 MCBS cost and use data.48 The researchers found that
enrollees of Medicare Part D plans had a 16% decrease in annual OOP costs with a 7% increase
in utilization compared to utilization and spending as calculated from the 2004 MCBS data.
Joyce et al. also concluded that poorer beneficiaries who are either dually eligible for Medicare
and Medicaid or receive Low-Income Subsidies (LIS) benefitted the most from Medicare Part D.
Zhang et al. analyzed data of beneficiaries continuously enrolled in a Medicare
Advantage plan between 2004 and 2007 and compared several groups to identify the effect of
Part D on OOP costs of the enrollees49. Their findings suggest that compared to beneficiaries
with stable continuous coverage for prescription drugs, beneficiaries without prior coverage or
those who had caps on spending had significant decreases in their OOP spending (13.4%, 95%
CI (-17.1%, -9.1%) and 15.9%, 95% CI (-19.1%, -12.8%), respectively) after implementation of
Medicare Part D.
In 2006, Safran et al. conducted a follow-up survey50 of surviving Medicare enrollees
surveyed in 200321 to estimate the effect of Medicare Part D on their OOP spending and
prescription utilization. In addition, they aimed to identify the strata of beneficiaries benefitting
the most by the enactment of Part D. Upon completion of the study, the researchers found that
except beneficiaries previously enrolled in Medicaid, all Part D enrollees reported a greater
utilization of prescription medications compared to 2003 (p-value < 0.001). They also found that
all Part D enrollees experienced a significant decrease in OOP spending, except those
beneficiaries previously reporting employer-sponsored coverage (p-value < 0.001). These effects
were more pronounced among beneficiaries without prior drug coverage and among those who
had capped benefits prior to enrolling in Part D.
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A recent systematic review by Polinski et al., appropriately summarizes the findings of
these studies by estimating that implementation of Part D was associated with 6-13% increase in
utilization of prescription drugs and 13-18% decrease in OOP spending for the enrollees51.
On Medication Adherence
A study by Madden et al. compared changes in use of self-reported cost-lowering
strategies before and after implementation of Medicare Part D (2005 and 2006) and compared it
to the changes from 2004 to 2005 from the MCBS52. The study design accounted for selfreported covariates including socio-demographic characteristics and health status. In addition,
the study design also accounted for interview sequence bias (i.e. when the same questions are
asked to the participants at different intervals, their responses are affected by their knowledge of
the purpose of the question from previous interview and this creates the interview sequence bias)
and year-to-year changes in reporting trend. The adjusted analyses found that the 2006 vs. 2005
odds ratio (OR) for self-reported cost-related non-adherence (CRN), as calculated from
responses to questions pertaining to medication strategies like skipping doses, taking less than
prescribed, not filling or refilling a prescription due to cost) relative to that for 2005 vs. 2004 was
0.85 (95% CI (0.74, 0.98), and the corresponding OR for spending less on basic needs after
implementation of Medicare Part D was 0.59 (95% CI (0.48, 0.72). This indicates that
implementation of Medicare Part D decreased the proportion of beneficiaries reporting CRN or
spending less on basic needs to cope with prescription costs. The subgroup analyses, however,
suggested that beneficiaries in fair to poor health, those with more co-morbidities and those with
higher incomes did not experience a significant change in self-reported CRN. This implies that
the financial needs of the sickest beneficiaries may not be fully addressed by Medicare Part D;
probably because they are more likely to reach the coverage gap.
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Zivin and colleagues used a similar study design as Madden et al. to examine the impact
of Medicare Part D on medication adherence among beneficiaries with and without depressive
symptoms53. The study reported that after controlling for historical changes (2004-2005) and
demographic characteristics, the group with depressive symptoms did not experience a
significant decrease in CRN (ratio of ORs = 0.85, 95%CI (0.65, 1.12)) from 2005-2006. By
contrast, there was a marginally significant decrease in CRN among beneficiaries without
depressive symptoms (ratio of ORs = 0.83, 95%CI (0.70, 0.97)). However, when the two groups
were compared with each other, the adjusted analyses indicate that there were no significant
decreases in CRNs between the two groups studied (Ratio of ORs = 0.98, 95% CI (0.73, 1.32)).
The study findings indicate that Medicare Part D did not improve CRN among beneficiaries with
depressive symptoms.
In another investigation, Safran and colleagues found similar results after comparing the
survey responses of the same group of Medicare beneficiaries in 2003 and 200654. The study
used the same measure of CRN as used by Madden et al. and concluded that self-reported CRN
significantly declined for beneficiaries who previously lacked prescription coverage (OR = 0.4,
p-value < 0.001), as well as for those who were previously enrolled in Medicare HMO or
Medigap/private plans (OR = 0.4 and 0.6, p-value < 0.001, and p-value < 0.01 respectively). By
contrast, however, those who switched from employer sponsored programs in 2003 to a Part D
plan in 2006 reported a significantly increased rate of CRN (OR = 1.7, p-value < 0.01).
Beneficiaries who retained their employer sponsored coverage in 2003 and 2006 reported the
lowest overall CRN rate and showed slightly lower rates in 2006 compared to 2003 (OR = 0.7, pvalue < 0.05).
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Zhang et al. studied pharmacy and medical claims data for beneficiaries aged 65 years or
older who were enrolled continuously from 2003 through 2007 with a large Pennsylvania insurer
to identify the impact of Medicare part D on adherence to medications used to treat or prevent
hypertension, hyperlipidemia and/or diabetes55. The researchers studied adherence behaviors
(measured using MPR) among 3 groups with poor insurance coverage prior to implementation of
Part D and compared them with a group that had continuous coverage through a retiree health
benefit program throughout the study period. Among the three intervention groups, one group
did not have drug coverage prior to 2006, one group had a quarterly spending cap of $150 and
the third group had a quarterly spending cap of $350. The study results showed that after
adjusting for covariates and applying propensity score weighting, the group with no prior
coverage (irrespective of the disease condition) experienced the greatest increase in adherence
after implementation of Part D (13.4% for patients taking anti- hyperlipidemics 95% CI (10.1,
16.8), 17.9% for anti-diabetic 95% CI (13.7, 22.1) and 13.5% for anti-hypertensive group 95%
CI (11.5, 15.5)). In comparison, the group with $350 quarterly cap experienced the lowest
increases in adherence for every disease condition (4.4% for patients taking anti-hyperlipidemics
95% CI (3.3, 5.6), 3.6% for anti-diabetic 95% CI (1.8, 5.3) and 2.5% for anti-hypertensive group
95% CI (1.7, 3.2)).
Based on the preceding literature review, it is reasonable to conclude that implementation
of Medicare Part D increased the overall utilization of drugs for the beneficiaries by decreasing
their OOP costs; however, the impact of the „coverage gap‟ still remains to be explored. The next
section presents a detailed review of studies that have looked at the impact of this „coverage gap‟
incorporated in the Part D benefit since its enactment 4 years ago.
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Section 2: Recent Literature on Medicare Part D Coverage Gap
Despite speculation of its potentially unfavorable effects on senior patients‟ adherence
and health outcomes, the “coverage gap” was incorporated into Part D. The purpose of the gap
was to encourage financial discipline and contain healthcare expenditures 56. It was believed that
in addition to encouraging cautious spending among the beneficiaries, the coverage gap would
offset the impact of the availability of insurance coverage for prescription drugs on Medicare‟s
overall costs. Given the brief time that has elapsed since the implementation of Medicare Part D,
only a few studies have examined the effects of the coverage gap on beneficiaries‟ medication
use and spending. The following sections describe the findings of this literature in detail.
Proportion of beneficiaries reaching the “gap”
Some studies have estimated the proportion of beneficiaries qualifying for entry and exit
from the coverage gap for specific disease conditions. Schmittdiel et al. studied the entry and exit
proportions from the coverage gap for beneficiaries enrolled in 2 large MA-PD health plans in
California and diagnosed with Type 2 diabetes. The study reported that 26% of the sample
entered the coverage gap at some point in 2006 and only 2% exited the gap57. In another
investigation using claims data for Type 2 Diabetes beneficiaries from Avalere Health‟s
DataFrame database and the Wolters Kluwer‟s Source Lx database, Karaca and colleagues found
that 43% of non-Medicaid beneficiaries enrolled in the PDPs reached the coverage gap in 2006
compared to 33% of those in MA-PD plans46. Kim et al. used nationally representative data on
patients hospitalized for atrial fibrillation between January, 2005 and December, 2006 and
estimated that 58.8% of their cohort entered the coverage gap in 2006 in a mean of just 199
days58.
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Several other studies estimated the proportion of beneficiaries reaching the coverage gap
for more diverse samples. Ettner et al. linked pharmacy, outpatient and inpatient claims data to
Census data for beneficiaries enrolled in a large MA-PD plan that serves eight states and found
that 15.9% of the beneficiaries who did not receive LIS, were not dually eligible for Medicare
and Medicaid, and did not have gap coverage in their plan entered the coverage gap in 2006;
with only 6.7% of these exiting into the catastrophic coverage zone59. Twelve percent of the
sample analyzed by Schneeweiss et al. reached the coverage gap in 200647. From a retrospective
study of beneficiaries enrolled in a Kaiser Permanente MA-PD plan, Raebel et al. estimated that
about 6% of their sample population reached the coverage gap in 200660. Zhang et al. studied
data from a large Pennsylvania insurer that offered MA-PD type coverage as well as employer
sponsored coverage for Part D beneficiaries in 2006. The researchers estimated that among
beneficiaries with employer-sponsored coverage, 40% reached the coverage gap in 2006,
whereas 25% of MA-PD enrollees did so by the end of 200661.
A study by researchers at Kaiser Family Foundation estimated that in 2007, of those
Medicare Part D beneficiaries who were neither dual eligible nor received low income subsidies,
26% reached the coverage gap and that most spent the rest of the year in the gap; only about 4%
of those who entered the coverage gap also reached the catastrophic coverage limit62. The study
also reported that almost half of those who reached the coverage gap in 2007 did so by the end of
August. Pedan et al.63 analyzed pharmacy claims data from 2 large retail pharmacy chains and
found that 18.5% of their sample population reached the coverage gap in 2007.
A few studies also reported the characteristics of beneficiaries reaching the coverage gap.
Overall, it can be concluded that older beneficiaries suffering from a large number of chronic
conditions were more likely to reach the coverage gap. A study by Kaiser Family Foundation
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reported that the proportion of beneficiaries reaching the gap increased with age (25% of those
aged 65-74 years vs. 33% aged 85 years and older)62. Raebel et al. also concluded that
beneficiaries reaching the gap were older and had more diseases compared to those who either
did not have a gap in coverage or did not reach it60 while Ettner et al. reported that age was
inversely proportional to the likelihood of entering the coverage gap59. Zhang et al. estimated the
effect of co-morbidities on reaching the coverage gap and found that the likelihood of having
spending greater than the threshold for the coverage gap increased with an increase in the
number of co-morbidities. For example, among the MA-PD enrollees, 17% of beneficiaries with
„only hypertension‟ reached the coverage gap whereas 34% with both hypertension and diabetes
and 61% with hypertension, diabetes and Congestive Heart Failure (CHF) did so in 2006 61.
Bayliss et al. studied the characteristics of beneficiaries reaching the coverage gap in both 2006
and 2007 using data from a not-for-profit HMO offering many MA-PD plans and found that
reaching the gap threshold in both years was a function of existence of chronic co-morbidities
and utilization of brand-name drugs. The study, however, found that socio-demographic factors
were not significant predictors of reaching the gap64.
Impact on medication utilization and spending
A report published by the Kaiser Family Foundation in 2008 was among the first studies
to present the consequences of the coverage gap in the Medicare Part D structure62. This study
utilized the IMS Health Longitudinal Prescription Database containing information on 4.5
million Part D enrollees using medications in 2007. The researchers reported that on average,
20% of enrollees reaching the coverage gap in 2007 decreased their medication usage during the
gap phase. Of these, 15% stopped taking one or more medications after reaching the coverage
gap, while 1% reduced their medication use in some other way. The study further estimated that
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monthly OOP expenditures nearly doubled during the gap (from $104 to $196), whereas for
those who also entered the catastrophic coverage, the monthly OOP spending increased during
the gap ($207 to $408) and then decreased after reaching the catastrophic coverage (from $408 to
$285). For those who did not enter the coverage gap, overall spending was much lower
throughout the year ($26 per month). One of the biggest strengths of this study was that it used
the claims data from a nationally representative sample of PDP enrollees using some medication
in 2007. However, this is also a limitation, because not including information on beneficiaries
not using medications implies that the actual proportion of beneficiaries reaching the coverage
gap might be much lower. Another limitation of the study is that the database did not contain
information about a beneficiary‟s phase status or Low-Income Subsidy status; these were
computed by the researchers. Therefore, any coding error in these might inflate or deflate their
estimates. An additional limitation of the study is that there is no information about medications
procured from pharmacy sources not included in the database (e.g. some patients also use mailorder pharmacy - which are not included in the IMS data - to get their medications and some
pharmacies do not submit data to IMS). This could affect the spending amounts that were used to
determine whether a beneficiary entered the gap in 2007 or not.
Sun and Lee studied prescription claims data for beneficiaries aged 65 years or older who
were continuously enrolled in either PDPs or non-Part D commercial plans from January 1, 2006
through December 31, 2006 as presented in a large pharmacy benefit management database65.
The study used a pre-post with control group study design. Cases were beneficiaries enrolled in
standard PDPs who reached the coverage gap by June 30, 2006. Controls were those enrolled in
non-Part D commercial plans. Direct analysis of medication utilization and costs were done for
both groups for two time periods: January 1, 2006 through June 30, 2006 (pre-period) and July 1,
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2006 through December 31, 2006 (post-period). Among cases, the number days of therapy
decreased by 15.85% while OOP spending increased by 88.94% after reaching the gap. Among
controls days of therapy increased by 1.77% while OOP spending decreased by 5.54%. Using
difference-in-difference models, the study found that being in the coverage gap decreased
medication utilization by 187.49 days of therapy and increased OOP spending by $796.49. This
study is of significance because it estimated the impact of the coverage gap on beneficiaries
enrolled in PDPs and used a quasi-experimental study design which helped account for a number
of biases. However, the results of this study need to be interpreted with caution because the PDP
was a part of a large pharmacy benefit management program which may not have represented the
nationally enrolled Medicare population.
Raebel and colleagues analyzed pharmacy claims data of beneficiaries enrolled in one of
the several MA-PD plans offered by the Kaiser Permanente of Colorado from January 1, 2006
through December 31, 200660. The researchers measured medication refill adherence (MRA) for
oral medications used for treating diabetes, hypertension, depression and anti-hyperlipidemics as
well as beta-blockers and diuretics. In this study, cases were defined as those who reached the
coverage gap at some time in 2006 and controls were those who either did not have a gap in
coverage or those who did not reach the coverage gap in 2006. The two groups were matched
using propensity scores and the controls were then assigned index dates to indicate the pre and
post-periods corresponding to the matched cases. The findings suggest that being in the coverage
gap significantly reduced MRA rates (p-value < 0.05) for all the therapeutic classes except antidiabetics and beta-blockers. The largest significant decrease in adherence (defined as MRA >
80%) was observed for patients taking diuretics (8.3% + 29.2), followed by those using
antidepressants (6.8% + 26.3), and anti-hypertensives (5.3% + 24.7). The smallest change in
33

adherence was observed for patients using statins or other anti-hyperlipidemic agents (3.6% +
22.4). However, the study also found that the adherence rates decreased for the control group as
well. Comparing the findings after matching, it was observed that the decreases in adherence for
cases using anti-hyperlipidemics and anti-hypertensive agents were significantly greater than the
decline in adherence rates for corresponding controls (p-value = 0.031 and 0.006 respectively).
Additionally, compared to the corresponding matched cohort, beneficiaries reaching the gap also
experienced greater decreases for beta-blockers (4.9% vs. 3.2% for controls), diuretics (9.7% vs.
7.7% for controls), and anti-diabetic medications (4.0% vs. 2.8% for controls); however, these
differences were not statistically significant.
In another examination, Zhang et al. compared medication usage of beneficiaries enrolled
in the MA-PD program of a large Pennsylvania health insurer to that of beneficiaries enrolled in
employer sponsored programs66. The MA-PD program offered coverage through two plans: one
plan offered some coverage for prescription drugs in the coverage gap while the other plan did
not offer any drug coverage while in the coverage gap (cases). The employer sponsored
programs did not have a gap in coverage throughout the year (controls). The control group was
assigned index dates to correspond with the cases‟ pre-gap and within-gap periods. Medication
utilization was measured as the number of prescriptions filled before and after reaching the
$2,250 threshold where the coverage gap began in 2006. After adjusting for underlying
characteristics like socio-demographics and chronic conditions, the researchers found that those
beneficiaries who reached the coverage gap and had no coverage reduced their medication use by
14% compared to those beneficiaries who did not experience gap. By comparison, beneficiaries
with coverage for generic prescriptions during the gap decreased their medication use by only
3%.
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A recent exploration by Fung et al. utilized information on beneficiaries with diabetes
from two different MA-PD sponsors who employed different delivery systems and offered
different plans to beneficiaries67. One of the two sponsors used an integrated delivery system
setting and offered a single plan without gap coverage. The responses of beneficiaries in this
group were compared to those of beneficiaries in an employer sponsored plan with no gap in
coverage throughout the year. The other was a network-model HMO that offered two plans: one
with coverage for generic drugs during the gap and another plan without drug coverage during
the gap. The study population comprised beneficiaries continuously enrolled in the plan from
January 1, 2005 through December 31, 2006, 65 years of age or older and having used 1 or more
anti-diabetic medications in 2005. The study examined the drug spending as well as OOP
expenditure faced by beneficiaries in the two settings during the coverage gap. In addition, the
study also measured adherence to oral anti-diabetic, hypertension and lipid-lowering medications
using the Proportion of Days Covered (PDC), which was calculated from the pharmacy
dispensing data. Adherence was defined as having PDC > 80% for the entire regimen. The study
found that the drug spending was 3% and 4% lower among beneficiaries with a gap compared to
beneficiaries with no gap and generic coverage respectively. Within the integrated system MAPD, beneficiaries with a gap had 189% higher OOP expenditures compared to those without gap
(employer sponsored group) whereas for the network model HMO system, the difference was
less pronounced (14% higher OOP costs for beneficiaries without coverage compared to those
with coverage for generic drugs only). The study further found that odds of being adherent were
significantly lower for beneficiaries reaching the gap versus employer sponsored group who had
no gap within the integrated MA-PD setting for all the three therapeutic drug classes: OR= 0.83,
95% CI (0.79 – 0.88) for oral anti-diabetic drugs, OR = 0.78, 95% CI (0.74, 0.83) for

35

hypertension drugs and OR = 0.69, 95% CI (0.65, 0.73) for lipid lowering agents. However, no
significant decrease in the odds of adherence to these medications was found between the two
groups using the network-model MA-PD setting.
A common strength of the three studies using MA-PD plan data is that they used quasiexperimental designs with matched control groups that helped account for a number of biases.
However, they also share a common limitation that the generalizability of their findings is
limited by the use of data from a managed care program that has greater control over utilization
of medications by its enrollees. The generalizability of these results is further limited by the fact
that most Part D enrollees are part of stand-alone PDPs and not MA-PDs.
All the aforementioned studies utilized data from drug plans. Another set of studies
analyzed pharmacy chain dispensing data. Schneeweiss et al. analyzed data generated from
computerized pharmacy dispensing information of three large pharmacy chains47. Among their
many aims was to study the impact of Medicare Part D coverage gap on medication adherence
measured using Defined Daily Doses (DDD) and on OOP spending in 2006. The study reported
that among patients who reached the coverage gap, use of study drugs (clopidogrel, statins, PPIs
and warfarin) decreased significantly compared to their usage in previous months. This decrease
ranged from 4.8% for statins to 6.3% for warfarin. There was also an increase in OOP spending
among these patients from $12 per 30 DDDs of warfarin to $65 per 30 DDDs of clopidogrel.
Another study using data from pharmacy chains was conducted by Pedan and
colleagues63. This study analyzed data for prescription drugs dispensed to beneficiaries aged 65
years and older from November 2006 through February 29, 2008 as obtained from 2 large
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pharmacy chains. The study reported that among the beneficiaries reaching the coverage gap in
2007, medication use decreased by 9.47% compared to their pre-gap usage.
Both studies mentioned above merit attention because they used pharmacy dispensing
data irrespective of the insurance plans in which the beneficiaries were enrolled. This increases
the generalizability of the findings. The studies, however, have many limitations. The datasets
used in both the studies did not contain plan related information which limited the ability to
determine when a beneficiary entered the coverage gap. As a proxy, the researchers assigned a
beneficiary to the gap when they had total spending more than the threshold for the start of
coverage gap in the respective years and when there was a change in copayments from 25% to
90%. This, however, is an important limitation because most Part D plans are required to offer a
drug benefit similar to that proposed by the Government but not necessarily use the same
thresholds. In such a situation, some beneficiaries classified as being in the gap might not
actually be in the gap and vice versa. The datasets also did not contain information about
prescriptions received by mail-order or other pharmacies. In addition, though the studies used a
pre-post time trend design, the lack of a control group to account for the underlying temporal
trends in medication use requires that the results be interpreted with caution. Despite this, these
results continue to indicate that being in the coverage gap adversely affects medication
utilization and OOP spending for Medicare Part D beneficiaries.
The coverage gap and cost-cutting strategies
Two studies explored the cost-cutting strategies used by Medicare beneficiaries to cope
with prescription drug expenditures after reaching the coverage gap. Cronk and colleagues
conducted a review of electronic medical and pharmacy records of members continuously
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enrolled in Kaiser Permanente Colorado MA-PD plans in 2006 to identify beneficiaries with and
without a gap in coverage68. The researchers then surveyed enrollees who reached the coverage
gap by October 1, 2006 (cases) and compared their responses to those of beneficiaries enrolled in
a retiree drug subsidy plan that did not include a gap in coverage and had total spending
corresponding to the threshold for the gap (i.e. $2,250 or more) by October 1, 2006 (controls).
The questionnaire comprised 14 questions adapted from a questionnaire developed by Tseng and
colleagues to identify the cost-lowering strategy/ies used to cope with high drug expenditures.
The study concluded that the cases were three times more likely to report using a cost-lowering
strategy compared to the controls (42% vs. 14%, p-value < 0.001). In particular, beneficiaries
experiencing a gap in coverage were significantly more likely to use mail-order pharmacy
(59.7% vs. 18.0%, p-value < 0.001) or switch to other medications because of cost (32.1% vs.
10.9%, p-value < 0.001). In addition, a significantly greater proportion of the cases reported
using less medication than prescribed because of cost (29.1% vs. 11.0%, p-value < 0.001), that
they stopped taking a medication because of cost (20.1% vs. 4.6%, p-value < 0.001) or that they
did not fill a new prescription because of cost (21.8% vs. 6.1%, p-value < 0.001). An equal
number of respondents in both groups reported receiving free samples or buying medications
outside the US because of cost. Significantly greater proportions of the cases also reported
cutting back on other activities (e.g. enjoyment, paying bills) or not receiving other medical care
because of their drug costs compared to the control group. In terms of predictors of using a costlowering strategy, the study results indicate that younger beneficiaries with limited drug
coverage, lower household income and poorer health status were at a higher risk of adopting one
or more strategies to lower their prescription drug cost.
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In another investigation, Duru et al. estimated the effect of having coverage for generic
medications during the gap on self-reported CRN by beneficiaries with diabetes who were
enrolled in various MA-PD and PDP plans and who did and did not use insulin. The study setting
utilized administrative claims information on generic drugs utilized by beneficiaries aged 65
years or older in 2005 and 2006 and then administered a computer-assisted telephone interview
(CATI) to eligible beneficiaries. The responses were compared for beneficiaries using insulin to
those of beneficiaries not using insulin. After adjusting for demographic and clinical
characteristics as well as non-response rates, the researchers observed that among insulin users,
generic-only coverage was associated with significantly lower rates of self-reported CRN than
those with no coverage in the gap (16% vs. 29%, p-value = 0.03). Among the insulin users, no
significant differences were observed for reporting the use of cost-cutting strategies like
switching to other medications, or shop around for lower prices. By contrast, for the group that
did not use insulin, there was no significant difference in the rates of reported CRN but
beneficiaries without gap coverage in this group were significantly more likely to switch to a
cheaper alternative (46% vs. 36%, p-value = 0.01) and shop around for lowest prices (36% vs.
22%, p-value < 0.001).
Although both these studies indicate that beneficiaries enrolled in a Part D plan with a
gap in coverage were more likely to adopt undesirable cost-lowering strategies, it is important to
note that these behaviors were not assessed separately after reaching the gap and therefore, it
cannot be concluded that the coverage gap was the cause of patients‟ utilizing more costlowering strategies. In addition, the studies were cross-sectional surveys and therefore suffer
from limitations related to response and recall biases.
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Gaps in Literature
The preceding review of the literature indicates that although Medicare Part D has
increased utilization of prescription medications and decreased OOP costs, the coverage gap
poses a significant challenge to beneficiaries‟ adherence. A few studies provide evidence that
having partial coverage during the coverage gap is better than having no drug coverage during
the coverage gap. However, there are several limitations to the studies reviewed that need to be
addressed in future research. For example, several studies lacked use of control groups to
account for selection bias introduced by the choice of enrolling in a plan that suits the
beneficiary‟s requirements. For those studies that attempted to overcome this limitation, the
design included use of comparison groups (e.g. non-elderly) that could not be considered as
being equal to beneficiaries enrolled in Medicare Part D.
In addition, the studies have primarily focused on MA-PD plans and therefore lack
generalizability since a majority of the beneficiaries are enrolled in PDPs. Those using a more
diverse population through pharmacy chains fail to account for variability introduced by being
enrolled in plans that offer different benefit structures.
Most studies have looked at either the difference in number of medications used after
reaching the coverage gap or the difference in beneficiaries considered to be adherent after
reaching the coverage gap. While these findings are significant, it is also important to understand
the extent to which beneficiaries change their medication adherence patterns during the coverage
gap using a standardized measure of medication adherence. For example, a 5% change in use of
a medication is significantly different from a 50% change in use and this effect is not taken into
account by studying the change in number of medications used.
Our study attempts to overcome these limitations by using a quasi-experimental study
design with a control group for comparison. In addition, the study utilizes data from a nationally
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representative sample of Medicare beneficiaries enrolled in PDPs and also accounts for
variability introduced by the availability of plans that offer coverage using different benefit
structures. The following chapter describes the objectives and specific aims of this research,
followed by a chapter presenting the detailed methods used in the conduct of this study before
presenting the study results.
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CHAPTER 3:
RESEARCH OBJECTIVES AND SPECIFIC AIMS

This chapter presents the main objectives of this research as well as the specific aims to meet
each objective. In this study, the „overall final sample‟ is defined as those who meet the general
inclusion and exclusion criteria as outlined in Chapter 4. The “No Gap Coverage” group is
defined as those who had no drug coverage when they reached the coverage gap; i.e. they had a
complete gap in drug coverage during the coverage gap. The “Some Gap Coverage” group is
defined as those who had coverage for some drugs when in the coverage gap; i.e. they had a
„partial‟ gap in drug coverage during the coverage gap.

Objective 1: To identify characteristics of beneficiaries reaching and not reaching the
coverage gap in 2008
Specific Aims:
1. To review the overall demographic characteristics of the final sample of beneficiaries
2. To compare the demographic characteristics of beneficiaries who did and did not have
coverage for prescription drugs during the gap
3. To compare the demographic characteristics of beneficiaries who did and did not reach
the coverage gap
4. To examine the medication related characteristics (i.e. total number of medications taken,
total number of medications from the 7 classes being evaluated, total number of classes
under evaluation across which medications are taken, total duration for which the
beneficiaries should have been taking the medication since the first fill date) of the
overall sample of beneficiaries
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5. To compare the medication related characteristics of beneficiaries who did and did not
have coverage for prescription drugs during the gap
6. To compare the medication related characteristics of beneficiaries who did and did not
reach the coverage gap
7. To examine the plan enrollment characteristics of the final sample of beneficiaries
8. To compare the plan enrollment characteristics of beneficiaries who did and did not have
coverage for prescription drugs during the gap
9. To compare the plan enrollment characteristics of beneficiaries who did and did not reach
the coverage gap
10. To compare the changes in Out-Of-Pocket expenses of beneficiaries in the overall sample
who did or did not reach the coverage gap
11. To compare the changes in Out-Of-Pocket expenses of beneficiaries in the “No Gap
Coverage” group who did or did not reach the coverage gap
12. To compare the changes in Out-Of-Pocket expenses of beneficiaries in the “Some Gap
Coverage” group who did or did not reach the coverage gap
13. To examine the demographic characteristics of beneficiaries for each therapeutic class of
medications being evaluated (ACE inhibitors, beta-blockers, calcium channel blockers,
diuretics, oral anti-diabetic agents, oral anti-hyperlipidemic agents, and proton pump
inhibitors)
14. To examine the medication related characteristics of beneficiaries for each therapeutic
class of medications being evaluated
15. To examine the plan enrollment characteristics of beneficiaries for each therapeutic class
of medications being evaluated
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16. To compare the demographic, medication, and plan related characteristics of beneficiaries
in the “No Gap Coverage” group who did or did not reach the coverage gap for each
therapeutic class of medications being evaluated before and after matching
17. To compare the demographic, medication, and plan related characteristics of beneficiaries
in the “Some Gap Coverage” group who did or did not reach the coverage gap for each
therapeutic class of medications being evaluated before and after matching
18. To compare the demographic, medication, and plan related characteristics of beneficiaries
who did reach the coverage gap in the “Some Gap Coverage” group to those of
beneficiaries who did reach the coverage gap in the “No Gap Coverage” group for each
therapeutic class of medications being evaluated before and after matching

Objective 2: To study the entry and exit times from the coverage gap in 2008
Specific Aims:
1. To estimate the proportion of beneficiaries reaching the coverage gap in the overall final
sample
2. To estimate the proportion of beneficiaries reaching the coverage gap for the “No Gap
Coverage” and the “Some Gap Coverage” groups
3. To estimate the proportion of beneficiaries reaching the coverage gap for each therapeutic
class under evaluation in the “No Gap Coverage” group
4. To estimate the proportion of beneficiaries reaching the coverage gap for each therapeutic
class under evaluation in the “Some Gap Coverage” group
5. To identify the month by which most beneficiaries reached the coverage gap in the final
sample
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6. To identify the month by which most beneficiaries reached the coverage gap within each
therapeutic class being evaluated for the “No Gap Coverage” group
7. To identify the month by which most beneficiaries reached the coverage gap within each
therapeutic class being evaluated for the “Some Gap Coverage” group

Objective 3: To study the impact of a complete gap in coverage on beneficiaries‟ adherence
to prescription medications
Specific Aims:
1. To compare the change in medication adherence during the coverage gap for the
beneficiaries of “No Gap Coverage” group who did or did not reach the coverage gap in
each therapeutic class before and after matching
2. To examine the proportion of beneficiaries who stopped taking medications during the
coverage gap for each therapeutic class in the “No Gap Coverage” group after matching
3. To examine the proportion of beneficiaries considered adherent before and during the
coverage gap for each therapeutic class in the “No Gap Coverage” group after matching

Objective 4: To study the impact of a „partial‟ gap in coverage on beneficiaries‟ adherence
to prescription medications
Specific Aims:
1. To compare the change in medication adherence during the coverage gap for the
beneficiaries of “Some Gap Coverage” group who did and did not reach the coverage gap
in each therapeutic class before and after matching
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2. To examine the proportion of beneficiaries who stopped taking medications during the
coverage gap for each therapeutic class in the

“Some Gap Coverage” group after

matching
3. To examine the proportion of beneficiaries considered adherent before and during the
coverage gap for each therapeutic class in the “Some Gap Coverage” group after
matching
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CHAPTER 4:
METHODS

This chapter describes the methods used in the conduct of this study. It highlights the
study design and the data sources used in the study followed by sample preparation and data
analysis to meet each objective.

Study Design
This investigation employs a quasi-experimental study design with a “before-after”
intervention and matched control groups. In an experimental setting, the investigator selects a
group of people with similar characteristics and divides them into two groups: one receiving the
intervention and the other not. However, in our analysis we retrospectively explore the effect of
a “natural intervention” (the Medicare Part D coverage gap) that could have effects on
beneficiaries‟ medication usage. The following section presents the source of data used in this
study.

Database Preparation
This was a retrospective analysis of claims and denomination (demographic and
enrollment) data of a 5% random sample of all Medicare beneficiaries as provided by the CMS
through its Research Data Assistance Center (ResDAC) located at University of Minnesota. The
study utilizes four different data files from the entire database: 5% Beneficiary Summary File
with Part D denomination, 5% Beneficiary Annual Summary File, 5% Part D Event Data File
with drug characteristics (16 or less variables), and the Plan Characteristics Files for 2008. The
following sections describe the variables used from each of these data files for further analyses.
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The Beneficiary Summary File
The Beneficiary Summary File provides demographic and enrollment information about
beneficiaries. Beginning in 2006, this file also provides Part D enrollment information. Table 1
shows the variables utilized from this file.
Although the Beneficiary Summary File provides information about most of the
demographic characteristics of the patients, it does not contain information about their income.
Therefore, the next section outlines the methods to determine beneficiaries‟ median household
income.
Table 1: Variables used from the Beneficiary Summary File
Variable Name

Description

BENE_ID

Encrypted beneficiary ID

SSA_STATE_CD

State code of the residence of a beneficiary

BENE_ZIP_CD

Zip code of the mailing address of a beneficiary

BENE_SEX_IDENT_CD

gender of the beneficiary

BENE_RACE_CD

race of the beneficiary

ESRD_SW

presence or absence of End-Stage Renal Disease

BENE_AGE_AT_END_REF_YR

Chronological age of the beneficiary at the end of the
year

CST_SHR_GRP_CD_01 – 12

Beneficiary‟s subsidy and/or co-pay status for each
month

RDS_IND_01 – 12

Retiree drug subsidy for each month

DUAL_STUS_CD_01 – 12

Medicaid eligibility by state for each month

PLAN_CVRG_MOS_NUM

Total number of months of Part D plan coverage

BENE_HMO_CVRAGE_TOT_MONS Total number of months in HMO coverage
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Calculating Median Household Income
The median household income for the beneficiary‟s zip code was calculated from the US
Census 2000 data. The paragraphs that follow present the methods to generate the income
information based on the beneficiary characteristics.
The zip code level information compatible with the CMS Beneficiary Summary File was
not directly available through the Census website. Therefore, we used the ZCTA 2000 File
available

through

the

Research

Triangle

Institute

https://rtispatialdata.rti.org/Download/Data/tabid/56/Default.aspx.69

(RTI)

website

at

Although this data file is

created from various sources, the median household income by zip code is extracted from the
Census 2000 data. We used three variables from this file: P056007, median household income in
1999 dollars age 65 – 74 years and P056008, median household income in 1999 dollars age 75+
years, and Location_Code; the 5-digit zip code. The zip code variable in The Beneficiary
Summary File (Bene_Zip_Cd) provided the full 9 digit mailing zip code of a beneficiary.
Therefore, it was re-formatted to retain the first 5 digits to correspond with the 5-digit zip code
available from the RTI datafile. This new variable was named Location_Code to maintain the
same variable name as available from the RTI datafile. The Beneficiary Summary File and the
income file generated from the RTI database were then sorted and merged by zip code (variable:
Location_Code) to include the two income variables in the denomination file.
A new income variable (variable: Income) was then created using the age information
from the denomination file and the two income variables used from the RTI file. This new
income variable contained information representing the beneficiary‟s median household income
based on their zip code and age. These income values were then converted to 2008 dollar values
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using the Consumer Price Index (CPI) values for years 2000 through 2008 as explained in the
next paragraph.
The CPI is a measure of the average change over time (generally a year) in the prices
paid by urban consumers for a market basket of consumer goods and services 70 (e.g. food and
beverages, transportation, housing, and medical expenses). The average annual change is
calculated as a percentage; therefore, each value representing the percent change was converted
to a number representing the proportional change adjusted for inflation over the last year. For
example, the CPI value for 2000 was 3.4%. This means that the inflation-adjusted equivalent of
1999 dollars in 2000 would be 103.4% of the 1999 value. In other words, in order to purchase
the same product (that was worth $100 in 1999) in 2000, one needs to pay $103.4. For simplicity
of calculation, we have converted all the percent change values to proportions. For example, if
1999 dollar value is 1, then with a 3.4% annual inflation rate, the 2000 value would be 1.034.
Since we wish to convert 1999 dollars to 2008, we need to account for annual inflation rates
throughout this period (Table 2).
Table 2: Consumer Price Index 2000-2008
Year

Annual %

Annual Proportion

2000

3.4

1.034

2001

2.8

1.028

2002

1.6

1.016

2003

2.3

1.023

2004

2.7

1.027

2005

3.4

1.034

2006

3.2

1.032

2007

2.8

1.028

2008

3.8

1.038

Source: Bureau of Labor Statistics Available at http://www.bls.gov/cpi/data.htm71
The following equation represents the formula used to obtain the 2008 dollar values.
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𝟐𝟎𝟎𝟖 𝑫𝒐𝒍𝒍𝒂𝒓 𝑽𝒂𝒍𝒖𝒆
= 𝟏𝟗𝟗𝟗 𝑫𝒐𝒍𝒍𝒂𝒓 𝑽𝒂𝒍𝒖𝒆
× 𝑪𝑷𝑰′ 𝟎𝟎 × 𝑪𝑷𝑰′ 𝟎𝟏 × 𝑪𝑷𝑰′ 𝟎𝟐 × 𝑪𝑷𝑰′ 𝟎𝟑 × 𝑪𝑷𝑰′ 𝟎𝟒 × 𝑪𝑷𝑰′ 𝟎𝟓 × 𝑪𝑷𝑰′ 𝟎𝟔
× 𝑪𝑷𝑰′ 𝟎𝟕 × 𝑪𝑷𝑰′ 𝟎𝟖
= 𝟏𝟗𝟗𝟗 𝑫𝒐𝒍𝒍𝒂𝒓 𝑽𝒂𝒍𝒖𝒆 × 𝟏. 𝟐𝟗𝟐

The Beneficiary Annual Summary File (BASF)
The BASF provides diagnosis and date of diagnosis of 21 chronic conditions. This file is
used to identify whether a beneficiary was suffering from chronic obstructive pulmonary disease
(COPD), chronic kidney disease (CKD), and/or any type of cancer. Specifically, the variables
presented in Table 3 were scanned for a date of diagnosis and if there was a date of diagnosis for
either of these variables for a beneficiary, then they were excluded from further analyses.

Table 3: Variables used to identify beneficiaries with COPD/CKD/Cancer
Variable

Description

CNCRBRSE

Earliest indication of Female Breast Cancer

CNCRCLRE

Earliest indication of Colorectal Cancer

CNCRPRSE

Earliest indication of Prostate Cancer

CNCRLNGE

Earliest indication of Lung Cancer

CNCENDME

Earliest indication of Endometrial Cancer

CHRNKDNE

Earliest indication of Chronic Kidney Disease

COPDE

Earliest indication of Chronic Obstructive Pulmonary Disease
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The Part D Event Data File and the Plan Characteristics File
The Part D event (PDE) data and the Drug and Plan Characteristics Files contain
elements that provide information on beneficiary demographics, plan characteristics, drug
characteristics (e.g. NDC number, days of supply, quantity supplied, and fill number) and
payment characteristics (e.g. patient paid amount, and Part D paid amount). The PDE data come
directly from the plan sponsors; however, they are not the same as individual drug claim
transactions recorded by the plan sponsors. Instead, these data are summary extracts using CMSdefined standard fields to facilitate payments to the plan sponsors. Table 4 lists the variables used
from the PDE data and the drug characteristics files. These variables were required to determine
the beneficiary‟s gap status, adherence, and costs incurred by the beneficiary. In addition, the
drug characteristics file was used to determine the generic equivalency of different medications
as determined by the First Databank, whereas the plan characteristics file helped us identify the
variation in benefit structures across plans. Specifically, the plan characteristics file was used to
determine whether a particular plan was PDP or MA-PD, whether it offered coverage for some
or all drugs during the coverage gap or not, whether it charged a deductible, used standard or self
determined coverage gap threshold and the type of cost-sharing used before reaching the
coverage gap. All the data files noted above can be linked using the de-identified variable called
Bene_ID. The Part D utilization files, however, did not identify a drug‟s therapeutic class. This
information was obtained from the First Databank proprietary classification system using the
NDC information provided in the Part D utilization files72.
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Table 4: Variables included from Part D utilization file
Variable Name

Description

BENE_ID

Encrypted Beneficiary ID

SRVC_DT

Date on which the prescription was filled

PROD_SRVC_ID

National Drug Code (NDC) number

QTY_DSPNSD_NUM

Number of dosage units dispensed (Quantity dispensed)

DAYS_SUPPLY_NUM

Number of days‟ supply of medication dispensed

FILL_NUM

Fill number of the current dispensed supply

DRUG_CVRG_STUS_CD

Drug Coverage status code (Part D covered or not)

CTSTRPHC_CVRG_CD

Catastrophic coverage code

PTNT_PAY_AMT

Non-reimbursed beneficiary paid amount

OTHR_TROOP_AMT

Payments that contribute to True Out of Pocket amount

CVRD_D_PLAN_PD_AMT Net amount paid by Medicare Part D for a „covered‟ drug
BENEFIT_PHASE

Benefit Phase of the Part D event

Drug Characteristics
BN

Brand Name of drug reported from First Data Bank

GNN

Generic Name of the drug reported from First Data Bank

GCDF

Dosage Form Code

GCDF_DESC

Dosage form code description

Plan Characteristics
ORGANIZATION_TYPE

Type of organization (PDP, MA-PD etc.)

GAP_COVERAGE_TYPE

Type of coverage offered in the gap

DRUG_BENEFIT_TYPE

Medicare Standard benefit or an equivalent benefit

DED_APPLY

How the deductible applies (if any)

PRE_ICL_APPLY

How the pre-coverage gap cost-sharing applies

ICL_APPLY

How the coverage gap cost-sharing applies
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The following figure summarizes the steps involved in preparing the database for sample
selection

Beneficiary Summary File

RTI Zip code level Income
File

Beneficiary Annual
Master Dataset for
further analyses

Summary File

Plan Characteristic Files

Part D Event Data
and Drug Characteristic

Therapeutic Class File
First DataBank

Files

Figure 3: Methods to prepare the Dataset for sample selection
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Selecting the sample of beneficiaries: general inclusion and exclusion criteria
The study examined the sampled beneficiaries‟ prescription drug usage of orally
administered drugs from the following seven therapeutic classes: anti-diabetic agents, antihyperlipidemic agents, beta-blockers, diuretics, angiotensin converting enzyme (ACE) Inhibitors,
calcium channel blockers, and proton-pump inhibitors (PPIs). These classes have been identified
by the Centers for Disease Control and Prevention (CDC) as a part of the 15 most widely used
classes of medications among community-dwelling seniors aged 65 years and over73. The
remaining classes of medications in this group could be used for either acute or chronic purposes
(e.g. pain medications, thyroid hormones, sex hormones, anti-histamines, anti-convulsants and
anxiolytics and antidepressants). The last class of drugs identified in this list by CDC is
„bronchodilators‟ which are generally used in aerosol format and hence excluded from analysis.
Beneficiaries were included in the analysis if they met the following inclusion criteria


Age 67 years and older: We include beneficiaries who were aged at least 67 years by the
end of the 2008. In other words, only those beneficiaries who are aged 66 years or more
in 2008 are included in our sample. By doing so, we ensured that the study population
had at least one full year of Medicare enrollment.



Enrolled in stand-alone prescription drug programs (PDPs) from January 1, 2008 through
December 31, 2008 (in other words, no MA-PD enrollees).



Non-subsidy recipients: The study aims to quantify the change in adherence rates after
entering the coverage gap and hence does not include beneficiaries who are dually
eligible for Medicare and Medicaid or who receive low-income subsidies (LIS) because
these beneficiaries are not subject to the coverage gap.



Alive at the end of 2008
55



Do not have cancer, COPD or end stage renal disease (ESRD): these beneficiaries are
excluded from our analysis because they have a different medication utilization and
spending pattern compared to the beneficiaries with other disease conditions



The specific medication related criteria for inclusion was that the beneficiary be taking at
least one oral medication (defined as either tablet or capsule) from one or more of the
above mentioned therapeutic classes for more than 90 days (at least 2 fills).
Following the selection of beneficiaries who met the above criteria, the sample was

further divided into groups based on presence of drug coverage during the gap
(„Gap_Coverage_type‟ = 10, and 20, 30, or 40). This resulted into creation of two groups: One
with some coverage in the gap (the „Some Gap Coverage‟ group with N = 8,529) and another
without any coverage in the gap (the “No Gap Coverage” group with N = 164,551). Within these
two groups, beneficiaries were further divided into individual 7 therapeutic classes based on their
medication use.
Within each class of medication evaluated, beneficiaries included for final analyses must
have had the first prescription in the class filled by March 31, 2008. Since no information was
available for the dates of diagnoses for most diseases treated by medications in the above
mentioned therapeutic classes, this criterion serves as a proxy to identify „established chronic
users‟ of medications only. We intended to include “established chronic users” only because
research has shown that the medication utilization pattern differs with the duration since the
disease is diagnosed74-76. We extended the first fill date to March 31, 2008 instead of January 1,
2008 to account for the receipt of a 90 day supply of a drug by December 31, 2007. i.e. if a
beneficiary refilled a prescription on December 31, 2007 for a 90 day supply, that medication
would last till March 30, 2008 and the beneficiary would need to refill it by March 31, 2008.
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If a beneficiary took medications from more than one class then he or she was included in
the analysis of all applicable classes. Figure 4 summarizes the creation of the required datasets
from the Master Dataset. The sections following Figure 4 present the methods of selecting and
preparing the sample to study the effect of losing all or some coverage while in the coverage gap
on medication adherence of beneficiaries meeting the general inclusion and exclusion criteria.

Master Dataset (all
beneficiaries)
N = 2,631,860

Inclusion Criteria:
 Age: 67 years or older at the end of the year
(Alive)
 Enrolled in PDPs for full year
 No Subsidy or Dual Eligibility
 No Cancer, COPD or ESRD

Selected Beneficiaries
N = 260,805
Medication related criteria:
 Take Tablets or Capsules in one or
more medications in one or more of
the designated 7 classes
Final Dataset
N = 173,080
Gap Coverage

No Gap Coverage

Some Gap Coverage

N = 164,551

N = 8,529

Figure 4: Methods for selecting the samples for the study
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Methods to prepare the sample for each analysis
To test the different hypotheses of this study, it was necessary to create different
comparison groups from the overall sample at a therapeutic class level based on whether or not
the beneficiaries had coverage for drugs while in the coverage gap. For each comparison, the
cohort of selected beneficiaries was divided into an intervention group and a matched control
group. A control group is required in the study to account for biases introduced by variation in
the baseline characteristics of the beneficiaries as well as their choice of enrolling in different
plans. Patients in the intervention group (for each analysis) were identified from the claims
database as those who met the afore-mentioned criteria and had at least one record of „PI‟, or II‟
values (indicating coverage gap) for the variable „benefit_phase‟ in the Part D event file. The
remaining records were used as potential controls. Thus, the potential control group consisted of
beneficiaries who did not experience the coverage gap during the year („Benefit_Phase‟ = „DD‟,
„DP‟ or „PP), and those who were catastrophically high spenders and skipped the coverage gap
by entering the catastrophic coverage phase after the initial coverage („Benefit_Phase‟ = „PC‟).
The latter are excluded from further analysis. The two groups (who did and did not reach the
coverage gap for each analysis) were then analyzed individually and also after being matched
using a propensity score technique.
Propensity Scoring
Propensity scores are useful in controlling for selection bias in situations where the
experimental units are not allotted to the treatment groups in a random fashion and therefore
have different distributions of the baseline covariates. A propensity score for an individual is
“the conditional probability of his or her treatment given the observed pretreatment covariates”77.
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Thus, units with similar propensity scores will tend to have similar levels of the covariates;
thereby removing bias due to the covariates from the estimates77.
Generally, a logistic regression is performed to calculate one‟s propensity to get one
treatment over the other with the dependent variable being the treatment received (variable with
1 and 0 values depending on the group they are in)78. While there is considerable debate about
which variables should be included as independent variables, a recent study done by Austin et
al.79 employed Monte Carlo simulations and found that “including only the true confounders
(those that are associated with both treatment assignment and outcome) resulted in greater
precision in estimating the treatment effect compared to the model that included variables
associated with treatment assignment or outcome alone.” The researchers concluded that this was
because the model that included scores calculated using the true confounders had the lowest
Mean Square Error (MSE) estimate among all the four models and also resulted in 24% more
matched pairs compared to any other model79. Therefore, only the „true confounders‟ will be
included in estimating the propensity scores in our study.
Following the calculation of propensity scores, the selection bias can be accounted for in
one or more of the following three ways: stratification, adjustment in the regression analysis and
matching78. Each of these techniques is a way to make an adjustment prior to or while
calculating the treatment effect. Matching helps in removing the bias before calculating the effect
whereas regression adjustment is made during the calculation. Stratification can be used in either
way. The following sections provide brief description for each method.
Stratification involves ranking of the observations based on the propensity scores and
dividing them into various strata based on their scores. Thus, in this method, observations with
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similar propensity scores are grouped together for the analysis. The outcome is then analyzed by
strata and a weighted estimated mean is obtained per stratum. The results for each stratum are
then combined and analyzed. Another method to analyze the information using stratification is to
incorporate the strata in the multivariate analysis 77, 78.
Another technique is to use the propensity score as an additional variable during the
regression analysis and not use the variables used to generate this estimate. This can take into
account the bias created by non-equivalent distribution of the variables between the two groups.
Matching is generally employed when the sample size is large and when there are
sufficient number of controls to match with the intervention group. If the sample size is not large
enough, then removing those cases and controls that do not match will reduce the size of the
sample and result in loss of power77, 78. If this technique can be used, then the procedure is to
match the observations in the two groups on their propensity scores and then analyze the
significance of differences in outcomes between the two groups using techniques for nonindependent samples (or matched pairs).
Objective: To quantify the change in medication adherence among beneficiaries who had “No
drug coverage” during the coverage gap
Within the “No Gap Coverage” group, for each therapeutic class of medications to be
analyzed, the beneficiary records were classified as being in the gap versus. not being in the gap
using the criteria mentioned earlier. The purpose of this analysis was to study the impact of
completely losing drug coverage during the coverage gap as compared to having stable coverage
throughout the year. Ideally, to attain this aim, we needed to have a control group that reached
the coverage gap and had no change in the coverage during the gap. Since our data did not

60

permit the use of such a control group, we compared the effects of losing coverage to those who
did not reach the gap in 2008. This is because it can be inferred that by not reaching the coverage
gap at any point in 2008, the beneficiaries maintained continuous coverage for their medications
throughout the year.
To account for the variation introduced by baseline characteristics as well as for the bias
introduced by the voluntary enrollment in the Medicare Part D programs, the two groups were
matched based on the propensity of a beneficiary to fall in the coverage gap (treatment
assignment). This was calculated by performing a logistic regression with Dependent variable =
“gap status” where (0 = No Gap and 1 = Gap) and covariates mentioned in a later section.
Objective: To quantify the change in medication adherence among beneficiaries who had
“some drug coverage” during the coverage gap
For this part of the analyses, we compared the group that reached the coverage gap and
continued to have some coverage for their prescription drug expenses to two groups. First the
group that retained some coverage during the gap was compared to the group that did not reach
the gap from the “Some Gap Coverage” group. The purpose of this comparison is to compare the
effectiveness of having some coverage during the gap to not losing the coverage throughout the
year. Again, as with the analysis to study the effect of losing complete coverage during the gap;
we needed to adjust for selection bias as well as variation introduced by differences in
beneficiaries‟ baseline characteristics. To do so, we again calculated the propensity of reaching
the gap (dependent variable = „Gap‟ where 0 = No Gap and 1 = Gap) and the independent
variables being those described in the next section.
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For the second part of the analyses, the change in these beneficiaries‟ adherence patterns
was compared to the change in adherence patterns of the group that reached the gap and lost all
coverage upon reaching the gap. Here, both the groups reached the coverage gap at some point in
the year; however, we did have to account for the selection bias introduced by the choice to
enroll in a plan with or without gap coverage rather than being randomly assigned to each plan.
In addition, the variation introduced by the baseline characteristics of the two groups also needed
to be adjusted for. Therefore, for this part of the analyses, we estimated the propensity of a
beneficiary being enrolled in a plan that offered some coverage during the gap (treatment
assignment dependent variable = „Gap_Coverage‟ where (0 = No Coverage and 1 = Coverage))
based on the independent variables explained in a later section.
Independent variables for propensity score calculation
In this study, the propensity scores were separately calculated for all comparison groups
for all therapeutic classes based on age, race, gender, income, the Chronic Disease Score (CDS),
total number of medications taken by the beneficiary, the duration of prescribed medication, drug
benefit type, and type of cost sharing in each phase of Part D. These variables are identified as
those that are known to be associated with experiencing the coverage gap (treatment) as well as
medication adherence (outcome). The effect of these variables on reaching the coverage gap has
been described elsewhere. The following paragraphs briefly describe how these variables affect
adherence to medications
Socio-demographic factors
Age: The effect of age on medication adherence is not clear. Some studies conclude that younger
patients are likely to be less adherent than older patients75, 80-83, whereas several others conclude
that age is not a significant predictor of adherence 84-87.
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Gender: Gender is found to be uncorrelated with adherence in general, with the exception of a
few studies that did find differences in adherence rates among males and females28, 81, 85.
Race: Race is a significant predictor of adherence with non-Caucasian race being significantly
associated with lower adherence76, 80, 83, 86, 88-91. For example, Steinman et al.
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found that non-

Caucasian Americans were almost 3 times more likely to report reduction in medication use
when faced with higher costs compared to Caucasians after controlling for income, drug
coverage and health status variables.
Financial factors
The literature indicates that low income translates into more cost related medication adherence 21,
22, 41, 92, 93

. Additionally, it has been established that absence of insurance coverage, as well as

having caps or gaps in coverage, leads to medication non-adherence9.
Medical factors
Disease-Related: The literature on effects of co-morbidities on medication adherence is less
conclusive. Some articles conclude that co-morbidity is not a significant predictor of medication
adherence85, 86 but others conclude that higher numbers of disease conditions led to higher rates
of non-adherence21,

41, 92, 93

. Depression is also often cited as a predictor associated with

significantly lower adherence rates among patients across a range of different chronic
conditions83, 94-96.Studies also suggest that the longer the duration of diagnosis of a disease, the
more likely a patient is to adhere to the therapy75, 76, 97
Medication-Related: Evidence clearly suggests that an increase in the frequency of
administration of medications decreases adherence rates74, 75, 82, 98, 99 . In other words, regimens
that require taking medications several times a day leads to lower adherence rates. However, the
effect of number of prescriptions taken is not clear. For example, Col et al.28, Coons et al.85,
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Donnan et al.75 as well as Mateo et al.97 report that the rates of non-adherence increase with an
increase in the number of prescriptions taken, whereas Grant et al.100 and Shalansky et al.101
conclude that non-adherence decreases with an increase in the number of prescription
medications taken.
Most of the above mentioned variables were directly available from the database. The
following paragraphs present the methods to calculate the variables that were not obtained from
the database.
1.

Calculating the CDS

Von Korff et al. used automated pharmacy data from an HMO for one year to calculate a
measure of severity of chronic diseases based on consensus of a multidisciplinary team of
physicians, pharmacists, epidemiologists and health service researchers102. This measure is called
the Chronic Disease Score or CDS. The CDS is calculated by grouping individual medications to
their respective therapeutic classes and then assigning weights (scores) to the classes depending
on the severity of the disease for which the class of medications is primarily used. The CDS
assigns greater scores to potentially life-threatening and advanced disease conditions that require
simultaneous use of medications from several therapeutic classes. By doing so, the CDS provides
a measure of severity of illness by taking complexity of regimen and progress of the disease
condition into account102.
Originally, the CDS was developed to represent 30 therapeutic classes and was validated
to predict hospitalization as well as mortality. From the results of their analyses, Von Korff et al.
concluded that a CDS of 7 or greater was associated with a 5 fold increase in risk of
hospitalization and a 10 fold increase in risk of mortality compared to CDS of 0102. The CDS
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was found to be a significant predictor of hospitalization and death even after adjusting for age,
gender and ambulatory care visits. Several studies have replicated and/or extended the validity of
the CDS since its development in 1991. Over time, the CDS has been shown to have good testretest reliability, construct validity with the RAND-36 instrument, and good predictive validity
for hospitalizations, mortality and health care visits103-109. Since we are assessing the adherence
patterns for selected classes of medications, the computation of the CDS for our study required
modification of the original algorithm (which was based on 30 therapeutic classes102). Table 5
describes the classes and associated weights involved in the calculation of the CDS for this
study.
Table 5: Chronic Disease Score Calculation
Disease Indicator

Therapeutic Class

Score/Weight

Heart Disease

ACE Inhibitors

3

Hypertension

Calcium channel blockers

2

Beta-blockers

1

Diuretics

1

Diabetes

Oral Anti-diabetic Agent

2

High Cholesterol

Anti-hyperlipidemics

1

Peptic Ulcers

Proton Pump Inhibitors

1

2.

Calculating total number of medications taken

The total number of medications was calculated as the total number of distinct generic
medications taken by a beneficiary who meets the inclusion criteria for this study. Thus the total
number of medications taken by a beneficiary included the medications taken within the 7
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therapeutic classes evaluated as well as medications from other classes not being evaluated for
adherence.
3.

Calculating the total duration of prescribed medication

The total duration of a medication prescribed in any class was calculated as the number
of days between the first fill date and December 31, 2008. Thus, for example, if a beneficiary
had their first fill on January 1, 2008 then the total number of days that they should be taking the
medication was calculated as (days between January 1, 2008 and December 31, 2008)
irrespective of whether or not they reached the coverage gap.
Propensity Score Matching
Following calculation of propensity scores, for each comparison in this study, we
matched the two comparison groups (e.g. those reaching the coverage gap were matched to those
who did not in the “No Gap Coverage” group) using the propensity score based Greedy 5

1

digit matching technique for SAS110. In this technique, propensity scores are arranged in
decreasing order and then observations are attempted to be matched on the first 5 digits of the
score. If all cases are not matched, then a four digit match is attempted. This process is repeated
until matches are attempted on the first digit of the propensity score. This maximizes the number
of matched pairs formed while minimizing error. Observations that cannot be matched using this
technique are excluded from the analysis.
Observations in the matched control group were then allotted index dates to match the
time of entrance into the coverage gap for the corresponding case. Thus, for example, if a
beneficiary in the intervention group entered the coverage gap on August 1, 2008, and remained
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in the gap for the rest of the year, he or she would have a “before” the intervention (coverage
gap) period of January 1, 2008 until July 31, 2008 and an “after” the intervention period of
August 1, 2008 through December 31, 2008. The matched control is then assigned an index date
of August 1, 2008 and in this particular example, his or her “before” period was from January 1,
2008 through July 31, 2008 and the “after” period was from August 1, 2008 through December
31, 2008. This design allowed analyses of the two groups controlling for variation in baseline
characteristics as well as potential secular trends that can affect adherence rates irrespective of a
beneficiary‟s gap status. The methods used to calculate medication adherence are outlined in the
next section.
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Measuring Medication Adherence
Methods to assess medication adherence include self-reporting, pill counting, patient
diaries and using claims data111. In this study, pharmacy claims data were used to measure
beneficiaries‟ adherence to prescribed medications in 2008. The use of retrospective claims data
for assessing adherence generally requires slight alteration of the theoretical definition presented
earlier, because claims data do not provide information on the act of taking the medication as
indicated. Thus, for assessing adherence from claims data, the definition was operationalized as
“the number of doses dispensed in relation to the dispensing period”19.
Several methods of measuring adherence to medications using retrospective claims data
have been proposed so far; however, the superiority of one method over the other is yet to be
ascertained. These methods include but are not limited to calculating gaps in filling prescriptions,
proportions of days covered and Medication Possession Ratio111. This study uses the most
popular measure of calculating medication adherence using claims data: Medication Possession
Ratio (MPR )112.
MPR is calculated using the formula noted below:
𝑴𝑷𝑹 =

𝑵𝒖𝒎𝒃𝒆𝒓 𝒐𝒇 𝒅𝒂𝒚𝒔 𝒐𝒇 𝒎𝒆𝒅𝒊𝒄𝒂𝒕𝒊𝒐𝒏 𝒔𝒖𝒑𝒑𝒍𝒊𝒆𝒅 𝒘𝒊𝒕𝒉𝒊𝒏 𝒕𝒉𝒆 𝒓𝒆𝒇𝒊𝒍𝒍 𝒊𝒏𝒕𝒆𝒓𝒗𝒂𝒍
𝑵𝒖𝒎𝒃𝒆𝒓 𝒐𝒇 𝒅𝒂𝒚𝒔 𝒊𝒏 𝒕𝒉𝒆 𝒓𝒆𝒇𝒊𝒍𝒍 𝒊𝒏𝒕𝒆𝒓𝒗𝒂𝒍

This is usually calculated by summing the number of days supplied for all but the last
refill, divided by the number of days between the first and the last refill. Therefore, at least two
fill dates are required to calculate this ratio.
Since we wanted to assess adherence levels before and during the coverage gap for each
comparison group in each therapeutic class, we calculated different MPR values for each period
for both the cohorts in each therapeutic class. The MPR for the time when a beneficiary was not
in the coverage gap was calculated as follows: The numerator equaled the total days of supply
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between the first fill in 2008 and the last refill before the date that the beneficiary entered the
coverage gap plus the days of supply between the last fill and the first date of reaching the
coverage gap. The latter was calculated by splitting the days of supply obtained with the last fill
to match the number of days left before reaching the coverage gap and carrying forward the
remaining into the coverage gap phase calculations (the same time period was used for the
matched control). The denominator was calculated as the total number of calendar days between
the day the beneficiary first reached the coverage gap and the date of first fill.
The MPR within the period when the beneficiary was in the coverage gap was calculated
as follows: the numerator equaled the total days of supply between the refill when the
beneficiary reached the coverage gap in 2008 and the refill when the beneficiary reached
catastrophic coverage or December 31 in 2008; whichever came first (the same time period is
used for the matched control). The denominator equaled the maximum of total number of
calendar days between the two fill dates used in the numerator and the total number of days a
beneficiary spent in the coverage gap. This is because when beneficiaries reach catastrophic
coverage, they are no longer in the coverage gap. However, if beneficiaries do not reach
catastrophic coverage by the end of December, they are still out of the coverage gap because
they re-enroll in the plan beginning January of every year. Again, the excess days of supply
before and during the coverage gap is split to match the corresponding days in that phase and the
remaining are carried over into the next phase. If a beneficiary ended the year in the coverage
gap phase but did have days of supply more than the days in the gap, then the excess days of
supply were excluded from the analysis
In this study we calculated adherence to solid oral dosage forms (tablets and capsules)
from one or more of the therapeutic classes mentioned earlier only. Generic drugs are
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therapeutically equivalent to the corresponding brand name drugs. Hence, if a beneficiary
switched from a brand name drug within a therapeutic class to a therapeutically equivalent
generic drug in the same class during the study period (e.g. from Zocor® to simvastatin), he or
she was considered as continuing with the same therapy in the calculation of MPR. Additionally,
the study examines changes in adherence rates by therapeutic class and hence substitution to a
chemically different but therapeutically equivalent drug within the same class (e.g. from
Lipitor® to Zocor®) was also considered as continuing with the same therapy in the calculation
of the MPR. However, switching between classes (e.g. from beta-blockers to diuretics for
hypertension) was not considered as being adherent. Beneficiaries taking medications from
multiple therapeutic classes were included in the analysis of every applicable class.

70

Measuring proportion of beneficiaries considered adherent before and during the coverage
gap
MPR can be presented as a continuous measure of adherence or dichotomized into
“adherent” or “non-adherent” groups. We used the most common threshold for this
dichotomization: MPR value ≥80% was classified as adherent and those with MPR < 80% were
classified as non-adherent.
The first use of 80% as a cut-point was a study done by Psaty et al. in 199023. This study
examined the relation between adherence to hypertensive medications and risk of developing
myocardial infarction. The researchers did not mention any rationale for selection of this cut-off,
just that „it was assumed to be 80%‟. This was a randomized clinical trial that found that patients
with less than 80% adherence to their medication (as measured by calculating MPR from a
computerized pharmacy database) have a 4 fold increase in risk of developing acute cardiac
events. As it appears, this was a disease specific measure.
Over the last decade, there has been an increasing interest to evaluate whether being
adherent to medications more than 80% of the time provided any clinical benefit. Several studies
done in this time period have concluded that having MPR value ≥ 80% significantly improved
clinical outcomes and/or reduced healthcare utilization and costs for specific disease condition
and studies indicate that there are significant improvements at and beyond this threshold. For
example, a study by Lau et al. found that among patients taking oral hypoglycemic agents to
control their diabetes, those who had MPR values less than 80% had higher odds of being
hospitalized compared to those who had MPR ≥ 80% (odds ratio: 2.53, with significant 95%
CI)113. A recent study by Karve et al. examined the validity of different cut-off values of MPR in
terms of predicting hospitalizations in a large Medicaid population database (predictive
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validity)114. This study found that the optimal cut-off value for MPR to predict any cause
hospitalization ranged between 0.63 and 0.89 and for disease specific hospitalization, the values
ranged from 0.58 to 0.85. Thus, it concluded that it is reasonable to select 0.80 as the cut-off
point. Hansen et al.
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attempted to measure the convergent validity of the measure with other

measures of adherence (patient self-report and electronic adherence measures) at different cut-off
points. This study found that at the widely used cut-point (80%), there was a balance between the
sensitivity and specificity in classifying the subjects with heart failure or hypertension for all
measures and that they correlate well with each other at this point. This study has limited
generalizability because it was conducted on patients with a specific disease condition. However,
both of these studies provide an empirical basis for using 80% as the cut-off value in classifying
patients as being adherent and non-adherent
Thus, we expect that using 80% as the cut-off in our study provides information of
practical relevance for policy makers and define a beneficiary as being adherent if their MPR
value is 0.8 or greater. This analysis is done by therapeutic class and by presence or absence of
drug coverage during the coverage gap after matching for both the groups that did or did not
reach the coverage gap.
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Measuring proportion of beneficiaries who stopped taking their medications during the
coverage gap
In this analysis, we examined the proportion of beneficiaries who stopped taking their
medications after reaching the coverage gap for each therapeutic class. This analysis was done
after matching to examine the effect on the matched control group as well. For this purpose, we
defined a person to have stopped taking their medications in the coverage gap phase if they were
found to have reached the coverage gap but had no days of supply (as calculated earlier) of
medications for that time. For example, if we assume that a person reached the coverage gap on
December 1, 2008 but had a 90 day supply of medications dispensed to him/her on October 1,
2008 This was included in the analysis by splitting the 90 day supply received on October 1 into
a 60 day supply before the gap and 30 day supply in the gap. Thus, it would not appear as if the
beneficiary discontinued the medication during the coverage gap phase. However, if the
beneficiary received a 30 day supply on October 1 and did not have any refill thereafter, then it
would indicate that s/he stopped taking his/her medications.
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Data Analyses
The following sections describe our data analysis:
Descriptive analyses
We performed several types of descriptive analyses. First, we studied the entire final
sample in terms of their demographics (age, race, gender, income), total number of medications
used, and out of pocket costs. The results were reported as means and standard deviations for the
following variables: age, income, total number of medications used and out-of-pocket costs. The
variables „race‟ and „gender‟ are reported as percentage of Caucasian population and percentage
of males and females respectively.
Next, we identified the percentage of beneficiaries who entered the coverage gap in 2008
overall and for each therapeutic class as well as months spent in the coverage gap. Following
this, within each therapeutic class, we studied the characteristics of beneficiaries who reached the
coverage gap in 2008 to understand their demographics, month of entry in the coverage gap,
CDS, total duration for which they should have taken their medication and total number of
medications as well as plan characteristics. For all variables except the median annual household
income (which was reported as median), results were reported as means and standard deviations
for all the continuous variables (age, total medications, total duration and CDS). As before, race
and gender are expressed as percentages. In addition, the percentage of beneficiaries having no
deductible, tiered cost-sharing and Medicare defined standard gap threshold were also reported
for each therapeutic class.
We performed similar analyses for the group that did not reach the coverage gap to study
the differences in the baseline characteristics of the two groups before matching. Appropriate
tests for significance in differences are reported in the next chapter depending on the variable
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type. In general, the significance of differences between the two groups for the categorical
variables was assessed by chi-square tests whereas that for the continuous variables was assessed
using the Wilcoxon Rank Sum Test.
The two groups were reassessed on the same variables after matching to check the quality
of matching. However, since the two groups were now matched pairs, the underlying assumption
of using independent samples in comparisons using the Wilcoxon Rank Sum test as well as Chisquare test is violated. Therefore, we used the appropriate tests of significance for paired data.
For continuous variables, we used the Wilcoxon Signed Rank Test whereas for categorical
variables the significance of difference was assessed using the McNemar‟s test.
Measuring the Impact of Coverage Gap on Adherence
We studied the impact of coverage gap on adherence rates to medications prescribed in
different therapeutic classes mentioned earlier. The main outcome of interest was change in
adherence to prescription medications after reaching the coverage gap. This was measured as a
difference of MPR before and MPR after reaching the gap. This value was obtained for each
beneficiary for both the treatment and the control group. The statistical significance was then
measured using the Wilcoxon signed rank test which tests for a significant difference between
the paired data. The test was performed by therapeutic classes of the drugs for both the treatment
and the control group. In other words, this first set of analysis tested for significance in change in
adherence rates using the paired data of beneficiaries who entered the coverage gap and similar
analysis was done for their matched controls. Thus, here, the beneficiaries in each group served
as their own controls.
The second set of analyses was done to account for the baseline characteristics of the
beneficiaries and changing time trends using the simple difference in difference (DD) technique.
75

This technique involves comparison of differences in the difference between the before and after
values of the outcome variable (here MPR values) for the treatment and control group. Thus, we
calculated the difference in MPR values before and after reaching the coverage gap for each
group and then calculated the difference of these differences.
Let Mt,b and Mt,a respectively represent the MPR value before and after reaching the
coverage gap for the treatment group and Mc,b and Mc,a respectively represent the MPR values
for matching time for the control group. Then, the DD estimator was calculated as:
𝑫𝑫 = 𝑴𝒕, 𝒃 − 𝑴𝒕, 𝒂 − (𝑴𝒄, 𝒃 − 𝑴𝒄, 𝒂)
We employed this simple analysis technique instead of using a regression that can control
for other baseline characteristics because we had already matched the two groups on other
baseline characteristics using the propensity score technique. The matched control group was
allotted index dates that correspond to the times before and within the coverage gap for the
matched case. Thus, the DD estimate obtained in our analysis accounted for both observed and
unobserved factors that can affect the change in adherence rates during the coverage gap and
hence provide a more robust association between the coverage gap status and change in
adherence rates116. The statistical significance of the differences between the groups was again
assessed using the Wilcoxon signed rank test for paired data.

This analysis was done at

therapeutic class level for the groups depending on whether or not they had drug coverage during
the coverage gap.
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CHAPTER 5
RESULTS

This chapter presents the sample size and the results obtained for each objective.

Sample Size
The master dataset created after merging all the CMS datasets as well as those created for
income and therapeutic class consisted of claims, demographic and enrollment information of
2,631,860 unique beneficiaries enrolled in Medicare in 2008. After applying the general
inclusion and exclusion criteria, the dataset comprised 250,890 unique beneficiaries. Upon
application of medication related criteria (i.e. taking one or more oral medications in one or more
of the 7 therapeutic classes), the final sample contained information of 173,080 beneficiaries.
These beneficiaries were then separated into two groups based on their enrollment in plans that
did or did not offer drug coverage in the coverage gap.

Thus, the two groups were a)

beneficiaries enrolled in plans that did not offer any coverage during the coverage gap (No Gap
Coverage Group (N = 164,551) and b) beneficiaries enrolled in plans that offered some coverage
during the coverage gap (Some Gap Coverage Group N = 8,529).
Within each of these two groups, beneficiaries were separated into therapeutic classes
being evaluated in this study. If a beneficiary took medications from more than one class among
those evaluated, then they are included in each applicable class. However, within each class, if
the first fill date was after March 31, 2008, then that record was deleted from further analyses.
Due to this criterion, although several beneficiaries took medications from the classes being
evaluated at some point in 2008, only those with a presumed full year of usage were included in
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further analyses. For example, in the „No Gap Coverage group, 40,060 beneficiaries were taking
ACE inhibitors in 2008; however, only 34,477 beneficiaries had records of filling the first
medication by March 31, 2008. Therefore, the rest were excluded from further analyses in the
study. Among the overall sample of beneficiaries included in the subsequent analyses, the most
widely used class of drugs was anti-hyperlipidemic agents, followed by beta-blockers, diuretics,
ACE inhibitors and calcium channel blockers. The classes of drugs used by a lesser proportion of
beneficiaries were PPI and oral anti-diabetic agents. Table 6 shows the sample sizes for each
therapeutic class being evaluated by the type of coverage during the gap.
Table 6: Sample Size by Therapeutic Class
Therapeutic Class

No Gap Coverage

Some Gap Coverage

ACE inhibitors

34,477

1,499

Beta-blockers

47,911

2,295

Calcium channel blockers

29,229

1,384

Diuretics

47,711

2,275

Oral anti-diabetic agents

17,500

845

Oral anti-hyperlipidemic agents

69,178

3,407

Proton pump inhibitors

23,925

1,117

The following section presents the descriptive characteristics of the overall sample as well as by
therapeutic class.
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Descriptive Characteristics
All beneficiaries (N = 173,080)
Overall, our sample was found to be older and predominantly Caucasian. The mean age
of the beneficiaries in our sample was 77.43 (+ 7.05) years. A little over 90% of the sample was
found to be Caucasian and almost three - quarters of the sample (73.35%) comprised females.
The sample had a median household income of $33,646. On average, beneficiaries in our sample
took 7.94 (+ 4.30) unique medications, and were predominantly enrolled in stand-alone
Prescription Drug Plans (PDPs) that offered coverage using some modification of the standard
Medicare Part D benefit structure (58.10%).
For the sample in our study, a majority were enrolled in plans that did not charge a
deductible (75.93%), had tiered cost-sharing (in contrast to Medicare defined coinsurance of
25%), had coverage gap and catastrophic coverage beginning at the Medicare defined amount
($2,510 in total spending and $4,050 in OOP spending respectively) and did not offer coverage
for any drugs in the coverage gap (95.07%).
Presence or absence of coverage during the gap
As with the overall sample, both groups (with or without coverage in the gap) were found
to be older, predominantly Caucasian, female and on several medications. The group with some
coverage in the gap was similar to the group without coverage in the gap in terms of
demographics. However, there were significant differences in the benefit structures offered by
the plans in the two groups. The beneficiaries in the “Some Gap Coverage” group were enrolled
in plans that offered drug coverage through „enhanced alternative‟ structure that did not charge a
deductible. By comparison, beneficiaries in the “No Gap Coverage” group were enrolled in plans
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that offered drug coverage through a variety of benefit structures. Only about a third of these
plans offered an „enhanced alternative‟ benefit structure, and a quarter of all plans charged a
deductible. In spite of these variations, it was interesting to note that plans in both the groups had
tiered cost sharing for covered prescription drugs and had coverage gap begin and end thresholds
that were the same as those defined by Medicare. Table 7 lists the characteristics of the overall
sample and of the two groups.
Table 7: Characteristics of beneficiaries overall and by type of coverage in the coverage
gap

Characteristic

Total
N=173,080

Age(Mean (Std. Dev*))

77.43(7.05)

No Gap
Coverage
N = 164,551
77.42(7.05)

Race (%Caucasian)

91.92

91.88

92.73

Gender (% Females)

73.35

73.29

74.58

Income**
(Median)
Total # of medications

33,646

33,662

33,259

7.94(4.3)

7.92(4.29)

8.31(4.41)

58.1

61.11

0

75.93

74.68

99.99

Drug benefit type
(% Standard or equivalent)
Deductible (% No)

Some Gap
Coverage
N = 8,529
77.8(7.01)

98.78
98.72
99.91
Initial Coverage Limit
(% beneficiaries with Medicare
defined amount)
99.24
99.2
99.99
Initial cost sharing
(% beneficiaries with tiers)
4.93
N/A
100
% beneficiaries with drug coverage
in coverage gap
Note: * Std. Dev means Standard Deviation, ** Income = median household income of
beneficiaries‟ zip-code
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Characteristics of beneficiaries by class
1.

No Gap Coverage Group (N = 164, 551)

(a)

Demographic Characteristics

As observed with the overall dataset, the mean age of the sample in each class was close
to 78 years of age. Additionally, approximately 90% of the sample in each therapeutic class was
Caucasian with most being females. Table 8 presents the demographic characteristics of the
sample by therapeutic class.
Table 8: Demographic characteristics of beneficiaries with no drug coverage in the
coverage gap by therapeutic class
Class

N

Gender
%Males %Females

Income**
Median $

ACE inhibitors

34,477

Age
Mean
(Std.Dev*)
77.49(7.06)

Race
%Caucasian
91.76

31.69

68.31

32,704

Beta-blockers

47,911

77.89(7.02)

93.17

26.47

73.53

32,612

Calcium channel 29,229
blockers
29,229
Diuretics

78.52(7.29)

89.37

22.63

77.37

32,609

78.36(7.31)

91.53

20.66

79.34

31,896

34.75

65.25

32,867

30.57

69.43

34,453

23.27

76.73

33,132

17,500 75.99(6.37)
85.38
Oral antidiabetic agents
69,178 76.39(6.41)
92.18
Oral antihyperlipidemic
agents
23,925 77.04(7.01)
91.92
Proton pump
inhibitors
Note: * Std. Dev means Standard Deviation, ** Income
beneficiaries‟ zip-code
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= median household income of

(b)

Medication Related Characteristics

As with the overall sample, the beneficiaries from each therapeutic class took at least 8
unique medications. In addition, a majority of the beneficiaries in each class concurrently took at
least 4 medications from an average of three of the classes being evaluated in this study. For
each class studied, the total duration that the beneficiaries were supposed to take the medications
was around 345 days. The medication related characteristics of the beneficiaries in each class are
outlined in Table 9 below:
Table 9: Medication related characteristics of beneficiaries with no drug coverage in the
coverage gap by therapeutic class
Total Rx*
Mean
(Std.Dev**)

Total Class†
Mean
(Std.Dev)

Total Rx
from classes††
Mean(Std.Dev)

ACE inhibitors

7.70(3.71)

3.11(1.29)

3.43(1.60)

Total
Duration†††
Mean
(Std.Dev)
346.79(19.82)

Beta-blockers

7.94(3.79)

3.06(1.25)

3.32(1.54)

345.32(20.96)

Calcium channel
blockers
Diuretics

8.13(3.67)

3.11(1.32)

3.46(1.82)

345.53(21.01)

8.35(3.91)

3.04(1.27)

3.37(1.53)

345.76(20.59)

Class

8.18(3.73)
3.27(1.34)
3.86(1.72)
350.01(16.18)
Oral anti-diabetic
agents
7.45(3.67)
2.77(1.29)
3.09(1.59)
344.29(21.67)
Oral antihyperlipidemic agents
9.08(4.17)
2.98(1.36)
3.38(1.59)
342.89(22.89)
Proton pump
inhibitors
Note: * Rx = Prescription Medications, ** Std. Dev = Standard Deviation, †Total Class =
number of classes under evaluation from which the beneficiaries took medications
simultaneously, †† Total Rx from classes = number of medications from the 7 classes evaluated,
††† Total Duration = number of days beneficiaries were supposed to take their medication since
the first fill date
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(c)

Plan Characteristics

Less than 1% of all enrollees in the No Gap Coverage group were enrolled in plans that
offered coverage through the standard Medicare Part D benefit structure. Most beneficiaries were
enrolled in plans that offered drug coverage through benefit structures that are considered
equivalent or enhanced when compared to the standard Part D design. A majority of plans did
not charge a deductible and had tiered cost-sharing as opposed to the standard 25% co-insurance
during the initial coverage period. As with the overall sample, almost all plans imposed Medicare
defined spending limits to determine a beneficiary‟s gap entry and exit times. Table 10 presents
these results in detail.
Table 10: Plan characteristics of beneficiaries with no drug coverage in the coverage gap by
therapeutic class
Class

ACE inhibitors

Drug Benefit Type

Deductible Pre-Gap
Gap
Applied
CostThreshold
Actuarially Basic Enhanced (%No)
sharing
(%Std.amt*)
Equivalent Alt.** Alt.
(%Tiers)
20.79
40.49
38.71
75.72
99.26
98.77

Beta-blockers

21.41

39.17

39.42

75.37

99.17

98.64

Calcium channel
blockers
Diuretics

21.48

40.25

38.27

74.92

99.16

98.67

22.09

39.02

38.89

74.74

99.27

98.73

21.67
40.18
38.15
74.28
99.13
98.67
Oral anti-diabetic
agents
20.63
40.19
39.18
76.10
99.36
98.85
Oral antihyperlipidemic
agents
21.19
39.94
38.87
75.64
99.15
98.71
Proton pump
inhibitors
Note: *Std.amt = Medicare defined Standard amount ($2,510 for 2008) ** Alt. = Alternative

83

2. Some Gap Coverage Group (N = 8,529)
(a)

Demographic and Medication related characteristics

The demographic characteristics of the beneficiaries in this group were in concordance
with the findings for the overall sample. In other words, within each therapeutic class,
beneficiaries with some drug coverage during the coverage gap were also older, predominantly
Caucasian and female. In addition, the medication taking behavior of the beneficiaries in this
group was also similar to that of the overall sample and the “No Gap Coverage” group. Tables 11
and 12 present the demographic and medication related characteristics of the beneficiaries in this
group.
Table 11: Demographic characteristics of beneficiaries with some drug coverage in the
coverage gap by therapeutic class
Class

N

Gender
%Males %Females

Income**
Median($)

ACE
inhibitors
Beta-blockers

1,499

Age
Mean
(Std.Dev*)
77.67(6.87)

Race
%Caucasian
92.66

31.49

68.51

32,489

2,295

78.13(6.92)

93.99

25.66

74.34

32,507

Calcium
channel
blockers
Diuretics

1,384

78.92(7.12)

89.74

20.66

79.34

31,827

2,275

78.77(7.26)

93.23

19.74

80.26

32,211

845
76.41(6.45)
87.22
34.67
65.33
33,241
Oral antidiabetic agents
3,407
76.75(6.36)
93.01
29.26
70.74
33,915
Oral antihyperlipidemic
agents
1,117
77.40(6.86)
92.87
23.46
76.54
32,531
Proton pump
inhibitors
Note: * Std.dev = Standard Deviation, ** Income = the median household income of the
beneficiaries‟ zip-code
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Table 12: Medication related characteristics of beneficiaries with some drug coverage in
the coverage gap by therapeutic class
Total Rx*
Mean
(Std.Dev**)

Total Class†
Mean
(Std.Dev)

Total Rx
from classes††
Mean(Std.Dev)

ACE inhibitors

7.83(3.61)

3.32(1.28)

3.54(1.60)

Total
Duration†††
Mean
(Std.Dev)
346.94(20.05)

Beta-blockers

8.07(3.78)

3.03(1.24)

3.39(1.54)

344.31(21.31)

Calcium channel
blockers
Diuretics

8.21(3.87)

3.21(1.29)

3.48(1.57)

344.14(21.67)

8.33(3.74)

3.08(1.23)

3.38(1.56)

345.12(21.39)

Class

8.35(3.68)
3.43(1.33)
3.96(1.67)
343.12(23.26)
Oral anti-diabetic
agents
7.51(3.59)
2.76(1.28)
3.15(1.59)
343.18(22.37)
Oral antihyperlipidemic agents
9.02(4.06)
3.02(1.36)
3.33(1.69)
341.77(23.89)
Proton pump
inhibitors
Note: * Rx = Prescription Medications, ** Std. Dev = Standard Deviation, †Total Class =
number of classes under evaluation from which the beneficiaries took medications
simultaneously, †† Total Rx from classes = number of medications from the 7 classes evaluated,
††† Total Duration = number of days beneficiaries were supposed to take their medication since
the first fill date

(b) Plan Characteristics
Since this group of beneficiaries are documented to have coverage for some drugs while
in the coverage gap, as expected, all the beneficiaries were enrolled in plans that offered
coverage through an „enhanced alternative‟ benefit design. In addition, no plan in this group
charged a deductible and all had tiered cost-sharing structures during the initial coverage limit
phase. In spite of these „enhanced‟ offerings, all the plans had a coverage gap starting at the
Medicare defined amount of $2,510 in total spending and catastrophic limits starting at $4,050 in
total OOP spending. It was interesting to note that although these beneficiaries had coverage for
drugs when in the coverage gap, this benefit was limited to some or all generic drugs only.
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Specifically, 54% of all beneficiaries in this group had all generic drugs covered during the
coverage gap, 38% had coverage limited to „preferred generics‟ and the remaining 8% had
coverage limited to only „a few‟ generic drugs when in the coverage gap. No plan in our sample
offered coverage for any brand name drugs during the coverage gap for this group.
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Characteristics of beneficiaries based on whether or not they reached the coverage gap
1.

Overall (N = 173,080)

Overall, 24.42% (N = 42,264) of our sample reached the coverage gap in 2008. Of these,
only 6.29% beneficiaries (N = 2,660) had some coverage for their prescription medications
during the coverage gap. The remaining 93.71% beneficiaries had no coverage for their
prescription drugs during the coverage gap. Among the “No Gap Coverage” group, 24.07%
reached the coverage gap. By comparison, 31.19% of those with some gap coverage reached the
coverage gap in 2008 (Figure 5). Overall, a little over half of the beneficiaries reaching the
coverage gap (59.92%) did so by September and spent about 97 days (+ 67 days) in the coverage
gap. Of these, 12.10% (3% of the total sample) reached the catastrophic coverage phase. It was
found that those reaching the catastrophic coverage phase were primarily beneficiaries reaching
the coverage gap in the first half of the year. In addition, beneficiaries receiving catastrophic
coverage spent approximately 83 days (+ 72 days) in that phase, which is consistent with the
finding that a majority of these beneficiaries reached the phase early in the year. Irrespective of
the level of analysis, the beneficiaries reaching the coverage gap did not have different
demographic characteristics when compared to those who did not reach the coverage gap. Figure
6 presents the demographic characteristics of the two groups by level of analysis.
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Figure 5: Percentage of beneficiaries reaching the coverage gap in 2008
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Figure 6: Demographic characteristics by gap and gap coverage status
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Although the two groups had similar demographic attributes, those who did reach the
coverage gap had higher prescription medication use and OOP spending compared to those that
did not reach the coverage gap in 2008. An average beneficiary reaching the coverage gap took
11.25 (+ 4.63) different medications compared to 7.39 (+ 3.75) medications taken by a
beneficiary not reaching the coverage gap throughout the year.

The OOP spending for a

beneficiary reaching the gap was found to be higher during both the pre-gap as well as the
coverage gap periods compared to stable lower spending experienced by beneficiaries not
reaching the coverage gap. Beneficiaries reaching the coverage gap spent an average $763.95 (+
$330.46) before reaching the coverage gap and $945.70 (+ $986.22) during the coverage gap. By
comparison, beneficiaries not reaching the coverage gap had an average OOP spending of only
$400.00 (+ $286.59) throughout the year. These numbers were similar when the groups were
compared based on presence or absence of gap coverage during the gap. For instance, for those
reaching the coverage gap in the “No Gap Coverage” group, the pre-gap spending was $768.30
(+ $329.50) and the „during gap‟ spending was $951.65 (+ $987.13) compared to an average
$396.00 (+ $285.85) in annual OOP spending for those who did not reach the coverage gap in
this group. Similarly, for those reaching the coverage gap in the “Some Gap Coverage” group,
the pre-gap as well as the „during gap‟ spending were found to be higher than the annual OOP
spending for those who did not reach the coverage gap in this group ($699.14 + $337.91 and
$857.07 + $968.34 respectively vs. $418.17 + $301.36).
Similar proportions of beneficiaries in both the groups were enrolled in coverage designs
considered to be equivalent or enhanced adaptations of the standard Medicare Part D benefit
structures. Figure 7 summarizes the enrollment statistics for each plan benefit design based on
presence or absence of drug coverage in the gap.
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Figure 7: Plan Characteristics of beneficiaries by gap and gap coverage status
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2. Characteristics by therapeutic class before and after matching
No Gap Coverage Group
The comparison groups comprised those who did and did not reach the coverage gap in
the “No Gap Coverage” group. Within the “No Gap Coverage” group, the beneficiaries were
divided into 7 therapeutic classes being studied and within each therapeutic class they were
further divided into two groups based on whether or not they reached the coverage gap in 2008.
The beneficiaries in the two groups in each class shared a few similar characteristics but there
was also variability with respect to some other baseline attributes. In order to generate reliable
estimates of the effect of losing all coverage in the coverage gap on beneficiaries‟ adherence
measures, it was necessary to make the two groups more comparable in terms of their baseline
characteristics. Therefore, the beneficiaries reaching the coverage gap were matched to those not
reaching the coverage gap on a variety of variables. These variables were: age, race, gender,
income, number of medications taken, duration of therapy, severity of disease as calculated using
CDS, type of benefit design, presence or absence of deductible, type of cost sharing before
reaching the coverage gap, and coverage gap threshold amount. The following paragraphs
outline the characteristics of the groups that did and did not reach the coverage gap by
therapeutic class before and after matching.
(a)

Oral anti-hyperlipidemic agents

This was the most widely used class of medications in the sample; with around 80,000
beneficiaries using one or more medications from this class at some point in 2008. However, the
proportion of beneficiaries having usage beginning in the first quarter of 2008 was less; only
69,178 beneficiaries were prescribed the medication since the beginning of the year. From this
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pool, 7,636 beneficiaries (11.04%) reached the coverage gap in 2008. A majority of beneficiaries
reached the coverage gap by November, with the largest proportion doing so between October
and November (41% and 70% respectively). However, only two of beneficiaries reached the
catastrophic phase and therefore the results after reaching the catastrophic phase are not shown.
Although the two groups were similar in a few characteristics (e.g. income and disease
severity), there were a number of other attributes that differed between the two (p-value < .05). A
greater proportion of the beneficiaries reaching the gap were Caucasians and male compared to
those not reaching the coverage gap (93.07% vs. 92.08% and 32.24% vs. 30.40% respectively).
In addition, beneficiaries reaching the coverage gap were a little older compared to those not
reaching the coverage gap in 2008. Beneficiaries reaching the coverage gap took about 10
different medications (vs. 7 for those not reaching the gap) over a relatively short duration of
time (312 days vs. 349 for those not reaching the gap). Greater proportions of beneficiaries
reaching the coverage gap were enrolled in plans that offered no additional benefit over a
standard benefit structure (61.38% vs. 60.75%) and that charged a deductible (26.9% vs. 23.53%
from those not reaching the gap). The use of propensity score matching resulted in 5,041
matched pairs (66.02% of the beneficiaries reaching the gap) that were similar to each other in
all the observed characteristics. Table 13 presents these results in detail.
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Table 13: Characteristics of beneficiaries in the “No Gap Coverage” group taking oral
anti-hyperlipidemic agents before and after matching
Variable

Before matching
Treatment
Control
p-value
N = 7,636
N = 61,542
76.52
76.19
0.0002*
Age
(6.47)
(6.33)
Mean(Std.dev**)
93.07
92.08
0.0328*
Race (%Caucasian)
Gender
(% Females)
Income†(Median)

After matching
Treatment Control p-value
N = 5,041
N = 5,401
76.19
75.98
0.0886
(6.32)
(6.33)
92.82
92.44
0.9964

67.76

69.60

0.0010*

66.46

66.55

0.9150

34,022

34,259

0.543

34,677

34,700

0.3500

9.63
7.19
<0.0001*
8.43
8.29
0.0594
# Medications
(3.93)
(3.51)
(3.34)
(3.91)
taken (Mean
(Std.Dev))
CDS††
3.62
3.41
0.23
3.48
3.42
0.1060
(2.12)
(1.92)
(2.11)
(2.15)
Mean(Std.dev)
Total Duration†††
311.57
349.35
<0.0001*
321.37
319.71 0.1344
(24.28)
(17.47)
(22.84)
(24.32)
Mean(std.dev)
61.38
60.75
<0.0001*
61.20
61.79
0.3114
Benefit Type
(% Basic Design)
73.1
76.47
<0.0001*
74.49
75.76
0.0580
Deductible (% No)
99.28
99.38
0.3176
99.35
99.39
0.7995
Pre-Gap
Costsharing
(% Tiers)
98.73
98.85
0.3435
98.73
98.97
0.2611
Gap Threshold
(% Std. amt***)
Note: * indicates significant differences between the groups as p-value <0.05, ** means Standard
Deviation and *** indicates Medicare Defined Standard amount ($2,510 in 2008), † Income =
Median household income of the beneficiaries, †† CDS = Chronic Disease Score, ††† Total
Duration = total number of days beneficiaries were supposed to take the medications since the
first fill date
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(b)

Beta-blockers

Out of 53,315 users of beta-blockers in this sample, 47,911 unique beneficiaries had
documented usage beginning by March 31. Among these beneficiaries, 11.06% reached the
coverage gap three-quarters of these did so by November. Only four beneficiaries reached the
catastrophic coverage; the remainder either stayed in the coverage gap for the rest of the year or
stopped taking the medication in this class.
Beneficiaries reaching the coverage gap in this group were found to be similar to those
not reaching the coverage gap in terms of age, race, income and disease severity; but had
different gender, medication and plan related characteristics. Beneficiaries reaching the coverage
gap had a significantly higher medication use for a significantly shorter duration of therapy. In
addition, a greater proportion of these beneficiaries were enrolled in plans that offered coverage
through basic alterations of the Standard Part D benefit design and that charged a deductible.
Again, the differences between the two groups were eliminated by matching those reaching the
coverage gap to those not reaching the coverage gap. However, in the process, we lost 18% of
the beneficiaries reaching the coverage gap because no match was found from the group not
reaching the coverage gap. Table 14 presents the characteristics of these beneficiaries before and
after matching.
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Table 14: Characteristics of beneficiaries in the “No Gap Coverage” group taking Betablockers before and after matching
Variable

Before matching
Treatment
Control
p-value
N = 5,928
N = 42,613
77.94
77.88
0.5148
Age
(6.97)
(7.02)
Mean(Std.dev**)
93.74
93.03
0.3746
Race (%Caucasian)
Gender
(% Females)
Income†(Median)

After matching
Treatment Control p-value
N = 3,821
N = 3,821
77.74
77.75
0.9200
(6.93)
(6.96)
93.54
92.25
0.5578

71.64

73.75

0.0012*

71.32

70.43

0.3791

32,905

32,590

0.1020

32,975

32,401

0.2907

10.24
7.66
<0.0001*
9.38
9.31
0.4276
# Medications
(3.88)
(3.67)
(3.34)
(5.14)
taken (Mean
(Std.Dev))
CDS††
3.80
3.63
0.0900
3.74
3.71
0.4586
(2.05)
(2.11)
(2.04)
(2.17)
Mean(Std.dev)
Total Duration†††
313.51
349.27
<0.0001*
322.59
322.38 0.4548
(24.14)
(16.73)
(21.31)
(26.45)
Mean(std.dev)
62.74
60.32
<0.0001*
62.68
62.21
0.1999
Benefit Type
(% Basic Design)
71.03
75.91
<0.0001*
72.10
73.38
0.3769
Deductible
(% No)
98.81
99.28
<0.0001*
98.98
99.24
0.2184
Pre-Gap
Costsharing
(% Tiers)
98.33
98.73
0.0766
98.46
98.93
0.069
Gap Threshold
(% Std. amt***)
Note: * indicates significant differences between the groups as p-value <0.05, ** means Standard
Deviation and *** indicates Medicare Defined Standard amount ($2,510 in 2008), † Income =
Median household income of the beneficiaries‟ zip-code, †† CDS = Chronic Disease Score, †††
Total Duration = total number of days beneficiaries were supposed to take the medications since
the first fill date
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(c)

Diuretics

Although 47,900 beneficiaries used a diuretic at some point in 2008, 47,711 had used a
medication from this class since the first quarter of the year. Of these, 10.37% reached the
coverage gap; a majority of which (70.78%) did so by November. Only two of these
beneficiaries reached the catastrophic coverage. Beneficiaries reaching the coverage gap were
found to be slightly older compared to those who did not reach the coverage gap. They took
almost 11 unique medications compared to 8 medications taken by beneficiaries not reaching the
coverage gap. As with the other groups, a greater proportion of beneficiaries reaching the
coverage gap were enrolled in plans that charged a deductible and offered coverage through a
benefit design considered equivalent to the standard Part D benefit structure (Table 15).
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Table 15: Characteristics of beneficiaries in the “No Gap Coverage” group taking Diuretics
before and after matching
Variable

Before matching
Treatment
Control
p-value
N = 4,948
N = 42763
78.59
78.37
0.0129*
Age
(7.28)
(7.29)
Mean(Std.dev**)
92.91
91.28
0.0011*
Race (%Caucasian)

After matching
Treatment Control p-value
N = 3530
N = 3,530
78.31
78.17
0.3661
(7.26)
(7.25)
92.46
90.85
0.1344

78.35
79.52
0.0556
78.75
78.64
0.9065
Gender
(% Females)
Income†
32,120
31,838
0.2517
32,460
33,035 0.0556
(Median)
10.99
8.05
<0.0001*
10.03
9.99
0.6397
# Medications
(3.98)
(3.78)
(3.47)
(5.33)
taken (Mean
(Std.Dev))
CDS††
3.97
3.81
0.6100
3.94
3.93
0.8084
(2.11)
(2.13)
(2.11)
(2.23)
Mean(Std.dev)
Total Duration†††
314.04
349.43
<0.0001*
323.48
323.23 0.4879
(24.14)
(16.62)
(21.19)
(27.23)
Mean(std.dev)
62.91
60.9
<0.0001*
62.35
62.04
0.5917
Benefit Type
(% Basic Design)
70.17
75.27
<0.0001*
71.42
73.06
0.2075
Deductible
(% No)
98.77
99.32
0.0034*
98.95
98.98
0.9955
Pre-Gap
Costsharing
(% Tiers)
98.45
98.76
0.3961
98.56
98.87
0.2489
Gap Threshold
(% Std. amt***)
Note: * indicates significant differences between the groups as p-value <0.05, ** means Standard
Deviation and *** indicates Medicare Defined Standard amount ($2,510 in 2008), † Income =
Median household income of the beneficiaries‟ zip-code, †† CDS = Chronic Disease Score, †††
Total Duration = total number of days beneficiaries were supposed to take the medications since
the first fill date
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(d)

ACE Inhibitors

Among all beneficiaries using ACE inhibitors (N = 40,060), 34,477 had usage beginning
in the first quarter of 2008 and hence were included in further analyses. In this group, only
5.64% reached the coverage gap in 2008; 61% of whom did so by November. None of these
beneficiaries reached catastrophic coverage in 2008. A lesser proportion of those reaching the
coverage gap were females compared to those who did not reach the coverage gap (65.26% vs.
68.57% respectively). In addition, a greater proportion of those reaching the coverage gap were
enrolled in plans with basic benefit designs that charged a deductible. The beneficiaries reaching
the coverage gap also took a significantly greater number of medications compared to
beneficiaries who did not reach the coverage gap (10.17 vs. 7.55). In addition, the severity of
disease in the group reaching the coverage gap was greater compared to those not reaching the
coverage gap. The differences between the two groups were eliminated by creating propensity
score based matched groups (Table 16).
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Table 16: Characteristics of beneficiaries in the “No Gap Coverage” group taking ACE
inhibitors before and after matching
Variable

Before matching
Treatment
Control
p-value
N = 1,943
N = 32,534
77.55
77.39
0.5640
Age
(7.21)
(7.04)
Mean(Std.dev**)
92.57
91.61
0.3761
Race (%Caucasian)

After matching
Treatment Control p-value
N = 1,373
N = 1,373
77.26
77.17
0.7390
(7.08)
(7.21)
92.28
90.68
0.1060

65.26
68.57
0.0023*
65.33
65.77
0.8023
Gender
(% Females)
Income†
32,232
32,710
0.2312
32,838
34,213 0.1126
(Median)
10.17
7.55
<0.0001*
9.06
8.96
0.2052
# Medications
(3.92)
(3.67)
(3.47)
(4.45)
taken (Mean
(Std.Dev))
CDS††
5.71
5.34
<0.0001*
5.61
5.56
0.4032
(1.62)
(1.53)
(1.61)
(1.69)
Mean(Std.dev)
Total Duration†††
306.22
349.22
<0.0001*
314.14
313.46 0.1808
(22.78)
(16.77)
(21.83)
(26.74)
Mean(std.dev)
63.05
61.18
<0.0001*
62.35
62.78
0.6011
Benefit Type
(% Basic Design)
70.87
76.01
<0.0001*
72.91
73.05
0.8939
Deductible
(% No)
99.54
99.24
0.1900
99.42
99.56
0.5930
Pre-Gap
Costsharing
(% Tiers)
99.28
98.76
0.0521
99.05
98.76
0.4328
Gap Threshold
(% Std. amt***)
Note: * indicates significant differences between the groups as p-value <0.05, ** means Standard
Deviation and *** indicates Medicare Defined Standard amount ($2,510 in 2008), † Income =
Median household income of the beneficiaries‟ zip-code, †† CDS = Chronic Disease Score, †††
Total Duration = total number of days beneficiaries were supposed to take the medications since
the first fill date
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(e)

Calcium channel blockers

From an aggregate of 31,346 beneficiaries taking calcium channel blockers at sometime
in 2008; 29,229 beneficiaries had a full year of medication use according to our criteria. Of
these, 3482 beneficiaries (11.91%) reached the coverage gap in 2008 and only two beneficiaries
reached the catastrophic coverage. Almost three quarters (73%) of beneficiaries reaching the
coverage gap did so by November.
A significantly greater proportion of beneficiaries reaching the coverage gap were
Caucasians (91.51% vs. 89.07%) and had a higher median annual household income compared to
those who did not reach the coverage gap ($32,933 vs. $31,971). In addition, beneficiaries
reaching the coverage gap were of similar age and gender but used significantly larger number of
prescription medications over a significantly shorter duration of therapy compared to those who
did not reach the coverage gap. Most of the beneficiaries reaching the coverage gap were
enrolled in plans offering coverage through actuarially equivalent Part D benefit with a
deductible. The propensity score matching resulted in 2,373 matched pairs with similar
characteristics beneficiaries who reached the coverage gap (68.15%). Table 17 presents the
results in detail:
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Table 17: Characteristics of beneficiaries in the “No Gap Coverage” group taking Calcium
channel blockers before and after matching
Variable

Before matching
After matching
Treatment
Control
p-value Treatment Control p-value
N = 3,482
N = 25,747
N = 2,373 N = 2,373
78.59
78.48
0.4916
78.38
78.14
0.2699
Age
(7.32)
(7.27)
(7.21)
(7.26)
Mean(Std.dev**)
91.51
89.07
<0.0001*
90.86
91.45
0.9972
Race (%Caucasian)
76.88
77.43
0.4641
76.53
77.08
0.6536
Gender
(% Females)
Income†
32,933
31,971
.0013*
33,269
33,309 0.6284
(Median)
10.41
7.82
<0.0001*
9.46
9.39
0.5319
# Medications
(3.85)
(3.71)
(3.45)
(5.04)
taken (Mean
(Std.Dev))
CDS††
4.57
4.54
0.0535
4.61
4.54
0.2415
(1.92)
(2.01)
(1.95)
(2.02)
Mean(Std.dev)
Total Duration†††
313.81
349.82
<0.0001*
324.16
323.57 0.1115
(24.46)
(16.29)
(21.71)
(26.29)
Mean(std.dev)
63.3
61.53
.0011*
63.55
61.53
0.6328
Benefit Type
(% Basic Design)
71.86
75.34
<0.0001*
72.69
74.04
0.2988
Deductible
(% No)
99.05
99.28
0.2754
98.99
99.21
0.4458
Pre-Gap
Costsharing
(% Tiers)
98.62
98.79
0.4028
98.76
98.48
0.4602
Gap Threshold
(% Std. amt***)
Note: * indicates significant differences between the groups as p-value <0.05, ** means Standard
Deviation and *** indicates Medicare Defined Standard amount ($2,510 in 2008), † Income =
Median household income of the beneficiaries‟ zip-code, †† CDS = Chronic Disease Score, †††
Total Duration = total number of days beneficiaries were supposed to take the medications since
the first fill date

(f)

Proton-Pump Inhibitors (PPI)

Approximately 25,000 beneficiaries took PPIs during 2008 and 23,925 had used them
since the first quarter of the year. Almost 18% of these beneficiaries (N=4,204) reached the
coverage gap and four beneficiaries reached the catastrophic coverage phase. Three-quarters
(74%) of the beneficiaries using PPIs reached the coverage gap by November. As with the other
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groups, the existing differences between the characteristics of beneficiaries in the two groups
were eliminated after employing propensity score matching technique which yielded 2,678
matched pairs (Table 18).
Table 18: Characteristics of beneficiaries in the “No Gap Coverage” group taking Proton
Pump Inhibitors before and after matching
Variable

Before matching
Treatment
Control
p-value
N = 2,492
N = 11,355
77.43
76.95
<0.0001*
Age
(7.28)
(6.99)
Mean(Std.dev**)
92.84
91.73
0.0140*
Race (%Caucasian)

After matching
Treatment Control p-value
N = 2,068
N = 2,068
77.08
76.89
0.3113
(6.99)
(6.92)
92.61
92.98
0.9926

76.15
76.73
0.4271
75.43
74.38
0.3788
Gender
(% Females)
Income†
33,226
33,107
0.2851
33,523
34,029 0.2306
(Median)
10.74
8.67
<0.0001*
9.73
9.59
0.2778
# Medications
(4.36)
(4.04)
(3.85)
(4.63)
taken (Mean
(Std.Dev))
CDS††
3.37
3.35
0.0348*
3.32
3.27
0.1845
(2.01)
(2.12)
(1.98)
(2.19)
Mean(Std.dev)
Total Duration†††
313.11
349.23
<0.0001*
324.85
324.24 0.4230
(24.11)
(16.83)
(20.81)
(24.77)
Mean(std.dev)
62.02
60.96
<0.0001*
61.69
61.46
0.7878
Benefit Type
(% Basic Design)
71.97
76.42
<0.0001*
73.00
73.49
0.4691
Deductible
(% No)
99.04
99.20
0.4084
98.99
98.98
0.7893
Pre-Gap
Costsharing
(% Tiers)
98.62
98.72
0.5939
98.81
98.81
1
Gap Threshold
(% Std. amt***)
Note: * indicates significant differences between the groups as p-value <0.05, ** means Standard
Deviation and *** indicates Medicare Defined Standard amount ($2,510 in 2008), † Income =
Median household income of the beneficiaries‟ zip-code, †† CDS = Chronic Disease Score, †††
Total Duration = total number of days beneficiaries were supposed to take the medications since
the first fill date

(g)

Oral anti-diabetic agents
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An aggregate of 22,836 beneficiaries from the overall sample took one or more oral antidiabetic agents in 2008. However, only 17,500 beneficiaries had a full year of medication use
and were included in further analyses. Almost 13% of these beneficiaries experienced the
coverage gap in 2008; 73% of whom did so by November and only one passed into the
catastrophic coverage phase.
The two groups within this therapeutic class were significantly different from each other
(Table 19). Those reaching the coverage gap were older beneficiaries who used more
medications in a shorter duration of time. The severity of their disease, however, was similar to
their peers who did not reach the coverage gap. As with other groups, greater proportions of
beneficiaries reaching the coverage gap were enrolled in plans that charged a deductible and
offered no additional benefit over the standard Part D structure. These differences were
accounted for after finding appropriate matched pairs from the two groups. However, in doing
so, 36.67% of beneficiaries who reached the coverage gap were not matched to anyone not
reaching the gap and were therefore excluded from the analyses.
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Table 19: Characteristics of beneficiaries in the “No Gap Coverage” group taking oral
anti-diabetic agents before and after matching
Variable

Before matching
Treatment
Control
p-value
N = 2,613
N = 14,887
76.69
76.08
0.0190*
Age
(6.31)
(6.42)
Mean(Std.dev**)
88.52
84.83
<0.0001*
Race (%Caucasian)

After matching
Treatment Control p-value
N = 1,655
N = 1,655
75.58
75.55
0.9291
(6.11)
(6.03)
87.37
87.43
0.7893

63.57
65.61
0.0439*
63.14
64.77
0.2855
Gender
(% Females)
Income†
33,053
32,839
0.0269*
33,304
34,238
0.229
(Median)
10.45
8.18
<0.0001*
9.46
9.48
0.5353
# Medications
(4.12)
(3.27)
(3.57)
(4.69)
taken (Mean
(Std.Dev))
CDS††
5.09
5.08
0.7705
5.07
5.08
0.7129
(1.99)
(2.03)
(2.07)
(2.16)
Mean(Std.dev)
Total Duration†††
312.73
350.01
<0.0001*
324.28
324.28 0.9962
(24.34)
(16.19)
(21.69)
(25.41)
Mean(std.dev)
63.91
61.48
<0.0001*
63.26
64.77
0.5518
Benefit Type
(% Basic Design)
71.18
74.82
0.0002*
73.11
72.57
0.8658
Deductible
(% No)
98.74
99.19
0.0030*
99.03
99.27
0.4497
Pre-Gap
Costsharing
(% Tiers)
98.55
98.69
0.5525
98.85
98.79
0.8658
Gap Threshold
(% Std. amt***)
Note: * indicates significant differences between the groups as p-value <0.05, ** means Standard
Deviation and *** indicates Medicare Defined Standard amount ($2,510 in 2008), † Income =
Median household income of the beneficiaries‟ zip-code, †† CDS = Chronic Disease Score, †††
Total Duration = total number of days beneficiaries were supposed to take the medications since
the first fill date
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Some Gap Coverage
Within the “Some Gap Coverage” group, the beneficiaries were divided into 7
therapeutic classes being studied and within each therapeutic class they were further divided into
two groups based on whether or not they reached the coverage gap in 2008. The beneficiaries in
the two groups in each class shared similar demographic and plan enrollment characteristics but
there was variability with respect to their medication taking behavior. As with the analyses for
the “No Gap Coverage” group, it was necessary to make the two groups more comparable in
terms of these characteristics before making reliable estimates of the effect of being in the
coverage gap on the beneficiaries‟ adherence to medications. The following paragraphs outline
the characteristics of the groups that did and did not reach the coverage gap by therapeutic class
before and after matching.
As with the “No Gap Coverage” group, oral anti-hyperlipidemic agents were the most
frequently used class of medications in this group, followed by beta-blockers, diuretics and ACE
inhibitors. Again, the least frequently used classes of medications were calcium channel
blockers, followed by PPIs and oral anti-diabetic agents. The greatest impact was seen in the
group taking PPIs; with almost a fifth (19.96%) of the beneficiaries in that group reaching the
coverage gap in 2008. This was followed by beneficiaries taking oral anti-diabetic agents
(16.33%), calcium channel blockers (14.81%), oral anti-hyperlipidemic agents (13.09%), betablockers (12.68%) and diuretics (11.34%). Only 6% of beneficiaries using ACE inhibitors
reached the coverage gap in this group.
As with the “No Gap Coverage” group, between 40% of beneficiaries reaching the
coverage gap (for all therapeutic classes) did so by October and 70% did so by November. As
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mentioned earlier, all the beneficiaries in this group had similar demographic and plan
enrollment characteristics, irrespective of whether or not they reached the coverage gap in 2008.
However, beneficiaries reaching the coverage gap were more likely to use a greater number of
prescription medications over a shorter duration of time compared to those who did not reach the
coverage gap.

Detailed characteristics of beneficiaries by therapeutic class evaluated are

presented in Tables 20-26.
Table 20: Characteristics of beneficiaries in the “Some Gap Coverage” group taking antihyperlipidemic agents before and after matching
Variable

Before matching
Treatment
Control
p-value
N = 446
N = 2,961
76.81
76.86
0.9992
(6.08)
(6.41)
95.07
92.71
0.3500

After matching
Treatment
Control
p-value
N = 235
N =235
76.67
77.27
0.1854
(6.01)
(6.19)
97.02
93.62
0.058

Age Mean
(Std.dev**)
Race
(%Caucasian)
70.19
70.82
0.7814
72.77
71.70
0.0903
Gender
(% Females)
Income†
32,945
34,039
0.0546
33,915
33,208
0.8216
(Median)
9.74
7.17
<0.0001*
8.46
8.15
0.3878
#Medications
(3.99)
(3.43)
(3.54)
(3.98)
taken (Mean
(Std.dev))
CDS††
2.89
2.66
0.0101*
2.82
2.69
0.4597
(1.87)
(1.78)
(1.93)
(1.81)
Mean(Std.dev)
310.65
348.05
<0.0001*
324.79
323.67
0.2425
Total
Duration†††
(23.79)
(17.53)
(21.53)
(25.75)
Mean(std.dev)
Note: * indicates significant differences between the groups as p-value <0.05, ** means Standard
Deviation, † Income = Median household income of the beneficiaries‟ zip-code, †† CDS =
Chronic Disease Score, ††† Total Duration = total number of days beneficiaries were supposed
to take the medications since the first fill date
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Table 21: Characteristics of beneficiaries in the “Some Gap Coverage” group taking betablockers before and after matching
Variable

Before matching
Treatment Control
p-value
N = 291
N = 2,004
78.21
78.08
0.6651
(6.78)
(7.19)
94.16
93.96
0.3736

After matching
Treatment
Control
p-value
N = 163
N =163
78.49
76.97
0.0535
(6.88)
(6.46)
94.48
90.80
0.6398

Age Mean
(Std.dev**)
Race
(%Caucasian)
73.88
74.41
0.8500
74.85
70.55
0.3621
Gender
(% Females)
Income†
31,784
32,662
0.2447
31,641
32,133
0.1948
(Median)
10.43
7.71
<0.0001*
9.17
8.69
0.1217
#Medications
(4.24)
(3.58)
(3.53)
(4.47)
taken (Mean
(Std.dev))
CDS††
3.01
2.84
0.3921
2.87
2.85
0.8282
(2.03)
(1.81)
(1.95)
(1.99)
Mean(Std.dev)
312.55
348.65
<0.0001*
323.62
323.32
0.5417
Total
Duration†††
(22.52)
(16.71)
(20.33)
(24.81)
Mean(std.dev)
Note: * indicates significant differences between the groups as p-value <0.05, ** means Standard
Deviation, † Income = Median household income of the beneficiaries‟ zip-code, †† CDS =
Chronic Disease Score, ††† Total Duration = total number of days beneficiaries were supposed
to take the medications since the first fill date
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Table 22: Characteristics of beneficiaries in the “Some Gap Coverage” group taking
diuretics before and after matching
Variable

Before matching
Treatment
Control
p-value
N = 258
N = 2,017
78.89
78.63
0.6055
(7.39)
(7.21)
94.57
93.06
0.4856

After matching
Treatment
Control
p-value
N = 128
N =128
79.51
78.43
0.3291
(7.29)
(6.95)
95.31
92.62
0.5998

Age Mean
(Std.dev**)
Race
(%Caucasian)
84.11
79.77
0.0994
83.59
79.87
0.6949
Gender
(% Females)
Income†
33,060
31,752
0.7989
30,920
31,798
0.863
(Median)
10.99
7.99
<0.0001*
10.05
10.23
0.3075
#Medications
(3.95)
(3.58)
(4.11)
(3.58)
taken (Mean
(Std.dev))
CDS††
3.26
2.97
0.0359*
3.25
3.21
0.4563
(1.98)
(1.87)
(1.85)
(1.97)
Mean(Std.dev)
312.59
349.28
<0.0001*
328.51
336.16
0.3852
Total
Duration†††
(24.04)
(17.05)
(19.59)
(34.85)
Mean(std.dev)
Note: * indicates significant differences between the groups as p-value <0.05, ** means Standard
Deviation, † Income = Median household income of the beneficiaries‟ zip-code, †† CDS =
Chronic Disease Score, ††† Total Duration = total number of days beneficiaries were supposed
to take the medications since the first fill date
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Table 23: Characteristics of beneficiaries in the “Some Gap Coverage” group taking ACE
inhibitors before and after matching
Variable

Before matching
Treatment Control
p-value
N = 86
N = 1,413
79.09
77.57
0.0435*
(7.06)
(6.84)
94.19
92.57
0.8954

After matching
Treatment
Control
p-value
N = 36
N =36
79.37
79.25
0.952
(7.99)
(6.22)
90.63
90.63
1

Age Mean
(Std.dev**)
Race
(%Caucasian)
72.09
68.29
0.4615
65.63
81.25
0.1317
Gender
(% Females)
Income†
29,573
32,589
0.0976
29,708
30,631
0.3024
(Median)
9.64
7.72
<0.0001*
8.22
9.41
0.1403
#Medications
(3.76)
(3.54)
(3.58)
(3.92)
taken (Mean
(Std.dev))
CDS††
5.57
4.07
<0.0001*
4.88
4.59
0.872
(1.96)
(1.91)
(2.09)
(1.96)
Mean(Std.dev)
304.21
349.55
<0.0001*
318.93
318.41
0.9345
Total
Duration†††
(20.94)
(16.77)
(21.72)
(31.66)
Mean(std.dev)
Note: * indicates significant differences between the groups as p-value <0.05, ** means Standard
Deviation, † Income = Median household income of the beneficiaries‟ zip-code, †† CDS =
Chronic Disease Score, ††† Total Duration = total number of days beneficiaries were supposed
to take the medications since the first fill date
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Table 24: Characteristics of beneficiaries in the “Some Gap Coverage” group on calcium
channel blockers before and after matching
Variable

Before matching
Treatment Control
p-value
N = 205
N = 1179
78.69
78.78
0.9411
(7.08)
(7.14)
93.17
89.14
0.4717

After matching
Treatment Control
p-value
N = 97
N =97
78.65
78.42
0.8230
(6.85)
(6.96)
91.75
85.57
0.1537

Age Mean
(Std.dev**)
Race
(%Caucasian)
79.02
79.39
0.9052
79.38
78.35
0.8575
Gender
(% Females)
Income†
32,587
31,744
0.3939
30,954
31,093
0.1601
(Median)
10.05
7.88
<0.0001*
8.68
8.84
0.7605
#Medications
(3.93)
(3.57)
(2.98)
(4.52)
taken (Mean
(Std.dev))
CDS Mean††
3.74
3.57
0.1437
3.44
3.62
0.4591
(1.82)
(1.81)
(1.55)
(2.02)
(Std.dev)
312.86
349.58
<0.0001*
326.32
327.24
0.6155
Total
Duration†††
(21.73)
(16.42)
(19.05)
(26.46)
Mean(std.dev)
Note: * indicates significant differences between the groups as p-value <0.05, ** means Standard
Deviation, † Income = Median household income of the beneficiaries‟ zip-code, †† CDS =
Chronic Disease Score, ††† Total Duration = total number of days beneficiaries were supposed
to take the medications since the first fill date
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Table 25: Characteristics of beneficiaries in the “Some Gap Coverage” group taking PPIs
before and after matching
Variable

Before matching
Treatment Control
p-value
N = 223
N = 894
77.98
77.24
0.2106
(7.14)
(6.64)
94.17
92.81
0.8098

After matching
Treatment
Control
p-value
N = 108
N =108
78.39
77.54
0.2824
(7.25)
(6.37)
93.26
89.81
0.1060

Age Mean
(Std.dev**)
Race
(%Caucasian)
79.37
75.84
0.2653
80.56
75.00
0.3428
Gender
(% Females)
Income†
32,531
32,548
0.8039
33,312
32,259
0.4872
(Median)
10.57
8.54
<0.0001*
9.68
9.32
0.6281
#Medications
(4.22)
(3.88)
(3.96)
(4.15)
taken (Mean
(Std.dev))
CDS††
2.56
2.67
0.5034
2.72
2.66
0.7924
(1.87)
(1.87)
(1.98)
(1.98)
Mean(Std.dev)
316.37
348.85
<0.0001*
331.16
330.47
0.5952
Total
Duration†††
(24.94)
(17.53)
(20.92)
(25.21)
Mean(std.dev)
Note: * indicates significant differences between the groups as p-value <0.05, ** means Standard
Deviation, † Income = Median household income of the beneficiaries‟ zip-code, †† CDS =
Chronic Disease Score, ††† Total Duration = total number of days beneficiaries were supposed
to take the medications since the first fill date
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Table 26: Characteristics of beneficiaries in the “Some Gap Coverage” group on oral antidiabetic agents before and after matching
Variable

Before matching
Treatment Control
p-value
N = 138
N =707
76.55
76.37
0.9536
(6.52)
(6.52)
89.86
86.70
0.2548

After matching
Treatment
Control
p-value
N = 61
N =61
76.52
75.85
0.9343
(7.38)
(5.77)
93.44
90.33
0.2531

Age Mean
(Std.dev**)
Race
(%Caucasian)
65.70
65.49
0.8223
68.85
62.3
0.4927
Gender
(% Females)
Income†
33,942
33,213
0.8287
33,068
34,133
0.4236
(Median)
10.14
8.08
<0.0001*
9.16
8.49
0.2850
#Medications
(4.06)
(3.71)
(3.51)
(3.57)
taken (Mean
(Std.dev))
CDS††
4.35
3.95
0.0673
4.11
4.09
0.9149
(2.05)
(1.95)
(1.96)
(2.29)
Mean(Std.dev)
311.66
349.26
<0.0001*
329.48
327.89
0.4150
Total
Duration†††
(25.52)
(17.01)
(22.02)
(26.33)
Mean(std.dev)
Note: * indicates significant differences between the groups as p-value <0.05, ** means Standard
Deviation, † Income = Median household income of the beneficiaries‟ zip-code, †† CDS =
Chronic Disease Score, ††† Total Duration = total number of days beneficiaries were supposed
to take the medications since the first fill date
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To study the effect of having “Some Gap Coverage” compared to not having any
coverage during the gap, we compared, within each therapeutic class, those beneficiaries from
the “Some Gap Coverage” group who reached the coverage gap and those from the “No Gap
Coverage” group who also reached the coverage gap. For almost every therapeutic class, the two
groups were similar in terms of demographics and medication related behavior except the CDS.
In addition, beneficiaries from both the groups were primarily enrolled in plans that had tiered
cost-sharing and coverage gap starting at the Medicare defined amount. The only major
difference was in the type of benefit structure used by the plans in which the beneficiaries were
enrolled. For the “Some Gap Coverage” everyone was enrolled in plans that offered coverage
through an „enhanced‟ alternative to the standard structure whereas a greater proportion of
beneficiaries with “No Gap Coverage” were enrolled in plans that offered coverage through
basic alteration of the standard Part D structure. In addition, no beneficiary from the “Some Gap
Coverage” group had a deductible whereas a significant proportion of beneficiaries in the “No
Gap Coverage” group were enrolled in plans that charged a front-end deductible.
Ideally, as with other analyses, it would be useful to eliminate these differences using the
propensity score matching technique. However, the sample size restriction as well as the
variables on which the two groups differed prevented the use of the matching technique. For
example, in the group that took oral anti-hyperlipidemic agents, 446 had “Some Gap Coverage”
whereas 7,636 had “No Gap Coverage”. Among the latter, only 38.62% (295) beneficiaries were
enrolled in an „enhanced alternative‟ benefit structure and even that did not offer coverage during
the gap. Thus, the sample sizes of the two groups were so similar that it would be difficult to
perform a match. In addition, since the benefit structure is what defines and differentiates them
into these two groups, there would not be any additional utility to match on this particular
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variable even if there was sufficient sample size. Therefore, no matching was performed for this
analysis. Tables 27-33 present the characteristics of the two comparison groups used for this
analysis by therapeutic class.
Table 27: Characteristics of beneficiaries on oral anti-hyperlipidemic agents based on “gap
coverage” status
Variable

Some Gap Coverage
N=446
76.81(6.08)

No Gap Coverage
N = 7,636
76.52(6.47)

p-value

Race (%Caucasian)

95.07

93.07

0.3701

Gender (% Females)

70.19

67.76

0.2871

Age Mean(Std.dev**)

0.2185

Income†
32,945
34,022
0.0239*
(Median)
9.74(3.99)
9.63(3.93)
0.8055
# Medications taken
(Mean (Std.Dev))
CDS††
2.89(1.87)
3.62(2.12)
<0.0001*
Mean(Std.dev)
Total Duration†††
310.65(23.79)
311.57(24.28)
0.4963
Mean(std.dev)
0
61.38
<0.0001*
Benefit Type
(% Basic Design)
100
73.1
<0.0001*
Deductible
(% No)
100
99.28
0.0721
Pre-Gap Costsharing
(% Tiers)
100
98.73
0.0299
Gap Threshold
(% Std. amt***)
Note: * indicates significant differences between the groups as p-value <0.05, ** means Standard
Deviation and *** indicates Medicare Defined Standard amount ($2,510 in 2008), † Income =
Median household income of the beneficiaries‟ zip-code, †† CDS = Chronic Disease Score, †††
Total Duration = total number of days beneficiaries were supposed to take the medications since
the first fill date
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Table 28: Characteristics of beneficiaries on beta-blockers based on “gap coverage” status
Variable

Some Gap Coverage
N=291
78.21(6.78)

No Gap Coverage
N = 5,298
77.94(6.97)

p-value

0.3879
Age
Mean(Std.dev**)
94.16
93.74
0.8676
Race
(%Caucasian)
73.88
71.64
0.4138
Gender
(% Females)
Income†
31,784
32,905
0.1466
(Median)
10.43(4.24)
10.24(3.88)
0.7948
# Medications taken
(Mean (Std.Dev))
CDS††
3.01(2.03)
3.80(2.05)
<0.0001*
Mean(Std.dev)
Total Duration†††
312.55(22.52)
313.51(24.14)
0.6400
Mean(std.dev)
0
62.74
<0.0001*
Benefit Type
(% Basic Design)
100
71.03
<0.0001*
Deductible
(% No)
100
98.81
0.0614
Pre-Gap Costsharing
(% Tiers)
100
98.33
0.0553
Gap threshold
(% Std. amt***)
Note: * indicates significant differences between the groups as p-value <0.05, ** means Standard
Deviation and *** indicates Medicare Defined Standard amount ($2,510 in 2008), † Income =
Median household income of the beneficiaries‟ zip-code, †† CDS = Chronic Disease Score, †††
Total Duration = total number of days beneficiaries were supposed to take the medications since
the first fill date
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Table 29: Characteristics of beneficiaries on diuretics based on “gap coverage” status
Variable

Some Gap Coverage
N=198
78.89(7.39)

No Gap Coverage
N = 2,899
78.59(7.28)

p-value

0.5334
Age
Mean(Std.dev**)
94.57
92.91
0.5045
Race
(%Caucasian)
84.11
78.35
0.0279*
Gender
(% Females)
Income†
33,060
32,120
0.8454
(Median)
10.99(3.95)
10.99(3.98)
0.9870
# Medications taken
(Mean (Std.Dev))
CDS††
3.26(1.98)
3.97(2.11)
<0.0001*
Mean(Std.dev)
Total Duration†††
312.59(24.04)
314.04(24.14)
0.3642
Mean(std.dev)
0
62.91
<0.0001*
Benefit Type
(% Basic Design)
100
70.17
<0.0001*
Deductible
(% No)
100
98.77
0.0887
Pre-Gap Costsharing
(% Tiers)
100
98.45
0.0599
Gap Threshold
(% Std. amt***)
Note: * indicates significant differences between the groups as p-value <0.05, ** means Standard
Deviation and *** indicates Medicare Defined Standard amount ($2,510 in 2008), † Income =
Median household income of the beneficiaries‟ zip-code, †† CDS = Chronic Disease Score, †††
Total Duration = total number of days beneficiaries were supposed to take the medications since
the first fill date
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Table 30: Characteristics of beneficiaries using ACE inhibitors based on “gap coverage”
status
Variable

Some Gap Coverage
N=86
79.09(7.06)

No Gap Coverage
N = 1,943
77.55(7.21)

p-value

0.0319
Age
Mean(Std.dev**)
94.19
92.57
0.8106
Race
(%Caucasian)
72.09
65.26
0.1919
Gender
(% Females)
Income†
29,573
32,232
0.2192
(Median)
9.64(3.76)
10.17(3.92)
0.2306
# Medications taken
(Mean (Std.Dev))
CDS††
5.57(1.96)
5.71(1.62)
0.3773
Mean(Std.dev)
Total Duration†††
304.21(20.94)
306.22(22.78)
0.5540
Mean(std.dev)
0
63.05
<0.0001*
Benefit Type
(% Basic Design)
100
70.87
<0.0001*
Deductible
(% No)
100
99.54
0.5270
Pre-Gap Costsharing
(% Tiers)
100
99.28
0.4296
Gap Threshold
(% Std. amt***)
Note: * indicates significant differences between the groups as p-value <0.05, ** means Standard
Deviation and *** indicates Medicare Defined Standard amount ($2,510 in 2008), † Income =
Median household income of the beneficiaries‟ zip-code, †† CDS = Chronic Disease Score, †††
Total Duration = total number of days beneficiaries were supposed to take the medications since
the first fill date
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Table 31: Characteristics of beneficiaries on calcium channel blockers based on “gap
coverage” status
Variable

Some Gap Coverage
N=205
78.69(7.08)

No Gap Coverage
N = 3,842
78.59(7.32)

p-value

0.6456
Age
Mean(Std.dev**)
93.17
91.51
0.7706
Race
(%Caucasian)
79.02
76.88
0.4785
Gender
(% Females)
Income†
32,587
32,933
0.9296
(Median)
10.05(3.93)
10.41(3.85)
0.1083
# Medications taken
(Mean (Std.Dev))
CDS††
3.74(1.82)
4.57(1.92)
<0.0001*
Mean(Std.dev)
Total Duration†††
312.86(21.73)
313.81(24.46)
0.7814
Mean(std.dev)
0
63.30
<0.0001*
Benefit Type
(% Basic Design)
100
71.86
<0.0001*
Deductible
(% No)
100
99.05
0.1615
Pre-Gap Costsharing
(% Tiers)
100
98.62
0.1109
Gap Threshold
(% Std. amt***)
Note: * indicates significant differences between the groups as p-value <0.05, ** means Standard
Deviation and *** indicates Medicare Defined Standard amount ($2,510 in 2008), † Income =
Median household income of the beneficiaries‟ zip-code, †† CDS = Chronic Disease Score, †††
Total Duration = total number of days beneficiaries were supposed to take the medications since
the first fill date
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Table 32: Characteristics of beneficiaries using PPIs based on “gap coverage” status
Variable

Some Gap Coverage
N=223
77.98(7.14)

No Gap Coverage
N = 4,204
77.43(7.28)

p-value

0.2251
Age
Mean(Std.dev**)
94.17
92.84
0.9463
Race
(%Caucasian)
79.37
76.15
0.2707
Gender
(% Females)
Income†
32,531
33,226
0.2563
(Median)
10.57(4.22)
10.74(4.36)
0.3955
# Medications taken
(Mean (Std.Dev))
CDS††
2.56(1.87)
3.37(2.01)
<0.0001*
Mean(Std.dev)
Total Duration†††
316.37(24.94)
313.11(24.11)
0.9256
Mean(std.dev)
0
62.02
<0.0001*
Benefit Type
(% Basic Design)
100
71.97
<0.0001*
Deductible
(% No)
100
99.04
0.2629
Pre-Gap Costsharing
(% Tiers)
100
98.62
0.1187
Gap Threshold
(% Std. amt***)
Note: * indicates significant differences between the groups as p-value <0.05, ** means Standard
Deviation and *** indicates Medicare Defined Standard amount ($2,510 in 2008), † Income =
Median household income of the beneficiaries‟ zip-code, †† CDS = Chronic Disease Score, †††
Total Duration = total number of days beneficiaries were supposed to take the medications since
the first fill date
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Table 33: Characteristics of beneficiaries using oral anti-diabetic agents based on “gap
coverage” status
Variable

Some Gap Coverage
N=138
76.55(6.52)

No Gap Coverage
N = 2,613
76.69(6.31)

p-value

0.2542
Age
Mean(Std.dev**)
89.86
88.52
0.5560
Race
(%Caucasian)
65.7
63.57
0.8256
Gender
(% Females)
Income†
33,942
33,053
0.7402
(Median)
10.14(4.06)
10.45(4.12)
0.2793
# Medications taken
(Mean (Std.Dev))
CDS††
4.35(2.05)
5.09(1.99)
<0.0001*
Mean(Std.dev)
Total Duration†††
311.66(25.52)
312.73(24.34)
0.5342
Mean(std.dev)
0
63.91
<0.0001*
Benefit Type
(% Basic Design)
100
71.18
<0.0001*
Deductible
(% No)
100
98.74
0.1841
Pre-Gap Costsharing
(% Tiers)
100
98.55
0.1537
Gap Threshold
(% Std. amt***)
Note: * indicates significant differences between the groups as p-value <0.05, ** means Standard
Deviation and *** indicates Medicare Defined Standard amount ($2,510 in 2008), † Income =
Median household income of the beneficiaries‟ zip-code, †† CDS = Chronic Disease Score, †††
Total Duration = total number of days beneficiaries were supposed to take the medications since
the first fill date
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Medication Adherence
1. Impact of having „No Drug Coverage‟ during the coverage gap on beneficiaries‟
adherence
To determine whether the coverage gap affected the extent to which beneficiaries having
no coverage during the coverage gap remained adherent to their prescribed regimen, the
medication possession ratios of beneficiaries reaching the coverage gap are first compared with
themselves before and after reaching the coverage gap and then with that of matched
beneficiaries that did not reach the coverage gap. Initially, the beneficiaries serve as their own
controls and any change in the adherence can be attributed to factors other than the observed
demographic, medication related and plan enrollment related characteristics. These „other
factors‟ can be being in the coverage gap or situations that cannot be captured in the database
(e.g. selection into specific plans or sudden changes in economic conditions).
Before matching the beneficiaries reaching the coverage gap to those who did not reach
the coverage gap, it was found that beneficiaries in most of the therapeutic classes exhibited
significantly less adherent behavior in the gap compared to their own filling pattern before
reaching the gap. The significance of the difference in the two values is estimated using the
Wilcoxon Signed Rank Test for paired data. The decrease in MPR ranged from 11% for oral
anti-diabetic agents to 38% for PPIs. Table 34 presents the MPR values before and after reaching
the coverage gap among beneficiaries with “No Gap Coverage” as well as for those who did not
reach the coverage gap in 2008.
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Table 34: Decrease in MPR† in the “No Gap Coverage” group before matching
Class
ACE inhibitors

Did not reach
the gap
0.73

Reached the Gap
Pre-Gap In Gap Difference p-value
0.86
0.59
0.27
<0.0001*

Beta-blockers

0.88

0.95

0.61

0.34

<0.0001*

Calcium channel blockers

0.86

0.96

0.60

0.36

<0.0001*

Diuretics

0.88

0.95

0.59

0.36

<0.0001*

Oral anti-diabetic agents

0.98

0.98

0.87

0.11

<0.0001*

Oral anti-hyperlipidemic
agents
Proton pump inhibitors

0.79

0.99

0.75

0.24

<0.0001*

0.68

0.96

0.58

0.38

<0.0001*

Note: † MPR = Medication Possession Ratio* indicates significant differences between the
groups at p-value <0.05
To reliably attribute the change in adherence values to the fact that the beneficiary was in
the coverage gap and not some other mediator, it was necessary to compare the change in
medication usage patterns of those reaching the coverage gap to those not experiencing the
coverage gap throughout the year. Therefore, for this part of the analyses, the change in
beneficiaries‟ adherence during the coverage gap phase was compared to the change in
adherence experienced by corresponding matched beneficiaries who did not reach the coverage
gap. After performing the match as specified earlier, the matched pairs were analyzed for the
change in adherence before and during the gap. Then these differences were compared using the
Wilcoxon Signed Rank Test.
The results indicate that for the most part, both groups experienced significant decreases
in adherence (Table 35). However, compared to those who did not reach the coverage gap, the
beneficiaries reaching the coverage gap decreased their adherence to medications to a greater
extent. For example, the decrease in adherence to beta-blockers after reaching the coverage gap
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was 3% greater than the decrease in adherence observed for the corresponding beneficiaries not
reaching the coverage gap during the same period. In absolute terms, beneficiaries using betablockers who reached the coverage gap decreased their adherence by 33% while in the gap;
whereas beneficiaries not reaching the coverage gap experienced a decrease of 30% in their MPR
for the same period (p-value = 0.006). Similar results were obtained for beneficiaries using oral
anti-diabetic agents (difference-in-difference = 9%, p-value < 0.0001), oral anti-hyperlipidemic
agents (difference-in-difference = 7%, p-value < 0.0001) and PPIs (difference-in-difference =
7%, p-value < 0.0001).
Beneficiaries using ACE inhibitors, calcium channel blockers or diuretic agents also
experienced greater reductions in adherence values compared to those reaching the coverage gap,
but these differences were not statistically significant. Among those who used calcium channel
blockers, the decrease in adherence for those reaching the coverage gap was 1% more than the
decrease observed for those not reaching the coverage gap (p-value 0.1906). The decrease in
adherence was 2% higher among those using diuretic medications and reaching the coverage gap
compared to those that did not reach the coverage gap (p-value 0.1572). However, the results
were reversed for beneficiaries taking ACE inhibitors. In this group, beneficiaries reaching the
coverage gap experienced a 1% smaller reduction in adherence compared to those who did not
reach the gap (p-value .3888).
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Table 35: Difference-In-Difference analyses of the decreases in MPR†s in the “No Gap
Coverage” group by therapeutic class after matching
Class

Reached the Did not reach Diff-in-Diff**
Gap
the Gap
0.25
0.26
-0.01

p-value

0.3888
ACE inhibitors
(N = 1,373 pairs)
0.33
0.30
0.03
0.006*
Beta-blockers
(N = 3,821 pairs)
0.33
0.32
0.01
0.1572
Calcium channel blockers
(N = 2,373 pairs)
0.35
0.33
0.02
0.1906
Diuretics
(N = 3,530 pairs)
0.41
0.32
0.09
<0.0001*
Oral anti-diabetic agents
(N = 1,655 pairs)
0.33
0.26
0.07
<0.0001*
Oral anti-hyperlipidemic agents
(N = 5,041 pairs)
0.36
0.29
0.07
<0.0001*
Proton pump inhibitors
(N = 2,678 pairs)
Note: † MPR = Medication Possession Ratio, * indicates significant differences between the
groups as p-value <0.05 ** means Difference-In-Difference, calculated as (Change in MPR after
reaching the gap for the „Reached Gap‟) – (Change in MPR after reaching the gap for „Did not
reach the Gap‟),

In a second set of analyses, the percentage of beneficiaries found to have stopped taking
their medications after reaching the coverage gap was estimated for the matched pairs. In
addition, we compared the proportion of beneficiaries considered to be adherent (MPR > 0.80)
before and after reaching the coverage gap for each therapeutic class.
The results indicate that a greater proportion of beneficiaries not reaching the coverage
gap appeared to have stopped taking their medications at the time corresponding to the coverage
gap. Overall, the group taking PPIs was most likely to stop taking the medications during the
coverage gap. A little over one fifth (21.51%) of the beneficiaries reaching the gap and 28.90%
of beneficiaries not reaching the gap in this group stopped taking their medications in the time
corresponding to the coverage gap. Beneficiaries using diuretics was another group in which
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12.85% and 23.40% of the beneficiaries who did and did not experience the coverage gap
stopped taking the medication during the time corresponding to the coverage gap. For all other
groups, the proportion of beneficiaries who discontinued taking medications during the time
corresponding to the coverage gap was in the range of 9% - 19%. The differences in the
proportion of beneficiaries stopping medications from the groups that did and did not reach the
coverage gap were statistically significant for all the classes evaluated. Table 36 presents these
results in detail.
Table 36: Percent of beneficiaries in the “No Gap Coverage” group stopping medications
during the coverage gap
Class
ACE inhibitors
(N = 1,373 pairs)
Beta-blockers
(N = 3,821 pairs)
Calcium channel blockers
(N = 2,373 pairs)
Diuretics
(N = 3,530 pairs)
Oral anti-diabetic agents
(N = 1,655 pairs)
Oral anti-hyperlipidemic agents
(N = 5,041 pairs)
Proton pump inhibitors
(N = 2,678 pairs)

Reached the
gap (%)
15.37

Did not reach
the gap (%)
18.43

p-value
<0.0001*

10.49

15.18

<0.0001*

12.85

18.71

<0.0001*

18.53

23.40

<0.0001*

9.49

13.41

<0.0001*

11.60

16.43

<0.0001*

21.51

28.90

<0.0001*

The proportion of beneficiaries considered adherent before and during the coverage gap
decreased for both the groups in all classes of medications evaluated. For example, among
beneficiaries using beta-blockers, 80.81% of the beneficiaries reaching the coverage gap were
considered adherent before reaching the coverage gap. However, only half of these beneficiaries
(44.21%) were found to be adherent during the coverage gap phase. For beneficiaries not
reaching the coverage gap, the numbers were 72.52% in the pre-gap period and 42.97% in the
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„during gap‟ period. These findings were consistent across all the remaining therapeutic classes
being evaluated. Table 37 presents these results in detail.
Table 37: Percentage of beneficiaries in the “No Gap Coverage” group considered
adherent* in the Pre-Gap and the During Gap periods by therapeutic class
Class

Reached gap
Did not Reach Gap
%adherent
% adherent %adherent
% adherent
Pre-Gap
During Gap Pre-Gap
During Gap
72.54
44.51
70.12
40.64

ACE inhibitors
(N = 1,373 pairs)
80.81
44.21
72.52
42.97
Beta-blockers
(N = 3,821 pairs)
82.68
46.08
71.35
40.18
Calcium channel blockers
(N = 2,373 pairs)
72.27
42.72
64.43
40.37
Diuretics
(N = 3,530 pairs)
84.65
68.61
72.71
48.88
Oral anti-diabetic agents
(N = 1,655 pairs)
78.82
49.64
76.86
42.99
Oral anti-hyperlipidemic
agents
(N = 5,041 pairs)
66.43
36.45
46.11
30.85
Proton pump inhibitors
(N = 2,678 pairs)
Note: * considered adherent = beneficiaries whose Medication Possession Ratio (MPR) > 0.80

Further, we evaluated the differences in percentage of beneficiaries considered adherent
before and after reaching the coverage gap in both the groups for statistical significance. The
tests indicate that the differences between the groups were statistically significant for all
therapeutic classes except ACE inhibitors. The decrease in percentages of beneficiaries
considered adherent was greater among those taking beta-blockers, calcium channel blockers,
diuretics or PPIs and reaching the coverage gap compared to those not reaching the coverage
gap. However, greater percentages of beneficiaries taking ACE inhibitors, oral anti-diabetic
agents, or oral anti-hyperlipidemic agents and not reaching the coverage gap were found to be
non-adherent at the time corresponding to the matched group‟s coverage gap (Table 38).
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Table 38: Difference-in-difference of decreases in percentages of beneficiaries in the “No
Gap Coverage” group considered adherent† during the coverage gap
Class

Reached the Did not reach Diff-in-Diff**
Gap
the Gap
28.03
29.48
-1.45

p-value

0.4010
ACE inhibitors
(N = 1,373 pairs)
36.60
29.55
7.05
<0.0001*
Beta-blockers
(N = 3,821 pairs)
36.60
31.17
5.43
<0.0001*
Calcium channel blockers
(N = 2,373 pairs)
29.55
24.06
5.49
<0.0001*
Diuretics
(N = 3,530 pairs)
16.04
23.83
-7.79
<0.0001*
Oral anti-diabetic agents
(N = 1,655 pairs)
29.18
33.87
-4.69
<0.0001*
Oral anti-hyperlipidemic agents
(N = 5,041 pairs)
29.98
15.26
14.72
<0.0001*
Proton pump inhibitors
(N = 2,678 pairs)
Note: † considered adherent = beneficiaries whose Medication Possession Ratio (MPR) > 0.80 *
indicates significant differences between the groups as p-value <0.05 ** means Difference-InDifference, calculated as (decrease in percent adherent after reaching the gap for the „Reached
the Gap‟) – (decrease in percent adherent after reaching the gap for „Did not reach the Gap‟)
These results indicate that among the beneficiaries taking beta-blockers and PPIs, those
reaching the coverage gap were more likely to reduce their medication usage to some extent
(inferred from the reduction in percentage considered adherent) rather than stopping it
completely as compared to those who did not reach the coverage gap. The net effect was that the
observed decrease in adherence (in other words, MPR) during the coverage gap for those
reaching it was significantly greater than for those not reaching the coverage gap. However, for
those taking oral anti-diabetic agents and oral anti-hyperlipidemic agents, the results indicate that
though beneficiaries reaching the coverage gap were less likely to stop taking their medications
altogether, there is still a significantly greater decrease in their MPR values compared to those
not reaching the coverage gap. Among those taking calcium channel blockers and diuretics, a
lesser proportion of beneficiaries reaching the coverage gap stopped the medications during that
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time compared to those not reaching the coverage gap. This was nullified by the fact that a
greater proportion of beneficiaries not reaching the coverage gap became non-adherent (MPR <
0.80) during the coverage gap period compared to those who reached the coverage gap. In other
words, there was no significant difference in the decrease in adherence (MPR) values between
the two groups for these therapeutic classes.
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2. Impact of having „Partial Drug Coverage‟ during the coverage gap on beneficiaries‟
adherence
To study the impact of having partial drug coverage during the gap, comparisons of
changes in MPR values before and after reaching the coverage gap were made with themselves
in the “Some Gap Coverage” group. It was found that the decrease in beneficiaries‟ adherence to
medications during the coverage gap was significant compared to their adherence values before
reaching the coverage gap for all therapeutic classes being studied. The greatest decline in
adherence was exhibited by the group taking PPIs (41%) whereas the smallest decrease was in
the group using oral anti-diabetic agents (18%). An analysis of the changes in adherence after
adding the comparison group that did not reach the coverage gap revealed that the percent
decrease in adherence in the group reaching the coverage gap was not significantly different than
the percent decrease experienced by the corresponding comparison group for any therapeutic
class. Tables 39 and 40 present these results in detail.
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Table 39: Decreases in MPR in the “Some Gap Coverage” Group by gap status before
matching
Class
ACE inhibitors

Did not reach
the gap
0.73

Reached the Gap
Pre-Gap In Gap Difference p-value
0.81
0.49
0.32
<0.0001*

Beta-blockers

0.88

0.96

0.66

0.30

<0.0001*

Calcium channel blockers

0.89

0.96

0.62

0.34

<0.0001*

Diuretics

0.88

0.95

0.59

0.36

<0.0001*

Oral anti-diabetic agents

0.98

1.02

0.84

0.18

<0.0001*

Oral anti-hyperlipidemic
agents
Proton pump inhibitors

0.79

0.98

0.67

0.31

<0.0001*

0.67

0.86

0.45

0.41

<0.0001*

Note: * indicates significant differences between the groups at p-value <0.05
Table 40: Difference-In-Difference analyses of decreases in MPR†s in the “Some Gap
Coverage” group by therapeutic class after matching
Class

Reached the Did not reach Diff-in-Diff** p-value
Gap
the Gap
0.18
0.17
0.01
0.8935

ACE inhibitors
(N = 36 pairs)
0.3
0.29
0.01
0.9786
Beta-blockers
(N = 163 pairs)
0.32
0.36
-0.04
0.5614
Calcium channel blockers
(N = 97 pairs)
0.32
0.2
0.12
0.6842
Diuretics
(N = 128 pairs)
0.47
0.29
0.18
0.0512
Oral anti-diabetic agents
(N = 61 pairs)
0.34
0.32
0.02
0.2426
Oral anti-hyperlipidemic agents
(N = 235 pairs)
0.42
0.2
0.22
0.0015
Proton pump inhibitors
(N = 108 pairs)
Note: † MPR = Medication Possession Ratio, * indicates significant differences between the
groups as p-value <0.05 ** means Difference-In-Difference, calculated as (Change in MPR after
reaching the gap for the „Reached Gap‟) – (Change in MPR after reaching the gap for „Did not
reach the Gap‟)
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As with the “No Gap Coverage” group, we estimated the proportion of beneficiaries who
stopped taking medications from a particular therapeutic class while in the coverage gap. We
also estimated the change in proportion of beneficiaries considered to be adherent (MPR > 0.80)
before and during the coverage gap phases. Among those with some gap coverage, a
considerable percentage of beneficiaries stopped taking medications during the coverage gap
phase. These percentages in this group ranged from 7.98% for beta-blockers to 30.56% for PPIs.
However, unlike the “No Gap Coverage” group, the percentage of beneficiaries not reaching the
coverage gap but stopping the medications was greater among those taking beta-blockers,
calcium channel blockers, diuretics and oral anti-hyperlipidemic agents; but less among those
taking ACE inhibitors, PPIs or oral anti-diabetic agents. None of these differences (except ACE
inhibitors), however, was statistically significant (Table 41).
Table 41: Percent of beneficiaries in the “Some Gap Coverage” group stopping medications
during the time corresponding to the coverage gap
Class
ACE inhibitors
(N = 36 pairs)
Beta-blockers
(N = 163 pairs)
Calcium channel blockers
(N = 97 pairs)
Diuretics
(N = 128 pairs)
Oral anti-diabetic agents
(N = 61 pairs)
Oral anti-hyperlipidemic agents
(N = 235 pairs)
Proton pump inhibitors
(N = 108 pairs)

Reached the
gap (%)
28.13

Did not reach
the gap (%)
6.25

p-value

7.98

11.66

0.2628

9.28

14.43

0.2670

17.97

19.53

0.7490

11.48

3.28

0.0802

10.64

11.91

0.6600

30.56

27.78

0.6528
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0.0102

The proportion of beneficiaries considered adherent during the coverage gap decreased
from the pre-gap values for both groups (those who did and did not reach the coverage gap). A
greater proportion of those taking ACE inhibitors, beta-blockers, calcium channel blockers and
oral anti-diabetic agents and not reaching the coverage gap were considered non-adherent at the
time corresponding to the matched group‟s coverage gap while the results were opposite for the
other classes evaluated. Only the difference for those taking PPIs was statistically significant.
Table 42 and 43 presents these results in detail.
Table 42: Percentage of beneficiaries considered adherent* in the Pre-Gap and the During
Gap periods by therapeutic class
Class

ACE inhibitors

Reached gap
Did not Reach Gap
%adherent
% adherent %adherent
% adherent
Pre-Gap
During Gap Pre-Gap
During Gap
59.38
46.88
74.19
47.88

Beta-blockers

88.34

54.6

89.76

47.24

Calcium channel blockers

82.47

49.48

81.45

45.36

Diuretics

73.44

45.31

67.72

49.22

Oral anti-diabetic agents

85.25

57.48

85.25

57.27

Oral anti-hyperlipidemic
agents
Proton pump inhibitors

78.3

44.25

71.55

42.13

58.33

30.55

34.58

26.85

Note: * considered adherent = beneficiaries whose Medication Possession Ratio (MPR) > 0.80
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Table 43: Difference-in-difference of decreases in percentages of beneficiaries in the “Some
Gap Coverage” group considered adherent† during the coverage gap
Class

Reached the Did not reach Diff-in-Diff**
Gap
the Gap
12.50
26.31
-13.81

p-value

0.1310
ACE inhibitors
(N = 36 pairs)
33.74
42.42
-8.78
0.1032
Beta-blockers
(N = 163 pairs)
32.99
36.09
-3.10
0.6528
Calcium channel blockers
(N = 97 pairs)
28.13
18.50
9.63
0.0672
Diuretics
(N = 128 pairs)
27.77
27.98
-0.21
0.9760
Oral anti-diabetic agents
(N = 61 pairs)
34.05
29.42
4.63
0.2846
Oral anti-hyperlipidemic agents
(N = 235 pairs)
27.78
7.73
20.05
<0.0001*
Proton pump inhibitors
(N = 108 pairs)
Note: † considered adherent = those with MPR > 0.80* indicates significant differences between
the groups as p-value <0.05 ** means Difference-In-Difference, calculated as (decrease in
percent adherent after reaching the gap for the „Reached the Gap‟) – (decrease in percent
adherent after reaching the gap for „Did not reach the Gap‟)

The results for those with “Some Gap Coverage” indicate that the proportions of
beneficiaries considered adherent or stopping the medications did not differ between those who
did and did not reach the coverage gap for all therapeutic classes except PPIs. For those taking
PPIs, similar proportions of beneficiaries stopped taking medications at the time of the coverage
gap but a greater proportion of those reaching the coverage gap were considered non-adherent
compared to those not reaching the coverage gap. Therefore, overall, it appears that there is a
significantly greater reduction in adherence (MPR) for those reaching the coverage gap in this
group compared to those not reaching the coverage gap.
From the previous analyses, it can be concluded that the decreases in adherence to
medications for beneficiaries reaching the coverage gap relative to the decreases in adherence of
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beneficiaries not reaching the coverage gap varied across therapeutic classes. Further, it is found
that the extent to which beneficiaries‟ MPR decreased within a therapeutic class also varied by
presence or absence of drug coverage in the gap. To study the significance of this variability
within the groups reaching the coverage gap, the differences in beneficiaries‟ adherence values
(i.e. MPRs) before and after reaching the coverage gap based on their “gap coverage” status were
compared using the Wilcoxon Rank Sum Test. As can be noted from Table 44 below, the
decreases in adherence values during the coverage gap were not significantly different between
groups for any of the therapeutic classes.
Table 44: Decreases in MPR†s during the coverage gap by gap coverage type and
therapeutic class
Class
ACE inhibitors

Some Gap Coverage
N
Decrease
86
0.32

No Gap Coverage
N
Decrease
1,943
0.27

p-value
0.2918

Beta-blockers

291

0.30

5,298

0.34

0.0727

Calcium channel blockers

205

0.34

3,842

0.36

0.4529

Diuretics

198

0.36

2,899

0.36

0.9123

Oral anti-diabetic agents

138

0.18

2,613

0.11

0.2918

Oral anti-hyperlipidemic
agents
Proton pump inhibitors

446

0.31

7,636

0.24

0.9006

223

0.41

4,204

0.38

0.1911

Note: † MPR = Medication Possession Ratio, * indicates significant differences between the
groups as p-value <0.05
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Main Conclusions
A significant proportion of beneficiaries reached the coverage gap in 2008. However,
most did so late in the year and spent the rest of the year in the gap. Also, the impact of coverage
gap on beneficiaries‟ adherence is mixed depending on whether or not they had coverage for
some drugs during the gap. The following chapter discusses the results as well as the study
strengths and limitations in detail. It also highlights the practical applications of these results.
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CHAPTER 6
DISCUSSION

This chapter discusses the results of the study as well as the strengths and limitations of
the study design. It also presents an overview of practical implications of the study results,
concluding remarks, and ideas for future research.

Objective 1:
The sample for our analysis was older, sicker and predominantly Caucasian. Almost
three-quarters of the sample comprised females and the median annual household income ranged
around $33,000. Most seniors in our sample took several medications simultaneously and used at
least 3 classes of medications being evaluated. A greater proportion of beneficiaries from our
sample were enrolled in stand-alone PDP plans and 95.07% did not have any coverage for drugs
during the coverage gap. Moreover, these beneficiaries were enrolled in plans that did not charge
a deductible and in those that had tiered cost-sharing structures rather than the standard 25%
coinsurance rate set by Medicare. Beneficiaries with drug coverage in the gap were limited to
coverage for generic drugs only. These socio-demographic characteristics as well as plan
enrollment profile are similar to the national estimates indicating that our sample was a
representative sample of all Medicare beneficiaries117.
Overall, the beneficiaries in our sample were found to have similar socio-demographic
characteristics irrespective of whether or not they reached the coverage gap or whether or not
they had coverage during the gap. This indicates that the socio-demographic characteristics of
beneficiaries that were included in this study are not significant in determining whether or not
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beneficiaries reached the coverage gap in a given year. These results are consistent with prior
findings that socio-demographic characteristics are not significant predictors of reaching the
coverage gap threshold64. The results however, do indicate that beneficiaries reaching the
coverage gap used significantly greater numbers of unique medications and had higher OOP
spending before and during the gap. The use of greater numbers of medications can be used as a
proxy for having greater number/severity of co-morbidities. In addition, though the differences
between the socio-demographic and plan enrollment characteristics varied by therapeutic class,
the number of medications and CDS were consistently higher among those who reached the
coverage gap compared to those who did not. These results are in accordance with prior
estimations that the likelihood of reaching the coverage gap increases with increases in comorbidity64, 66, 118.

Objective 2:
Almost a quarter of all beneficiaries in our sample reached the coverage gap in 2008.
This finding is similar to prior estimates by researchers at Kaiser Family Foundation62. However,
this proportion is greater than found by other studies that estimated that between 6 and 19% of
their samples reached the coverage gap in a given year118-121. It should be noted, however, that the
study done by Kaiser Family Foundation used data from a representative sample of beneficiaries
enrolled in PDPs whereas the other studies used data from beneficiaries enrolled in MA-PD
plans, which are inherently different from PDPs.
When comparing beneficiaries with some drug coverage during the gap to those without
any drug coverage during the gap, we found that the two groups were similar in terms of their
demographic and medication taking behavior, but that a greater proportion of beneficiaries with
“Some Gap Coverage” reached the coverage gap. These results hold at the therapeutic class level
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analyses as well. In our opinion, these findings are consistent with the basic economic theory of
insurance and demand; the presence of some drug coverage during the gap may lead to an
increased utilization of medications before the gap, and therefore increase the chances of
reaching the coverage gap.
At the therapeutic class level, the greatest proportion of beneficiaries reaching the gap
were those who took proton pump inhibitors group, followed by those taking oral anti-diabetic
agents, beta-blockers and oral anti-hyperlipidemic agents. Beneficiaries using ACE inhibitors
were the least likely to have experienced the coverage gap. These results were consistent in
groups with and without gap coverage.
A majority of our sample reaching the coverage gap did so by September which is a
month later than the previous estimates of beneficiaries reaching the gap by August62. This could
be due to adaptation to the benefit structure. To the best of our knowledge this is the first study to
estimate the effect of coverage gap two years into its implementation and we hypothesize that
since the beneficiaries were exposed to the Part D benefit design for at least a couple of years,
they would have been able to adjust their medication usage accordingly. A study by Hsu et al.122
tested a similar assumption and found that those who were aware of having a gap in coverage
were significantly more likely to adopt one or more cost-cutting strategies throughout the year
which could be translated as a measure to delay their entry to the coverage gap.
On average, beneficiaries reaching the coverage gap spent about three months in the
phase. Only 3% of the total sample reached the catastrophic coverage phase. These beneficiaries
were those who reached the coverage gap in the first quarter of the year and had quite high
expenditures on medications. There was no difference in the time taken to reach the coverage
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gap based on presence or absence of gap coverage. These estimates are also consistent with prior
research indicating that a very small percentage of beneficiaries reach the catastrophic coverage
level and that most of the beneficiaries reaching the coverage gap remain in that phase through
the rest of the year62, 119, 123.

Objectives 3 and 4:
Our study results indicate that the impact of experiencing a coverage gap on
beneficiaries‟ adherence to prescription medications depends on the therapeutic class of
medication evaluated as well as presence or absence of drug coverage during the coverage gap.
When compared with themselves, beneficiaries in all therapeutic classes experienced a
significant reduction in their adherence during the coverage gap irrespective of the presence or
absence of gap coverage. For the group with “No Gap Coverage”, the decrease in MPR values
during the gap ranged from 11% for those using oral anti-diabetic agents to 38% for those using
PPIs. Similar results were obtained for those reaching the coverage gap and having “Some Gap
Coverage” (18% for oral anti-diabetic users and 41% for PPIs). These estimates are consistent
with the hypothesis that adherence would be adversely affected during the coverage gap, but are
greater than previous studies62, 66, 118.
In the “No Gap Coverage” group, the decrease in adherence (MPR) for beneficiaries
reaching the coverage gap was 1% (for calcium channel blockers) to 9% (for oral anti-diabetic
agents) more than the decrease in adherence for beneficiaries not reaching the coverage gap. The
difference in the differences was statistically significant for those using beta-blockers, oral antidiabetic agents, oral anti-hyperlipidemic agents or PPIs. For those in the “Some Gap Coverage”
group also, MPR values declined during the time corresponding to the coverage gap irrespective
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of whether or not they reached it, but the difference between these decreases were not
statistically significant for any class except PPI, the group in which the MPR values for
beneficiaries reaching the coverage gap decreased by 22% more than those not reaching the
coverage gap. Overall, the findings that adherence decreased for both the groups is consistent
with a prior study in which Raebel et al found that adherence decreased more for those reaching
the coverage gap and, to a lesser but still substantial extent, for those who did not reach the
gap60.
In addition, the results indicate that a substantial proportion of beneficiaries stopped
taking their medications during the coverage gap phase for both those who did and did not reach
the coverage gap, independent of gap coverage. The extent of beneficiaries stopping their
medications ranged from about 10% to 25% depending on the class and group being evaluated.
This finding is consistent with that of the study by Kaiser Family Foundation that found that as
many as 20% of their sample stopped taking medications during the coverage gap62.
The proportion of beneficiaries considered to be adherent also decreased during the
coverage gap phase for both those who did and did not reach the coverage gap, for all classes of
medications irrespective of gap coverage. The extent of decrease in percentage of beneficiaries
considered adherent during the coverage gap in both groups varied with therapeutic class and
presence of gap coverage. These results, however, are counter-intuitive in the fact that the
percentages of beneficiaries stopping medications or becoming non-adherent at the time of the
coverage gap were greater for those not reaching the coverage gap compared to those who did
reach the coverage gap for most comparisons.
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A possible explanation for the findings that a significant proportion of beneficiaries either
stopped or became non-adherent even though they did not reach the coverage gap can be drawn
from the studies that estimated the impact of having a cap on spending for prescription
medications. This is because the group that did not reach the coverage gap in our study did have
a „cap‟ of $2,510 on their drug spending and an awareness of this cap could lead to decreased
utilization of medications. A study by Hsu et al. tested a similar hypothesis and found that the
group not reaching the coverage gap was more aware of having a gap in coverage compared to
those who did reach the coverage gap and therefore modified their medication taking behaviors
accordingly122. Such findings have also been noted in the literature before the implementation of
Medicare Part D among seniors with capped benefits38-40, 124.
Given this, it is reasonable to state that our results indicate a greater need for providing
„uninterrupted‟ and/or „uncapped‟ drug coverage to all Medicare beneficiaries. As proposed by
the newly signed health reform law, provision of uninterrupted coverage is proposed to be
achieved by phasing in subsidies for drugs during the coverage gap every few years until the gap
is eliminated completely. For example, the current timeline125 suggests provision of a rebate
worth $250 to beneficiaries reaching the gap between July and December of 2010. For the
following years, the manufacturers have agreed to provide 50% rebate for the brand name drugs
purchased by beneficiaries in the gap. Beginning in January 2011, the Government will start
offering 7% discount on generic drugs and increase the discount gradually till 2020 when the gap
is proposed to be eliminated. The subsidies for brand name drugs will be offered from January
2013 till the total cost to beneficiaries reaches 25% (50% by manufacturer and upto 25% by the
Government) in 2020.
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These are a few steps in the right direction, but as is apparent from the plan, it will take
several years to be fully implemented. Implementing this policy reform might not be feasible in
the long run because providing coverage throughout the year will lead to increase in utilization
of the medications and, in turn, increase government spending on prescription drugs. A recent
publication in the Kaiser Health News bulletin, reported that the Congressional Budget Office
has estimated the cost of elimination the coverage gap by 2019 to be $42.6 billion 126. There is
also a possibility of further delay in implementation of all the provisions due to political as well
as financial pressures that may develop over the course of time. Thus, the beneficiaries still have
to cope with having interruptions and/or caps in drug coverage for several more years to come.
An additional possible reason for finding decreases in adherence as well as percentage of
beneficiaries considered adherent during the coverage gap for both the groups that did and did
not reach the coverage gap can be due to financial barriers like having limited income or
changing economic times like the Great Recession of 2008. However, we believe that we were
able to account for these effects to some extent through techniques like propensity score
matching and the difference-in-difference analysis.
Another possible reason for such findings may be the availability of non-recorded
medications (e.g. cash pays for $4 generics or over the counter medications; especially for PPIs).
In other words, it is possible that the beneficiaries utilized their medications as prescribed but
purchased them from sources that were not recorded in the insurance claims data. The
availability of such medications could have a significant beneficial effect on beneficiaries‟ OOP
spending as well as help them delay reaching the coverage gap. As a result, there could have
been significant use of such medications, especially, among those not reaching the coverage gap
than those who did reach it. Therefore, together, it would appear that the beneficiaries not
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reaching the gap stopped or reduced their medication utilization to a greater extent as compared
to those reaching the gap.
In addition, a review of the literature suggests that cost-related medication non-adherence
is a very complex phenomenon. A model developed by Piette et al. summarizes the known
predictor/s of medication non-adherence (either alone or in combination of more than one) to be
socio-demographic, complexity of regimen, drug coverage, OOP costs, number of co-morbid
conditions, physical, emotional and social health status, perceived need of medications, adverse
effects of medications, patient – provider relationship, effect on Health Related Quality of Life
(HRQoL) and health system characteristics127. Therefore, it is possible that non-financial barriers
to medication adherence may exist for not only those who experience a coverage gap, but also
for the entire senior population enrolled in stand-alone PDP plans, due to which the entire sample
in our analysis experienced varied degree of decreases in adherence during the time
corresponding to the coverage gap. While we were able to account for a few of these factors
(socio-demographic factors, drug coverage, co-morbid conditions, health system characteristics
and complexity of drug regimen), the effect of a number of predictors (health beliefs, perceived
need for medications, effects on HRQoL and physician patient relationship) remains to be
explored. Therefore, it is possible that a lack of awareness among the patients, personal beliefs or
other non-financial factors might increase the rates of non-adherence despite the availability of
uninterrupted drug coverage through the proposed health reform.
In summary, we believe that it is reasonable to state that our study results have policy
implications for all beneficiaries enrolled in Medicare Part D and beyond. Firstly, our results
indicate that there is a need to provide uninterrupted and/or uncapped coverage for prescription
drugs to the seniors. Secondly, we also suggest that it would be beneficial to educate all
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Medicare beneficiaries; especially those with multiple chronic diseases and who take several
medications at a time; about the importance of medication adherence as well as strategies that
can help them continue taking their medications as prescribed throughout the year while enrolled
in the Part D program. These strategies include choosing a plan that has providers and a
formulary structure that meet the beneficiary‟s requirements, obtaining supplemental coverage,
and switching to generic medications early in therapy.
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Strengths and Limitations
Evidence from the literature suggests that beneficiaries reduce the use of medications
during the coverage gap. However, the degree to which a lack of coverage in the gap reduces
adherence rates remained to be explored. Ours is one of the first studies to quantify the extent to
which adherence rates decreased during the coverage gap for beneficiaries taking one more of
the most widely used medications among seniors. Further, most studies to date limited their
analyses to data from single health plans offering MA PD drug plans and thus may have limited
application to beneficiaries enrolled in stand-alone PDPs. In addition, the studies done to date are
limited to data up to the year of 2007. To the best of our knowledge, ours is the first study to use
the CMS claims and denomination data files to estimate the impact of Medicare Part D coverage
gap on adherence of beneficiaries enrolled in stand-alone PDPs two years into the program‟s
implementation. As a result, our findings reflect the impact of the gap after the beneficiaries have
had two years to learn about the program and develop strategies to cope with it.
The study design accounts for different types of effects that can introduce biases in our
estimates. First, it uses eligible beneficiaries as their own controls in assessing the change in
medication adherence rates during the coverage gap. Since the same cohort of patients is
observed before and after the intervention, this reduces potential bias introduced due to
differences in beneficiary characteristics between the two study periods. This is further
controlled by using a matched control group that did not experience a coverage gap. The second
stage of analysis estimates the difference in change in adherence rates (before and during the
gap) between cases and matched controls. This helps us to control biases introduced by choices
in plan selection as well as potential temporal trends like the changing economy and changing
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overall prevalence of diseases. Together, these controls help us to more accurately measure the
association between the gap and change in adherence.
The study, however, also has limitations. The use of retrospective claims data implies that
the study is affected by limitations related to secondary data sources. One of the main limitations
is that using only the information from the database compels us to assume that all the filled
prescriptions were taken as prescribed128. Despite this, it is known that claims data are relatively
accurate measures of the dates and times at which most prescription medications are taken by a
patient and therefore do provide information about „possessing‟ a medication128. In addition, we
believe that the population studied for this research had limited incentives to „not‟ take their
medications if they were filled because our sample included senior Medicare beneficiaries who
generally have limited sources of income and several concomitant chronic diseases that require
continuous use of medications.
We could not, however, account for medications taken by the beneficiaries that are not
billed through Medicare as those transactions are not recorded in the claims data. Examples
include free samples, over-the-counter medicines, borrowed medicines, and prescriptions paid
for with cash (such as $4 generics at Wal-Mart or Target). The result of this is that we could
have underestimated the adherence to medications in our sample. In other words, it is possible
that some beneficiaries did not really stop treatment for their conditions, but since they moved to
alternatives that are not captured in the database (e.g. $4 generics), they were considered as being
non-adherent according to our definition.

This supports the argument for forming a

comprehensive dataset that also captures information of such drugs that are not paid for by the
insurance but are still dispensed as being equivalent to the prescription medications.
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In addition, switching between therapeutic classes of medications was not allowed in our
adherence calculations which might also lead to underestimation of adherence to medications.
However, we believe that since the report was generated at a therapeutic class level, allowing the
switch between classes would have generated inaccurate estimates of effects of the coverage gap
within a particular therapeutic class.
Our results indicate that being in the coverage gap was not a significant indicator of
decrease in adherence in the group with “Some Gap Coverage”. This is because among those
with some drug coverage during the coverage gap, the extent of decreases in adherence for those
reaching the coverage gap was similar to those not reaching the coverage gap. However, in a
separate analysis, it was found that having some drug coverage during the gap was not
significantly different from having no drug coverage during the gap. Previous results indicate
that having some coverage during the coverage gap was beneficial for the seniors 66, 67, 129 but the
impact of “Some Gap Coverage” during the coverage gap on medication adherence was not clear
in our study. These results need to be interpreted with caution because the sample size of groups
with some form of coverage during the coverage gap was close to about 100 beneficiaries only.
In addition, even though the groups that did and did not have gap coverage were similar to each
other in terms of most of their characteristics, there were differences in their plan enrollment
characteristics which could affect their medication taking behavior. Owing to sample size issues,
it was not possible to match these two groups with each other to generate reliable estimates.
We were not able to evaluate the effects of other known predictors of medication nonadherence (e.g. side effects or adverse reactions of the drugs, health beliefs, and patients‟
relationship with the physician) because this database did not collect information on these
variables. These predictors could have affected our adherence values in either direction.
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Additionally, we did not eliminate the overlaps caused by using multiple drugs in the same
therapeutic class and hence we might have overestimated the adherence rates.112
The income and therapeutic class information were not available in the CMS database
and were obtained by linking our database with other data sources. The income information was
gathered from Census data which has been widely used as a measure of a person‟s financial
status. The concern is that the Census data presents the median household income in a zip-code,
not at the level of a beneficiary‟s individual income. The therapeutic classification was obtained
from First Databank based on the NDC numbers provided in the CMS Part D event file.
However, the NDC as well as the classification system used both came from First Data Bank and
therefore, we are less concerned about the differences introduced by use of an external source for
this information. In addition, it is reasonable to believe that all the study limitations had similar
effects on the groups that did and did not reach the coverage gap. Therefore, much of the bias
introduced because of these limitations would be minimized between the groups.
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Conclusions and Future Research
In conclusion, the impact of „coverage gap‟ in our sample is not clear. Though there are
reductions in adherence values for those reaching the coverage gap independent of presence of
gap coverage, medication adherence decreased for all beneficiaries as the year progressed. The
reductions were greater for some therapeutic classes for those reaching the coverage gap in the
“No Gap Coverage” group compared to those not reaching the coverage gap; however, the
coverage gap did not seem to significantly affect the adherence values of those with “Some Gap
Coverage”.
Future research should study the effects of the coverage gap for the same group of
beneficiaries over several years because it would provide information about whether prior
experiences help beneficiaries make effective choices in subsequent years or not. In addition, it
would be useful to compare the effects of being in the coverage gap with no coverage to
beneficiaries who reached the coverage gap and had full coverage during the gap. As evidence
from the literature suggests, decreases in adherence to medications leads to worse clinical
outcomes which can increase the cost of therapy. Therefore, future research should be directed at
studying the impact of Medicare Part D coverage gap on utilization of other health care services.
It would also be useful to conduct studies that examine the effects of non-financial barriers like
health beliefs, effects on HRQoL, patient-physician relationship and awareness about Part D on
medication adherence while being in the coverage gap.
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